https://flcube.com/innovent-biologics-cldn18-2-targeted-adc-ibi343-earns-fda-fast-track-status/2025-01-10T22:32:41+08:00https://flcube.com/alchemab-therapeutics-partners-with-eli-lilly-to-discover-als-treatments/2025-01-10T22:23:07+08:00https://flcube.com/roche-gains-fda-510k-clearance-for-roche-digital-pathology-dx-with-ventana-dp-600/2025-01-10T22:12:46+08:00https://flcube.com/tcmtech-files-for-ipo-on-hong-kong-stock-exchange-showcasing-tcm-ai-leadership/2025-01-10T21:49:22+08:00https://flcube.com/verdiva-bio-launches-with-usd-411-million-series-a-financing-for-biopharma-development/2025-01-10T21:36:49+08:00https://flcube.com/medilink-and-zai-lab-collaborate-on-lrrc15-targeted-adc-drug-zl-6201/2025-01-10T21:08:59+08:00https://flcube.com/bayers-elinzanetant-meets-all-primary-endpoints-in-phase-iii-oasis-4-study/2025-01-10T20:28:51+08:00https://flcube.com/inmagene-biopharmaceuticals-posts-positive-results-for-img-007-in-atopic-dermatitis/2025-01-10T20:05:28+08:00https://flcube.com/brainaurora-medical-technology-ipos-on-hong-kong-stock-exchange/2025-01-10T19:42:43+08:00https://flcube.com/nmpa-releases-89th-batch-of-reference-drugs-for-gqce-work/2025-01-10T19:15:42+08:00https://flcube.com/chinas-nhc-aims-for-over-90-child-friendly-hospitals-by-2030/2025-01-10T19:09:53+08:00https://flcube.com/stryker-to-acquire-inari-medical-for-usd-4-9-billion-to-boost-vte-pipeline/2025-01-10T19:02:12+08:00https://flcube.com/gsk-launches-cabotegravir-injection-in-china-for-hiv-pre-exposure-prophylaxis/2025-01-10T18:10:53+08:00https://flcube.com/insilico-medicine-raises-usd-100-million-in-financing-round-led-by-pudong-and-hong-kong/2025-01-10T00:01:54+08:00https://flcube.com/haier-biomedical-terminates-acquisition-plan-for-shanghai-raas/2025-01-09T23:56:45+08:00https://flcube.com/grifols-as-plans-to-sell-stake-in-shanghai-raas-blood-products-co-ltd-for-up-to-1-5-billion/2025-01-09T23:49:52+08:00https://flcube.com/shanghai-raas-receives-nmpa-approval-to-initiate-clinical-trial-for-hemophilia-preventive-treatment/2025-01-09T23:49:52+08:00https://flcube.com/grifols-completes-sale-of-20-stake-in-shanghai-raas-to-haier-group-for-rmb-12-5-billion/2025-01-09T23:49:51+08:00https://flcube.com/nhsa-revises-2024-nrdl-drug-information-based-on-public-feedback/2025-01-09T23:30:20+08:00https://flcube.com/eli-lilly-chinas-neuroscience-vp-jiang-yifei-departs-for-new-opportunities/2025-01-09T23:22:25+08:00https://flcube.com/fourier-intelligence-secures-usd-109-million-in-series-e-funding-for-robotics-innovation/2025-01-09T23:12:05+08:00https://flcube.com/astellas-padcev-and-keytruda-combo-cleared-by-nmpa-for-urothelial-cancer/2025-01-09T22:57:34+08:00https://flcube.com/huidagene-therapeutics-receives-ema-orphan-designation-for-hg004-gene-therapy/2025-01-09T22:48:52+08:00https://flcube.com/china-medical-system-licenses-alpha-cognitions-zunveyl-for-dementia-treatment-in-asia/2025-01-09T22:41:13+08:00https://flcube.com/huahai-pharmaceutical-to-transfer-rights-to-innovative-antidepressant-hht001-via-public-listing/2025-01-09T22:28:24+08:00https://flcube.com/mabwells-9mw2821-granted-breakthrough-therapy-designation-by-cde-for-urothelial-carcinoma/2025-01-09T22:21:05+08:00https://flcube.com/kelun-pharmaceuticals-generic-mulpleta-gains-nmpa-approval-in-china/2025-01-09T22:12:01+08:00https://flcube.com/alloy-therapeutics-and-sanofi-collaborate-on-cns-drug-development-with-anticlastic-antisense-platform/2025-01-09T22:02:30+08:00https://flcube.com/medtronics-harmony-tpv-system-gains-ce-mark-for-minimally-invasive-heart-valve-treatment/2025-01-09T21:21:40+08:00https://flcube.com/biocytogen-and-acepodia-partner-to-develop-dual-payload-bispecific-adcs-for-oncology/2025-01-09T21:10:43+08:00https://flcube.com/sanofis-sarclisa-gains-nmpa-approval-for-multiple-myeloma-treatment-in-china/2025-01-09T20:58:26+08:00https://flcube.com/araris-biotech-and-chugai-pharmaceutical-collaborate-on-novel-adc-development/2025-01-09T20:48:07+08:00https://flcube.com/mirror-biologics-and-merck-kgaa-collaborate-on-phase-ii-trial-for-colorectal-cancer-immunotherapy/2025-01-09T20:25:49+08:00https://flcube.com/johnson-johnsons-posdinemab-receives-fda-fast-track-designation-for-alzheimers-disease/2025-01-09T20:12:05+08:00https://flcube.com/boston-scientific-set-to-acquire-bolt-medical-for-up-to-usd-900-million/2025-01-09T20:01:53+08:00https://flcube.com/chinas-central-committee-and-state-council-outline-reforms-for-elderly-care-services/2025-01-09T19:50:47+08:00https://flcube.com/xtalpis-ailux-biologics-partners-with-ucb-for-ai-driven-drug-discovery/2025-01-09T19:41:16+08:00https://flcube.com/shanghai-opens-door-to-wholly-foreign-owned-hospitals-in-key-areas/2025-01-09T19:32:11+08:00https://flcube.com/nhsa-strengthens-medical-security-rights-for-workers-in-china/2025-01-09T19:27:04+08:00https://flcube.com/haihe-pharmas-glumetinib-receives-conditional-approval-for-nsclc-treatment/2025-01-09T01:58:56+08:00https://flcube.com/amvision-biotech-secures-rmb-100-million-in-series-a-financing-for-ophthalmology-innovation/2025-01-09T01:56:49+08:00https://flcube.com/jw-therapeutics-initiates-clinical-study-for-carteyva-in-first-line-high-risk-large-b-cell-lymphoma/2025-01-09T01:53:04+08:00https://flcube.com/evaheart-med-raises-usd-100-million-in-series-a-funding-led-by-sinovac/2025-01-09T01:50:35+08:00https://flcube.com/hq-pharma-and-shanxi-hcxf-partner-to-expand-oral-soluble-film-rd-and-production/2025-01-09T01:45:04+08:00https://flcube.com/biocytogen-and-janssen-sign-licensing-agreement-for-renlite-platform/2025-01-09T01:38:07+08:00https://flcube.com/lifetech-scientifics-ibs-angel-stent-receives-ce-mdr-certification-in-eu/2025-01-09T01:34:49+08:00https://flcube.com/olipharma-raises-funds-in-pre-series-a-round-to-expand-manufacturing-facilities/2025-01-09T01:32:20+08:00https://flcube.com/inventiva-and-chia-tai-tianqing-file-clinical-trial-for-lanifibranor-with-cde/2025-01-09T01:28:41+08:00https://flcube.com/simcere-pharmaceutical-initiates-clinical-study-for-bispecific-antibody-sim0237-in-advanced-tumors/2025-01-09T01:24:05+08:00https://flcube.com/ausperbio-and-asymchem-form-strategic-partnership-for-new-drug-rd-and-services/2025-01-09T01:21:40+08:00https://flcube.com/nhsas-2022-healthcare-security-report-reveals-break-even-performance/2025-01-09T01:18:42+08:00https://flcube.com/bio-thera-solutions-initiates-phase-i-study-for-trop2-targeting-adc-bat8008/2025-01-09T01:16:40+08:00https://flcube.com/astellas-and-seagen-file-for-nmpa-approval-of-enfortumab-vedotin-for-urothelial-carcinoma/2025-01-09T01:13:34+08:00https://flcube.com/healirna-secures-rmb-100-million-in-pre-series-a-funding-for-nucleic-acid-drug-development/2025-01-09T01:10:53+08:00https://flcube.com/innocare-pharma-initiates-clinical-study-for-bcl2-inhibitor-icp-248-in-china/2025-01-09T01:02:46+08:00https://flcube.com/thederma-pharmaceuticals-raises-rmb-100-million-for-ahr-targeted-autoimmune-therapies/2025-01-09T01:00:09+08:00https://flcube.com/xinrui-medtech-secures-pre-series-a-funding-for-cardiovascular-device-development/2025-01-09T00:56:59+08:00https://flcube.com/msds-gardasil-vaccine-gains-nmpa-approval-for-use-in-males-aged-9-to-26/2025-01-08T20:02:12+08:00https://flcube.com/bayers-nubeqa-seeks-nmpa-approval-for-new-prostate-cancer-indication/2025-01-08T19:49:48+08:00https://flcube.com/ge-healthcares-allia-igs-pulse-receives-nmpa-clearance-for-launch-in-china/2025-01-08T19:43:39+08:00https://flcube.com/inceptor-bio-and-grit-biotechnology-partner-to-advance-car-t-therapy-ib-t101-for-solid-tumors/2025-01-08T19:24:27+08:00https://flcube.com/pku-1st-hospital-partners-with-baheal-pharmaceutical-on-integrin-targeted-inhibitor-project/2025-01-08T19:00:52+08:00https://flcube.com/takeda-and-fudan-universitys-imi-launch-ai-based-rare-disease-screening-and-diagnosis-project/2025-01-08T18:43:21+08:00https://flcube.com/linkedcare-raises-hundreds-of-millions-in-series-e-funding-led-by-state-owned-investors/2025-01-08T17:47:42+08:00https://flcube.com/grand-life-sciences-partners-with-cali-biosciences-for-cpl-01-commercialization-in-china/2025-01-08T17:37:15+08:00https://flcube.com/insilico-medicines-ism5411-shows-positive-results-in-phase-i-studies-for-inflammatory-bowel-disease/2025-01-08T17:16:58+08:00https://flcube.com/glyconex-licenses-spd8-biosimilar-to-undisclosed-company-for-osteoporosis-treatment/2025-01-08T17:11:07+08:00https://flcube.com/yiling-pharmaceutical-withdraws-clinical-filing-for-g201-na-in-assisted-reproduction/2025-01-08T16:56:27+08:00https://flcube.com/dizals-sunvozertinib-receives-priority-review-from-fda-for-egfr-exon-20-nsclc/2025-01-08T16:30:43+08:00https://flcube.com/boehringer-ingelheim-and-sutro-achieve-commercial-scale-manufacturing-of-luvelta/2025-01-08T16:21:43+08:00https://flcube.com/variant-bio-partners-with-novo-nordisk-to-discover-novel-targets-for-metabolic-diseases/2025-01-08T16:03:16+08:00https://flcube.com/abbvie-exercises-option-for-capsidas-neurodegenerative-disease-program/2025-01-08T15:45:28+08:00https://flcube.com/eyebright-medicals-loong-crystal-pr-receives-nmpa-class-iii-medical-device-approval/2025-01-08T15:34:01+08:00https://flcube.com/cspc-pharmaceutical-group-receives-nmpa-approvals-for-adc-sys6045-and-pde4b-inhibitor-syh2059/2025-01-08T13:54:07+08:00https://flcube.com/kelun-biotechs-anti-her2-adc-a166-receives-nmpa-review-for-expanded-indication/2025-01-08T13:44:50+08:00https://flcube.com/postera-expands-partnership-with-pfizer-to-launch-new-adc-collaboration/2025-01-08T13:16:02+08:00https://flcube.com/merck-kgaa-adopts-quris-ais-bio-ai-platform-for-drug-development-pipeline/2025-01-08T11:51:03+08:00https://flcube.com/hansoh-and-gsks-hs-20093-receives-fda-breakthrough-therapy-designation-for-osteosarcoma/2025-01-08T11:28:58+08:00https://flcube.com/silicon-valley-bank-collapse-impacts-tech-and-biotech-sectors-globally/2025-01-08T00:59:11+08:00https://flcube.com/chipscreens-epidaza-receives-tfda-approval-for-breast-cancer-treatment-in-taiwan/2025-01-08T00:44:36+08:00https://flcube.com/allorion-therapeutics-raises-usd-50-million-in-series-b-financing-to-advance-drug-development/2025-01-08T00:35:14+08:00https://flcube.com/xtalpi-and-chia-tai-tianqing-achieve-phase-ii-milestone-in-cancer-drug-development/2025-01-08T00:30:27+08:00https://flcube.com/overland-pharmaceuticals-partners-with-gobroad-healthcare-to-strengthen-cell-therapy-research/2025-01-08T00:28:10+08:00https://flcube.com/haihe-pharmaceutical-initiates-global-phase-i-clinical-study-for-bet-bd2-inhibitor-hh3806/2025-01-08T00:24:36+08:00https://flcube.com/cansino-biologics-initiates-phase-ib-study-for-innovative-protein-based-pneumococcal-vaccine/2025-01-08T00:22:55+08:00https://flcube.com/zenshine-pharmaceuticals-raises-rmb-100-million-in-series-b-financing-for-drug-development/2025-01-08T00:18:05+08:00https://flcube.com/livzon-pharmaceutical-secures-exclusive-rights-to-onconics-gerd-treatment-zastaprazan/2025-01-08T00:15:55+08:00https://flcube.com/cstones-ayvakit-shows-significant-improvements-in-ism-at-aaaai-meeting/2025-01-08T00:10:41+08:00https://flcube.com/cspc-pharmaceuticals-pd-1-monoclonal-antibody-enlangsubai-completes-nmpa-market-approval-filing/2025-01-08T00:08:03+08:00https://flcube.com/pasteur-institute-suspends-joint-venture-with-chinese-academy-of-sciences/2025-01-08T00:05:15+08:00https://flcube.com/boston-scientific-launches-replace-study-for-farapulse-pfa-system-in-china/2025-01-08T00:03:21+08:00https://flcube.com/lanssonpharms-anti-depression-drug-ls21031-receives-cde-approval-for-clinical-trials/2025-01-08T00:01:09+08:00https://flcube.com/gsks-nucala-gains-nmpa-approval-for-severe-eosinophilic-asthma-in-china/2025-01-07T23:53:53+08:00https://flcube.com/juventas-cell-therapys-cnct19-receives-fda-ind-approval-for-r-r-b-all-treatment/2025-01-07T23:51:54+08:00https://flcube.com/bio-thera-solutions-initiates-first-patient-dosing-in-phase-i-study-of-bat8007/2025-01-07T23:47:29+08:00https://flcube.com/antengene-to-begin-phase-i-clinical-study-of-atg-022-for-advanced-solid-tumors/2025-01-07T23:45:32+08:00https://flcube.com/guangdong-zhongshengs-ray1225-receives-nmpa-approval-for-clinical-study/2025-01-07T23:43:39+08:00https://flcube.com/annji-pharma-signs-usd-250-million-licensing-deal-with-avenue-therapeutics-for-kennedys-disease-drug/2025-01-07T23:41:11+08:00https://flcube.com/vcanbios-vum02-gains-cde-review-for-liver-failure-and-ards-clinical-trials/2025-01-07T23:33:38+08:00https://flcube.com/luye-pharmas-biosimilar-ba9101-completes-phase-iii-study-enrollment-with-ocumension/2025-01-07T23:31:25+08:00https://flcube.com/immunophage-biotech-raises-rmb-200-million-in-series-b1-financing-for-clinical-trials/2025-01-07T23:28:25+08:00https://flcube.com/akeso-biopharma-enrolls-first-subject-in-phase-iii-study-of-cadonilimab-for-gastric-cancer/2025-01-07T23:25:19+08:00https://flcube.com/astellas-pharmas-xtandi-gains-momentum-in-china-with-positive-phase-iii-arches-study-results/2025-01-07T23:23:14+08:00https://flcube.com/world-orphan-drug-alliance-expands-to-china-with-rarestone-group-partnership/2025-01-07T23:01:41+08:00https://flcube.com/mabpharm-files-nda-for-cmab009-biosimilar-to-erbitux-targeting-metastatic-colorectal-cancer/2025-01-07T22:59:17+08:00https://flcube.com/neowise-biotechnology-secures-rmb-200-million-in-series-a-financing-round/2025-01-07T22:52:03+08:00https://flcube.com/singde-yiyang-secures-series-a-financing-to-expand-wellness-services-in-china/2025-01-07T22:35:54+08:00https://flcube.com/nmpa-releases-65th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2025-01-07T22:30:54+08:00https://flcube.com/nhsa-launches-crackdown-on-medical-insurance-fund-management-with-new-inspection-measures/2025-01-07T22:29:10+08:00https://flcube.com/meinian-onehealth-and-astra-biotechnology-partner-on-hypersensitive-blood-biomarker-detection/2025-01-07T22:27:17+08:00https://flcube.com/cde-issues-guidelines-on-single-arm-clinical-trials-for-antitumor-drugs/2025-01-07T22:20:46+08:00https://flcube.com/xtalpi-and-dp-technology-partner-to-accelerate-pre-clinical-drug-development-with-ai/2025-01-07T22:09:38+08:00https://flcube.com/immuneonco-gains-nmpa-approval-for-phase-ib-ii-study-of-imm27m-in-advanced-tumors/2025-01-07T22:02:47+08:00https://flcube.com/arkbio-and-calibr-renew-collaboration-to-develop-first-in-class-respiratory-drug-ak0705/2025-01-07T21:59:12+08:00https://flcube.com/agena-biosciences-cyp2c19-genotyping-kit-gains-nmpa-approval-for-cardiovascular-applications/2025-01-07T21:52:57+08:00https://flcube.com/ping-an-life-insurance-reports-steady-profit-growth-and-expands-managed-care-services/2025-01-07T21:45:08+08:00https://flcube.com/akeso-biopharma-reports-422-increase-in-product-sales-boosted-by-cadonilimab-and-penpulimab/2025-01-07T21:42:42+08:00https://flcube.com/cstone-pharmaceuticals-reports-97-54-revenue-growth-in-2022-driven-by-drug-sales-and-licensing-fees/2025-01-07T21:39:57+08:00https://flcube.com/henlius-ox40-monoclonal-antibody-hlx51-gains-nmpa-approval-for-phase-i-clinical-study/2025-01-07T21:37:04+08:00https://flcube.com/boao-lecheng-and-shanghai-biomed-center-form-long-term-partnership-for-medical-innovation/2025-01-07T21:34:11+08:00https://flcube.com/haisco-pharmaceuticals-egfr-protac-hsk40118-gains-nmpa-approval-for-clinical-trials/2025-01-07T21:32:30+08:00https://flcube.com/aim-vaccine-initiates-phase-i-clinical-study-for-mcv4-meningococcal-vaccine-in-china/2025-01-07T21:30:25+08:00https://flcube.com/bochuang-biotechnology-secures-angel-funding-for-high-purity-collagen-and-innovative-medical-product-development/2025-01-07T21:24:12+08:00https://flcube.com/nmpa-accepts-market-filing-for-guangdong-zhongshengs-covid-19-drug-ray1216/2025-01-07T21:19:37+08:00https://flcube.com/mabwell-biosciences-9mw3811-gains-nmpa-approval-for-clinical-trials-in-china/2025-01-07T21:17:25+08:00https://flcube.com/everest-medicines-xerava-receives-nmpa-approval-for-complicated-intra-abdominal-infections/2025-01-07T21:15:23+08:00https://flcube.com/beijing-initiates-volume-based-procurement-for-ophthalmology-and-orthopedics-medical-consumables/2025-01-07T21:05:00+08:00https://flcube.com/fosun-pharmas-generic-remodulin-gains-nmpa-approval-for-pulmonary-arterial-hypertension/2025-01-07T21:03:08+08:00https://flcube.com/remegen-gains-nmpa-approval-for-phase-i-iia-study-of-rc88-with-junshi-bios-pd-1-inhibitor/2025-01-07T20:57:03+08:00https://flcube.com/triastek-partners-with-boehringer-ingelheim-to-advance-3d-printed-drug-dosage-forms/2025-01-07T20:53:38+08:00https://flcube.com/merck-kgaa-completes-acquisition-of-hub-organoids-expanding-cell-culture-portfolio/2025-01-07T18:25:40+08:00https://flcube.com/amgens-imdylltra-gains-conditional-approval-in-uk-for-extensive-stage-small-cell-lung-cancer/2025-01-07T18:11:53+08:00https://flcube.com/mabwell-bioscience-files-for-ipo-on-hong-kong-stock-exchange-expanding-biopharma-reach/2025-01-07T18:05:19+08:00https://flcube.com/wuxi-biologics-to-sell-irish-vaccine-assets-to-msd-for-usd-500-million/2025-01-07T17:59:23+08:00https://flcube.com/junshi-biosciences-loqtorzi-gains-regular-approval-for-melanoma-treatment-in-china/2025-01-07T17:43:42+08:00https://flcube.com/simcere-zaimings-sim0505-receives-nmpa-approval-for-clinical-trials-in-advanced-solid-tumors/2025-01-07T17:13:44+08:00https://flcube.com/nmpa-releases-88th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2025-01-07T17:04:34+08:00https://flcube.com/huahui-healths-hh-003-gains-priority-review-status-for-chronic-hepatitis-d-treatment/2025-01-07T16:57:16+08:00https://flcube.com/wuxi-biologics-and-candid-therapeutics-ink-global-research-agreement-for-trispecific-t-cell-engager/2025-01-07T16:50:34+08:00https://flcube.com/amoytop-biotechs-pegfilgrastim-gains-nmpa-approval-for-preeclampsia-clinical-trials/2025-01-07T16:41:15+08:00https://flcube.com/hengrui-pharmaceuticals-files-ipo-prospectus-in-hong-kong-amid-record-deal-making/2025-01-07T16:32:47+08:00https://flcube.com/changchun-bcht-partners-with-baosight-software-for-biopharmaceutical-digitization/2025-01-07T13:44:27+08:00https://flcube.com/cde-announces-90th-batch-of-reference-preparations-for-gqce/2025-01-07T13:40:01+08:00https://flcube.com/solasia-pharma-licenses-episil-to-genescience-for-greater-china-region/2025-01-07T13:36:35+08:00https://flcube.com/alebund-pharmaceuticals-completes-series-c-financing-to-advance-kidney-disease-pipelines/2025-01-07T13:16:22+08:00https://flcube.com/nmpa-denies-market-approval-for-hengruis-plinabulin-in-chemotherapy-induced-neutropenia/2025-01-06T23:13:23+08:00https://flcube.com/sciclone-pharmaceuticals-vaborem-approved-for-phase-iii-clinical-trial-in-china/2025-01-06T23:09:30+08:00https://flcube.com/janssen-withdraws-carvykti-from-uk-market-amid-manufacturing-concerns/2025-01-06T23:06:05+08:00https://flcube.com/beigene-declines-option-for-leap-therapeutics-dkn-01-development-rights-in-asia/2025-01-06T23:02:09+08:00https://flcube.com/gracell-secures-non-exclusive-license-for-cell-therapies-from-seagen/2025-01-06T22:55:29+08:00https://flcube.com/vas-healthcare-raises-rmb-100-million-in-angel-financing-for-robot-development/2025-01-06T22:50:28+08:00https://flcube.com/hainan-poly-pharms-generic-gadovist-receives-fda-approval-for-mri-use/2025-01-06T22:30:51+08:00https://flcube.com/jacobio-pharmas-jab-24114-receives-cde-approval-for-phase-i-iia-clinical-study/2025-01-06T22:27:59+08:00https://flcube.com/hengrui-pharmaceuticals-dexmedetomidine-nasal-spray-approved-by-nmpa/2025-01-06T22:25:22+08:00https://flcube.com/asiflyer-bio-raises-millions-in-pre-series-a-funding-for-botox-and-zfp-technology/2025-01-06T22:22:08+08:00https://flcube.com/tot-biopharmaceutical-terminates-phase-iii-study-for-her2-targeted-adc-taa013/2025-01-06T22:17:10+08:00https://flcube.com/shouyao-holdings-receives-cde-approval-for-phase-ii-study-of-third-generation-alk-inhibitor/2025-01-06T22:14:35+08:00https://flcube.com/enlight-medical-technologies-to-acquire-synexmed-expand-vascular-intervention-capabilities/2025-01-06T22:12:15+08:00https://flcube.com/likang-life-sciences-personalized-neoantigen-vaccine-lk101-receives-ind-approval/2025-01-06T21:52:01+08:00https://flcube.com/affamed-technologies-edof-intraocular-lenses-receive-fda-approval-in-taiwan/2025-01-06T21:46:22+08:00https://flcube.com/walvax-biotechnology-announces-positive-results-for-rq3013-mrna-vaccine/2025-01-06T21:44:06+08:00https://flcube.com/yifan-pharmaceuticals-f-652-cleared-for-phase-ii-trial-in-alcoholic-hepatitis/2025-01-06T21:41:46+08:00https://flcube.com/biontech-acquires-global-rights-to-oncoc4s-anti-ctla-4-antibody-onc-392/2025-01-06T21:38:59+08:00https://flcube.com/cygnus-bio-raises-millions-in-series-c-financing-for-sequencing-technology/2025-01-06T21:36:07+08:00https://flcube.com/ll-biopharma-completes-series-b-financing-for-tumor-immunotherapy-development/2025-01-06T21:29:56+08:00https://flcube.com/tl-biotechnology-secures-rmb-100-million-in-series-a-financing/2025-01-06T21:23:26+08:00https://flcube.com/yiling-pharmaceuticals-bio-008-receives-nmpa-approval-for-clinical-trials/2025-01-06T21:21:11+08:00https://flcube.com/lbx-pharmacy-partners-with-gilead-sciences-to-enhance-disease-management-in-china/2025-01-06T21:19:03+08:00https://flcube.com/hengrui-pharmaceuticals-shr8028-receives-nmpa-review-for-dry-eye-treatment/2025-01-06T21:16:42+08:00https://flcube.com/jiangsu-recbios-recov-vaccine-receives-emergency-use-authorization-in-mongolia/2025-01-06T21:05:26+08:00https://flcube.com/wuxi-apptec-reports-71-8-revenue-growth-in-2022-financials/2025-01-06T21:03:03+08:00https://flcube.com/luye-pharmas-ba1102-biosimilar-to-xgeva-accepted-for-cde-review/2025-01-06T21:00:09+08:00https://flcube.com/bayers-nubeqa-receives-additional-nmpa-approval-for-mhspc-treatment-fineline-info-tech/2025-01-06T20:56:11+08:00https://flcube.com/advenchen-labs-al8326-and-hengruis-shr-a1811-receive-breakthrough-therapy-designations/2025-01-06T18:58:06+08:00https://flcube.com/merck-peking-university-launch-public-health-training-projects-for-young-and-middle-aged-talent/2025-01-06T18:54:49+08:00https://flcube.com/biokins-bl-b01d1-receives-nmpa-approval-for-phase-ii-solid-tumor-study/2025-01-06T18:52:53+08:00https://flcube.com/junshi-biosciences-js010-receives-nmpa-approval-for-migraine-clinical-trials/2025-01-06T18:50:53+08:00https://flcube.com/immunotech-biopharms-car-t-19-d2-receives-nmpa-approval-for-dlbcl-clinical-trial/2025-01-06T18:48:36+08:00https://flcube.com/smith-nephew-partners-with-medmotion-for-digital-health-innovation/2025-01-06T18:46:28+08:00https://flcube.com/aidea-pharma-and-china-meheco-partner-to-expand-medical-and-pharmaceutical-services/2025-01-06T18:41:38+08:00https://flcube.com/3sbio-inc-reports-7-5-revenue-growth-in-2022-financials/2025-01-06T18:38:55+08:00https://flcube.com/joincare-pharmaceutical-acquires-rights-to-taigens-pa-endonuclease-inhibitor-tg-1000/2025-01-06T18:35:53+08:00https://flcube.com/reistone-biopharmas-ivarmacitinib-shows-positive-results-in-phase-iii-quartz3-study/2025-01-06T18:31:38+08:00https://flcube.com/sinopharm-forms-joint-ventures-with-foreign-medical-equipment-firms/2025-01-06T18:27:19+08:00https://flcube.com/beigene-marks-topping-off-of-new-biologics-facility-in-new-jersey/2025-01-06T18:17:15+08:00https://flcube.com/beigene-launches-latam-expansion-with-new-office-in-sao-paulo-brazil/2025-01-06T18:16:38+08:00https://flcube.com/beigene-and-springworks-therapeutics-report-positive-phase-ib-results-for-lifirafenib-and-mirdametinib-combination/2025-01-06T18:16:37+08:00https://flcube.com/beigenes-tislelizumab-chemo-combo-excels-in-rationale-305-trial-for-gastric-cancer/2025-01-06T18:16:36+08:00https://flcube.com/beigene-and-the-max-foundation-collaborate-to-expand-access-to-brukinsa-for-cll-patients/2025-01-06T18:16:35+08:00https://flcube.com/beigenes-tislelizumab-secures-first-approvals-outside-china-mainland-in-macau/2025-01-06T18:16:35+08:00https://flcube.com/beigenes-tislelizumab-approved-in-china-for-first-line-esophageal-squamous-cell-carcinoma/2025-01-06T18:16:34+08:00https://flcube.com/beigene-presents-groundbreaking-clinical-data-at-asco-annual-meeting/2025-01-06T18:16:33+08:00https://flcube.com/asieris-pharmaceuticals-to-present-phase-i-results-of-apl-1202-combo-at-asco/2025-01-06T18:16:33+08:00https://flcube.com/beigenes-brukinsa-receives-canadian-approval-for-chronic-lymphocytic-leukemia/2025-01-06T18:16:32+08:00https://flcube.com/cde-indicates-priority-review-for-overland-adcts-zynlonta-and-beigenes-brukinsa/2025-01-06T18:16:13+08:00https://flcube.com/beigene-to-showcase-brukinsa-data-at-icml-highlighting-efficacy-in-relapsed-follicular-lymphoma/2025-01-06T18:16:12+08:00https://flcube.com/abbvie-inc-files-lawsuit-against-beigene-over-btk-inhibitor-brukinsa/2025-01-06T18:16:12+08:00https://flcube.com/beigene-initiates-first-in-human-trial-for-next-generation-bcl-2-inhibitor-bgb-21447/2025-01-06T18:16:11+08:00https://flcube.com/luye-pharmas-goserelin-acetate-microspheres-approved-by-nmpa-for-prostate-cancer-treatment/2025-01-06T18:16:11+08:00https://flcube.com/beigene-secures-exclusive-licensing-deal-with-duality-biotherapeutics-for-novel-drug-development/2025-01-06T18:16:10+08:00https://flcube.com/chime-biologics-leads-biolabs-and-beigene-form-strategic-partnership-for-lag-3-mab-lbl-007/2025-01-06T18:16:10+08:00https://flcube.com/novartis-terminates-tigit-targeted-antibody-deal-with-beigene-retains-rights-to-ociperlimab/2025-01-06T18:16:09+08:00https://flcube.com/beigenes-tislelizumab-receives-positive-chmp-opinion-for-esophageal-cancer-treatment/2025-01-06T18:16:08+08:00https://flcube.com/beigenes-brukinsa-receives-us-fda-review-for-relapsed-refractory-follicular-lymphoma-snda/2025-01-06T18:16:08+08:00https://flcube.com/beigene-and-bristol-myers-squibb-celgene-settle-partnership-termination-set-for-2023/2025-01-06T18:16:07+08:00https://flcube.com/hainan-boao-lecheng-partners-with-beigene-to-boost-medical-tourism-and-biotech-innovation/2025-01-06T18:16:07+08:00https://flcube.com/beigenes-q2-2023-financial-report-highlights-81-8-yoy-product-revenue-growth/2025-01-06T18:16:06+08:00https://flcube.com/asieris-pharmaceuticals-apl-1202-shows-positive-interim-analysis-in-mibc-trial-with-beigenes-tislelizumab/2025-01-06T18:16:05+08:00https://flcube.com/luye-pharmas-botawei-receives-nmpa-approval-for-breast-cancer-treatment/2025-01-06T18:16:05+08:00https://flcube.com/beigene-regains-full-rights-to-tislelizumab-after-terminating-novartis-deal/2025-01-06T18:16:04+08:00https://flcube.com/nona-biosciences-and-beigene-form-partnership-to-advance-antibody-discovery/2025-01-06T18:16:04+08:00https://flcube.com/chinas-nhc-expands-rare-disease-list-includes-21-cancer-types/2025-01-06T18:16:03+08:00https://flcube.com/beigenes-brukinsa-receives-positive-chmp-opinion-for-follicular-lymphoma-treatment/2025-01-06T18:16:03+08:00https://flcube.com/beigene-submits-supplementary-bla-for-tislelizumab-in-small-cell-lung-cancer/2025-01-06T18:16:02+08:00https://flcube.com/beigenes-tislelizumab-shows-promising-results-in-esmo-presentations-for-gc-gejc-and-nsclc/2025-01-06T18:15:44+08:00https://flcube.com/beigenes-brukinsa-gains-nice-recommendation-for-cll-treatment-in-the-uk/2025-01-06T18:15:43+08:00https://flcube.com/amoy-diagnostics-receives-nmpa-approval-for-msi-detection-kit-as-companion-diagnostic-for-immunotherapy/2025-01-06T18:15:42+08:00https://flcube.com/beigenes-zw25-on-track-for-priority-review-for-cholangiocarcinoma-treatment-by-cde/2025-01-06T18:15:42+08:00https://flcube.com/zymeworks-and-beigene-terminate-licensing-agreement-for-zw49-adc/2025-01-06T18:15:41+08:00https://flcube.com/beigene-ltd-reports-q3-2023-financial-results-with-102-yoy-revenue-increase/2025-01-06T18:15:40+08:00https://flcube.com/ciie-2023-danaher-boehringer-ingelheim-merck-jj-beigene-and-fosun-pharma-announce-china-partnerships/2025-01-06T18:15:40+08:00https://flcube.com/beigene-ltd-opens-global-industrialization-base-for-small-molecule-drugs-in-suzhou/2025-01-06T18:15:39+08:00https://flcube.com/beigene-ltd-strikes-exclusive-global-license-deal-with-ensem-therapeutics-for-cdk2-inhibitor/2025-01-06T18:15:38+08:00https://flcube.com/beigenes-brukinsa-secures-additional-eu-approval-for-follicular-lymphoma-treatment/2025-01-06T18:15:38+08:00https://flcube.com/bio-thera-secures-fda-approval-for-avzivi-a-biosimilar-to-roches-avastin/2025-01-06T18:15:37+08:00https://flcube.com/beigenes-tislelizumab-secures-12th-indication-approval-in-china-for-hcc-first-line-treatment/2025-01-06T18:15:37+08:00https://flcube.com/beigene-submits-additional-application-for-tislelizumab-in-nsclc-in-china/2025-01-06T18:15:36+08:00https://flcube.com/beigenes-tislelizumab-receives-chmp-recommendation-for-three-nsclc-indications-in-europe/2025-01-06T18:15:35+08:00https://flcube.com/china-anti-cancer-association-forms-consortium-for-standardizing-cancer-research-ethics-reviews/2025-01-06T18:15:35+08:00https://flcube.com/beigenes-brukinsa-outperforms-acalabrutinib-in-maic-for-relapsed-refractory-cll-says-beigene/2025-01-06T18:15:34+08:00https://flcube.com/beigene-subsidiary-pi-health-cayman-to-be-merged-in-deal-valued-at-41-8-million/2025-01-06T18:15:34+08:00https://flcube.com/beigenes-brukinsa-receives-fda-approval-for-relapsed-or-refractory-follicular-lymphoma/2025-01-06T18:15:33+08:00https://flcube.com/beigene-launches-legal-action-against-sandoz-and-msn-over-brukinsa-patent-infringement/2025-01-06T18:15:32+08:00https://flcube.com/beigene-launches-charitable-access-program-for-brukinsa-in-low-income-countries/2025-01-06T18:15:32+08:00https://flcube.com/beigenes-tislelizumab-receives-fda-approval-for-esophageal-squamous-cell-carcinoma/2025-01-06T18:15:13+08:00https://flcube.com/beigene-terminates-partnership-with-shoreline-therapeutics-for-nk-cell-therapies/2025-01-06T18:15:12+08:00https://flcube.com/beigene-and-genfleet-join-forces-for-dlbcl-trial-combining-brukinsa-and-gfh009/2025-01-06T18:15:12+08:00https://flcube.com/mabwell-bioscience-receives-nmpa-approval-for-biosimilar-version-of-amgens-xgeva/2025-01-06T18:15:11+08:00https://flcube.com/beigene-launches-guangzhou-adc-production-park-to-strengthen-manufacturing-muscle/2025-01-06T18:15:10+08:00https://flcube.com/immuneonco-receives-nmpa-approval-for-phase-iii-clinical-trial-of-cd47-inhibitor-timdarpacept/2025-01-06T18:15:10+08:00https://flcube.com/beigenes-tislelizumab-secures-ec-approval-for-three-nsclc-indications/2025-01-06T18:15:09+08:00https://flcube.com/beigenes-q1-2024-revenue-jumps-68-yoy-on-strength-of-brukinsa-and-tislelizumab-sales/2025-01-06T18:15:08+08:00https://flcube.com/tislelizumab-approved-by-chinas-nmpa-as-first-line-therapy-for-gastric-cancer/2025-01-06T18:15:08+08:00https://flcube.com/beigenes-brukinsa-secures-conditional-approval-in-china-for-r-r-follicular-lymphoma/2025-01-06T18:15:07+08:00https://flcube.com/zymeworks-and-beigene-submit-bla-in-china-for-zanidatamab-as-second-line-her2-positive-btc-treatment/2025-01-06T18:15:06+08:00https://flcube.com/beigene-to-terminate-partnership-with-newbridge-pharmaceuticals-for-mena-region/2025-01-06T18:15:06+08:00https://flcube.com/beigenes-tislelizumab-approved-by-chinas-nmpa-for-first-line-extensive-stage-small-cell-lung-cancer/2025-01-06T18:15:05+08:00https://flcube.com/beigene-receives-nmpa-greenlight-for-bg-c9074-clinical-trial-in-advanced-solid-tumors/2025-01-06T18:15:05+08:00https://flcube.com/beigenes-q2-2024-revenues-surge-56-yoy-highlighted-by-strong-u-s-market-performance/2025-01-06T18:15:04+08:00https://flcube.com/beigene-launches-flagship-us-facility-in-new-jersey-to-expand-oncology-rd-and-manufacturing/2025-01-06T18:15:04+08:00https://flcube.com/beigene-advances-r-r-cll-sll-treatment-with-fda-fast-tracked-bgb-16673-in-phase-i-ii-clinical-trial/2025-01-06T18:15:03+08:00https://flcube.com/abbvie-accuses-beigene-of-trade-secret-theft-in-btk-degrader-dispute/2025-01-06T18:15:02+08:00https://flcube.com/beigene-positions-for-global-growth-with-strong-half-year-results-and-rd-investment/2025-01-06T18:15:02+08:00https://flcube.com/beigenes-tislelizumab-receives-israeli-nod-for-oesophageal-cancer-treatment/2025-01-06T18:15:01+08:00https://flcube.com/beigenes-fgfr2b-adc-bg-c137-enters-phase-i-clinical-trial-for-advanced-solid-tumors/2025-01-06T18:14:32+08:00https://flcube.com/beigene-prices-tevimbra-10-below-competitors-following-fda-approval-for-esophageal-cancer-treatment/2025-01-06T18:14:31+08:00https://flcube.com/beigenes-tevimbra-approved-in-china-for-nsclc-patients-as-neoadjuvant-and-adjuvant-therapy/2025-01-06T18:14:31+08:00https://flcube.com/guangzhou-releases-first-batch-of-innovative-drugs-and-medical-devices-list-featuring-local-companies/2025-01-06T18:14:30+08:00https://flcube.com/beigenes-pd-1-inhibitor-tevimbra-scores-first-us-prescription-offers-more-affordable-option/2025-01-06T18:14:29+08:00https://flcube.com/beigene-cco-yin-min-detained-amid-investigation-company-affirms-compliance-standards/2025-01-06T18:14:29+08:00https://flcube.com/astrazenecas-china-president-leon-wang-confirmed-to-assist-in-investigation-amid-fraud-allegations/2025-01-06T18:14:28+08:00https://flcube.com/shanghai-pharmaceutical-co-ltd-secures-multiple-partnerships-at-ciie/2025-01-06T18:14:28+08:00https://flcube.com/beigene-to-rebrand-as-beone-medicines-emphasizing-global-commitment-to-cancer-care/2025-01-06T18:14:27+08:00https://flcube.com/beigene-ltd-to-become-beone-medicines-ltd-emphasizing-global-oncology-commitment/2025-01-06T18:14:27+08:00https://flcube.com/beigene-reaches-patent-settlement-with-msn-pharmaceuticals-for-brukinsa/2025-01-06T18:14:26+08:00https://flcube.com/beigenes-tevimbra-receives-ec-approval-for-first-line-escc-and-g-gej-adenocarcinoma-treatments/2025-01-06T18:14:25+08:00https://flcube.com/zymeworks-and-jazz-pharmaceuticals-ziihera-gets-green-light-for-her2-btc-treatment/2025-01-06T18:14:25+08:00https://flcube.com/nanjing-leads-biolabs-commences-ipo-process-with-focus-on-innovative-therapies/2025-01-06T18:14:24+08:00https://flcube.com/mabwell-bioscience-enters-licensing-agreement-for-biosimilar-denosumab-in-peru/2025-01-06T18:14:23+08:00https://flcube.com/amgens-blincyto-meets-primary-endpoint-in-phase-iii-aall1731-study-for-pediatric-b-all/2025-01-06T18:14:22+08:00https://flcube.com/beigenes-tevimbra-receives-fda-approval-for-her2-negative-gastric-cancer-treatment/2025-01-06T18:14:21+08:00https://flcube.com/roche-partners-with-china-resource-medicine-to-promote-xofluza-in-china/2025-01-06T18:07:01+08:00https://flcube.com/jacobio-pharma-partners-with-merck-to-evaluate-cd73-mab-and-keytruda-combination/2025-01-06T18:03:58+08:00https://flcube.com/astrazenecas-calquence-receives-conditional-approval-in-china-for-mcl/2025-01-06T17:58:32+08:00https://flcube.com/biohaven-acquires-global-rights-for-dual-tyk2-jak1-inhibitor-bhv-8000-from-highlightll/2025-01-06T17:56:06+08:00https://flcube.com/hinova-pharmaceuticals-hc-1119-nda-accepted-for-review-by-nmpa/2025-01-06T17:50:01+08:00https://flcube.com/boehringer-ingelheim-initiates-phase-iii-fibroneer-studies-for-pde4b-inhibitor-bi-1015550/2025-01-06T17:47:44+08:00https://flcube.com/grand-pharmaceutical-group-reports-15-1-revenue-growth-in-2022-financials/2025-01-06T17:45:44+08:00https://flcube.com/ascentage-pharmas-2022-revenue-soars-with-olverembatinib-sales/2025-01-06T17:42:18+08:00https://flcube.com/ping-an-good-doctor-reports-revenue-decline-but-medical-services-growth-in-2022/2025-01-06T17:40:03+08:00https://flcube.com/jd-healthcare-reports-52-3-revenue-growth-in-2022-financial-report/2025-01-06T17:35:48+08:00https://flcube.com/wuxi-biologics-reports-48-4-revenue-growth-in-2022-financial-report/2025-01-06T17:33:05+08:00https://flcube.com/everest-medicines-partners-with-guangdong-provincial-peoples-hospital-in-kidney-disease-research/2025-01-06T17:30:20+08:00https://flcube.com/sihuan-pharmaceuticals-km501-receives-clinical-trial-approval-for-her2-positive-tumors/2025-01-06T17:27:53+08:00https://flcube.com/4b-technologies-fb1001-receives-cde-approval-for-clinical-trials/2025-01-06T17:25:14+08:00https://flcube.com/remegens-rc48-receives-two-clinical-trial-approvals-for-breast-cancer-treatments/2025-01-06T17:20:35+08:00https://flcube.com/chinas-plan-to-strengthen-medical-and-healthcare-service-system-unveiled/2025-01-06T17:16:55+08:00https://flcube.com/alphax-bio-raises-millions-for-spatial-proteomics-and-tumor-immune-microenvironment-research/2025-01-06T17:14:03+08:00https://flcube.com/luye-pharmas-lurbinectedin-gains-priority-review-status-for-sclc-treatment/2025-01-06T17:07:53+08:00https://flcube.com/guangdong-zhongshengs-ray1216-receives-conditional-approval-for-covid-19-treatment/2025-01-06T17:04:48+08:00https://flcube.com/hengrui-pharmaceuticals-hrs-5965-receives-nmpa-approval-for-clinical-study-in-hemolytic-anemia/2025-01-06T17:01:39+08:00https://flcube.com/sunshine-guojian-completes-patient-enrollment-for-ssgj-611-phase-ii-study-in-atopic-dermatitis/2025-01-06T16:58:55+08:00https://flcube.com/henlius-biotechs-serplulimab-accepted-for-ema-review-for-es-sclc-treatment/2025-01-06T16:55:39+08:00https://flcube.com/sino-biopharmaceuticals-f-star-therapeutics-signs-second-licensing-deal-with-takeda/2025-01-06T16:51:00+08:00https://flcube.com/zhaoke-ophthalmology-signs-distribution-agreement-with-kwangdong-for-nvk002-in-south-korea/2025-01-06T16:45:44+08:00https://flcube.com/yhlo-biotech-partners-with-ncrcid-to-develop-advanced-tuberculosis-diagnostics/2025-01-06T16:33:13+08:00https://flcube.com/everest-medicines-receives-280-million-from-gileads-immunomedics-following-partnership-cancellation/2025-01-06T16:30:51+08:00https://flcube.com/akeso-biopharma-and-lanova-medicines-collaborate-on-clinical-studies-for-cancer-therapies/2025-01-06T16:26:10+08:00https://flcube.com/gsks-nucala-receives-new-indication-approval-in-china-for-crswnp/2025-01-06T16:14:10+08:00https://flcube.com/chinas-healthcare-bureaus-remove-drug-quantity-limits-to-enhance-nrdl-access/2025-01-06T15:51:50+08:00https://flcube.com/shengwei-kunteng-raises-rmb-200-million-in-series-a-financing-for-poct-development/2025-01-06T15:01:00+08:00https://flcube.com/hangzhou-highlightll-pharma-completes-pre-series-c-financing-round/2025-01-06T14:41:51+08:00https://flcube.com/aosaikangs-generic-livtencity-accepted-for-review-by-chinas-nmpa/2025-01-06T14:34:25+08:00https://flcube.com/sinobioway-medicine-partners-with-happy-life-tech-for-clinical-trial-services/2025-01-06T14:15:48+08:00https://flcube.com/balance-medtechs-interventional-pulmonary-valve-receives-fast-track-designation-from-nmpa/2025-01-06T13:40:09+08:00https://flcube.com/micurx-pharmaceuticals-mrx-5-receives-nmpa-approval-for-ntm-infections-clinical-study/2025-01-06T13:00:09+08:00https://flcube.com/huahai-pharmaceuticals-hb0028-and-hb002-1t-cleared-for-clinical-study-by-nmpa/2025-01-06T12:49:47+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-approval-for-hrs-6768-clinical-trial/2025-01-06T12:37:56+08:00https://flcube.com/chinas-state-council-aims-to-enhance-drug-and-medical-device-regulation-by-2027/2025-01-06T12:28:09+08:00https://flcube.com/milestone-biotechnologies-secures-nearly-100-million-yuan-in-series-a-funding/2025-01-05T18:02:16+08:00https://flcube.com/astrazenecas-tagrisso-receives-nmpa-approval-for-egfr-mutated-nsclc-treatment/2025-01-03T21:24:09+08:00https://flcube.com/nmpa-approves-lynparza-as-adjuvant-treatment-for-high-risk-breast-cancer-patients/2025-01-03T21:13:39+08:00https://flcube.com/gilead-sciences-sunlenca-receives-nmpa-approval-for-multidrug-resistant-hiv-1-infection/2025-01-03T20:14:41+08:00https://flcube.com/winhealth-pharmas-difelikefalin-receives-nmpa-review-for-market-approval/2025-01-03T20:03:58+08:00https://flcube.com/shanghai-enacts-new-regulations-for-drug-and-medical-device-administration/2025-01-03T19:51:44+08:00https://flcube.com/thedermas-tan-118-receives-tacit-clinical-approval-from-chinas-cde-for-global-trials/2025-01-03T19:43:11+08:00https://flcube.com/shenzhen-hepalink-pharmaceuticals-to-distribute-gabapentin-in-us-under-new-agreement/2025-01-03T19:14:24+08:00https://flcube.com/innovent-biologics-taletrectinib-gains-nmpa-approval-for-ros1-positive-nsclc/2025-01-03T18:59:01+08:00https://flcube.com/zhaoke-ophthalmologys-nvk002-anda-accepted-for-review-by-chinas-nmpa/2025-01-03T18:36:09+08:00https://flcube.com/grand-pharmaceutical-initiates-study-on-gpn00289-for-liver-cancer-treatment/2025-01-03T18:09:32+08:00https://flcube.com/scg-cell-therapys-scg142-receives-nmpa-approval-for-hpv-related-solid-tumor-clinical-trial/2025-01-03T17:59:28+08:00https://flcube.com/huadong-medicines-hdm1005-receives-nmpa-approval-for-mafld-mash-clinical-trial/2025-01-03T17:32:55+08:00https://flcube.com/cygenta-partners-with-izvarino-pharma-for-comprehensive-cdmo-services/2025-01-03T16:45:59+08:00https://flcube.com/pfizer-collaborates-with-atavistik-bio-to-discover-allosteric-therapeutics/2025-01-03T15:48:31+08:00https://flcube.com/nmpa-grants-conditional-approval-for-chinas-first-mscs-therapy-for-agvhd/2025-01-03T14:55:59+08:00https://flcube.com/10th-national-vbp-round-results-announced-contracts-worth-over-rmb1-3-billion/2025-01-02T20:19:12+08:00https://flcube.com/genesis-medtechs-ireach-omnia-receives-nmpa-approval-for-rectal-cancer-surgery/2025-01-02T20:06:19+08:00https://flcube.com/eli-lilly-co-launches-mounjaro-tirzepatide-in-china-for-diabetes-and-weight-management/2025-01-02T19:56:58+08:00https://flcube.com/prime-gene-therapeutics-secures-over-rmb300-million-in-series-b-financing/2025-01-02T19:49:09+08:00https://flcube.com/brii-biosciences-to-acquire-full-rights-to-brii-179-from-vbi-vaccines/2025-01-02T19:35:08+08:00https://flcube.com/shanghai-pharmaceuticals-halts-development-of-i001-b-i022-and-c012-in-the-us/2025-01-02T14:24:34+08:00https://flcube.com/astellas-pharmas-vyloy-approved-by-nmpa-for-cldn18-2-positive-gastric-cancer/2025-01-02T13:49:57+08:00https://flcube.com/sichuan-kelun-biotechs-ketailai-receives-nmpa-approval-for-nasopharyngeal-carcinoma-treatment/2025-01-02T13:37:50+08:00https://flcube.com/sino-biopharmaceuticals-chia-tai-tianqing-secures-exclusive-promotion-rights-for-naldemedine-in-china/2025-01-02T13:22:50+08:00https://flcube.com/hutchmeds-orpathys-receives-priority-review-for-nsclc-treatment-in-china/2025-01-02T13:02:34+08:00https://flcube.com/innovent-biologics-strikes-licensing-deal-with-roche-for-ibi3009-adc/2025-01-02T12:51:54+08:00https://flcube.com/maxvax-biotechnology-secures-rmb-200-million-in-convertible-bonds-financing/2025-01-02T12:43:21+08:00https://flcube.com/zhaoke-ophthalmologys-tab014-achieves-positive-phase-iii-results-for-wamd/2025-01-02T12:15:01+08:00https://flcube.com/hutchmed-to-divest-45-stake-in-shanghai-hutchison-pharmaceuticals-for-608-million/2025-01-02T11:37:03+08:00https://flcube.com/lees-pharmaceutical-subsidiary-secures-distribution-deal-for-nvk002-in-south-korea/2025-01-01T13:33:13+08:00https://flcube.com/sihuan-pharmaceuticals-xzp-km602-and-xzp-6877-secure-clinical-trial-approvals-for-solid-tumors/2025-01-01T12:52:57+08:00https://flcube.com/shenzhen-yhlo-biotech-partners-with-ncrcid-for-advanced-tuberculosis-diagnostics/2025-01-01T12:45:22+08:00https://flcube.com/everest-medicines-receives-280-million-from-gilead-sciences-for-partnership-cancellation/2025-01-01T12:37:13+08:00https://flcube.com/akeso-biopharma-and-lanova-medicines-collaborate-on-ak112-and-lm-302-combo-for-solid-tumors/2025-01-01T12:25:01+08:00https://flcube.com/cspc-pharmaceuticals-mrna-vaccine-sys6006-receives-emergency-use-authorization-in-china-2/2025-01-01T12:03:24+08:00https://flcube.com/boston-scientific-launches-athletis-peripheral-balloon-dilatation-catheter-in-china-2/2025-01-01T11:58:43+08:00https://flcube.com/cde-launches-technical-guidelines-for-pediatric-anti-tumor-drug-clinical-rd/2025-01-01T11:47:21+08:00https://flcube.com/huarun-pharmaceutical-co-ltd-announces-private-placement-to-fund-expansion-projects/2025-01-01T11:44:55+08:00https://flcube.com/cde-releases-guidance-on-pre-phase-iii-clinical-trial-meetings-for-innovative-chemical-drugs/2025-01-01T11:42:09+08:00https://flcube.com/alphamab-oncologys-jskn033-advances-to-phase-iii-trial-for-platinum-resistant-ovarian-cancer/2025-01-01T11:11:08+08:00https://flcube.com/frontera-therapeutics-advances-to-phase-ii-with-ft-003-for-diabetic-macular-edema/2025-01-01T10:54:15+08:00https://flcube.com/johnson-johnsons-rybrevant-combo-approved-by-ec-for-first-line-nsclc-treatment/2025-01-01T10:37:35+08:00https://flcube.com/novartis-announces-positive-results-from-phase-iii-steer-study-on-sma-treatment/2025-01-01T10:03:25+08:00https://flcube.com/xtalpi-inc-partners-with-amazon-web-services-to-accelerate-life-sciences-innovation/2024-12-31T22:46:26+08:00https://flcube.com/jiangxi-jemincare-group-gets-nmpa-approval-for-prostate-cancer-drug-jmx-2006/2024-12-31T17:48:25+08:00https://flcube.com/carsgen-therapeutics-initiates-trial-for-universal-car-t-therapy-kj-c2219-in-china/2024-12-31T17:34:37+08:00https://flcube.com/we-doctor-holdings-limited-files-for-ipo-on-hong-kong-stock-exchange/2024-12-31T16:46:31+08:00https://flcube.com/shinva-medical-instrument-to-acquire-stake-in-wuhan-zhongzhi-biotechnologies-for-ivd-expansion/2024-12-31T14:58:30+08:00https://flcube.com/hinova-pharmaceuticals-hp568-earns-fda-clinical-trial-approval-for-er-her2-breast-cancer/2024-12-31T14:27:39+08:00https://flcube.com/cansino-biologics-menhycia-receives-market-approval-in-indonesia/2024-12-31T14:18:36+08:00https://flcube.com/cspc-pharmaceutical-group-receives-nmpa-approval-for-syh9016-clinical-study-in-solid-tumors/2024-12-31T13:47:29+08:00https://flcube.com/micurx-pharmaceuticals-mrx-5-receives-fda-orphan-drug-designation-for-ntm-infections/2024-12-30T22:44:16+08:00https://flcube.com/hengrui-pharmaceuticals-and-ideaya-biosciences-ink-licensing-deal-for-shr-4849/2024-12-30T22:38:51+08:00https://flcube.com/carsgen-therapeutics-satricabtagene-autoleucel-shows-positive-results-in-phase-ii-study/2024-12-30T22:30:30+08:00https://flcube.com/argenxs-vygart-hytrulo-approved-in-japan-for-chronic-inflammatory-demyelinating-polyneuropathy/2024-12-30T22:19:39+08:00https://flcube.com/daiichi-sankyos-datroway-approved-in-japan-for-hr-her2-breast-cancer/2024-12-30T21:15:16+08:00https://flcube.com/shanghai-ark-biopharmaceutical-partners-with-partex-to-advance-ai-driven-drug-development/2024-12-30T20:34:30+08:00https://flcube.com/zhongheng-group-and-fosun-pharmaceutical-form-jv-to-boost-overseas-business/2024-12-30T20:16:55+08:00https://flcube.com/huadong-medicine-partners-with-synerk-pharmatech-for-hypertension-sirna-drug-development/2024-12-30T19:45:31+08:00https://flcube.com/nmpa-releases-87th-batch-of-reference-drugs-for-generic-quality-consistency/2024-12-30T18:38:00+08:00https://flcube.com/bristol-myers-squibbs-opdivo-qvantig-receives-fda-approval-for-expanded-indications/2024-12-30T18:29:33+08:00https://flcube.com/hitgen-inc-initiates-phase-ii-clinical-trial-for-hg146-in-adenoid-cystic-carcinoma/2024-12-30T18:01:17+08:00https://flcube.com/reforgene-medicine-secures-hundreds-of-millions-in-financing-for-gene-therapy-expansion/2024-12-30T17:39:03+08:00https://flcube.com/xtalpi-inc-partners-with-nccs-and-duke-nus-to-advance-ai-driven-drug-discovery/2024-12-30T17:29:23+08:00https://flcube.com/danaher-corporation-opens-joint-office-in-beijings-chaoyang-district/2024-12-30T17:17:01+08:00https://flcube.com/wuxi-biologics-partners-with-sino-biopharmaceutical-for-first-in-class-monoclonal-antibody-development/2024-12-30T17:04:55+08:00https://flcube.com/hainan-free-trade-port-gets-green-light-for-temporary-import-of-special-medical-foods/2024-12-30T16:44:54+08:00https://flcube.com/cspc-pharmaceuticals-mrna-vaccine-sys6006-receives-emergency-use-authorization-in-china/2024-12-29T17:13:28+08:00https://flcube.com/boston-scientific-launches-athletis-peripheral-balloon-dilatation-catheter-in-china/2024-12-29T17:11:20+08:00https://flcube.com/cde-launches-technical-guidelines-for-pediatric-anti-tumor-drug-development/2024-12-29T17:09:19+08:00https://flcube.com/huarun-pharmaceutical-co-ltd-announces-private-placement-to-fund-expansion-and-rd/2024-12-29T17:07:13+08:00https://flcube.com/cde-issues-new-guidance-on-pre-phase-iii-clinical-trial-meetings-for-innovative-drugs/2024-12-29T17:01:28+08:00https://flcube.com/brii-biosciences-halts-development-of-antibody-cocktail-for-covid-19-treatment/2024-12-29T16:59:46+08:00https://flcube.com/berry-genomics-partners-with-mgi-tech-to-advance-cancer-diagnostics-and-screening/2024-12-29T16:57:50+08:00https://flcube.com/shanghai-bio-heart-begins-radius-htn-study-for-iberis-rdn-system-in-france/2024-12-29T16:52:29+08:00https://flcube.com/pharmablock-expands-us-presence-with-new-rd-facility-in-west-chester/2024-12-29T16:50:25+08:00https://flcube.com/cspc-pharmaceutical-receives-nmpa-approval-for-generic-otezla-equivalent/2024-12-29T16:45:14+08:00https://flcube.com/nmpa-introduces-procedures-to-adjust-chemical-generic-reference-preparations/2024-12-29T16:41:09+08:00https://flcube.com/bj-bioscience-partners-with-msd-for-phase-i-clinical-trial-of-bj-001-and-keytruda/2024-12-29T16:39:02+08:00https://flcube.com/acotec-scientifics-vericor-receives-marketing-approval-from-thailand-fda/2024-12-29T16:33:31+08:00https://flcube.com/canbridge-pharmaceuticals-completes-enrollment-in-phase-ii-gbm-trial-for-can008/2024-12-29T16:25:39+08:00https://flcube.com/chongqing-genrixs-xeligekimab-for-psoriasis-accepted-for-market-approval-review/2024-12-29T16:23:18+08:00https://flcube.com/genrix-bio-seeks-china-approval-for-new-xeligekimab-use-in-axial-spondyloarthritis/2024-12-29T16:19:45+08:00https://flcube.com/chongqing-genrix-bio-pharmaceutical-gets-nmpa-clearance-for-il-4r%ce%b1-mab-candidate-gr1802/2024-12-29T16:18:57+08:00https://flcube.com/genrix-bio-pharmaceutical-partners-with-china-resource-medicine-for-expanded-market-coverage/2024-12-29T16:18:03+08:00https://flcube.com/genrix-bio-and-chongqing-pharmaceutical-group-form-strategic-partnership-to-boost-market-launch/2024-12-29T16:16:46+08:00https://flcube.com/chongqing-genrixs-gr1803-earns-breakthrough-therapy-designation-in-china-for-rrmm-treatment/2024-12-29T16:15:57+08:00https://flcube.com/chongqing-genrix-bio-pharmaceutical-receives-nmpa-approval-for-xeligekimab-first-domestic-anti-il-17-antibody/2024-12-29T16:14:37+08:00https://flcube.com/jiangsu-hengrui-and-chongqing-genrix-launch-anti-il-17-therapies-for-psoriasis-in-china/2024-12-29T16:13:45+08:00https://flcube.com/jd-healthcare-and-genrix-bio-join-forces-to-revolutionize-patient-care-and-pharmacy-services/2024-12-29T16:13:16+08:00https://flcube.com/hansoh-pharmaceutical-reports-2022-revenues-and-highlights-growth-in-innovative-drugs/2024-12-29T16:07:33+08:00https://flcube.com/national-adr-monitoring-report-highlights-oncology-drugs-and-elderly-patient-safety/2024-12-29T16:05:10+08:00https://flcube.com/chinas-new-internet-advertising-regulations-impact-pharmaceutical-sector/2024-12-29T16:03:28+08:00https://flcube.com/fosun-pharma-reports-12-66-yoy-revenue-growth-and-increased-rd-investment-in-2022-financial-report/2024-12-29T16:01:43+08:00https://flcube.com/shenzhen-hepalinks-oncovent-secures-licensing-deal-with-orient-europharma-for-oregovomab/2024-12-29T15:58:42+08:00https://flcube.com/kintor-pharmaceutical-realigns-funds-from-covid-19-studies-to-other-pipeline-candidates/2024-12-29T15:46:52+08:00https://flcube.com/genor-biopharmas-lerociclib-accepted-for-review-by-chinas-nmpa-for-breast-cancer-treatment/2024-12-29T15:44:07+08:00https://flcube.com/pfizer-partners-with-hcrc-to-support-healthy-china-initiative/2024-12-29T15:42:00+08:00https://flcube.com/innovent-biologics-sees-6-7-revenue-increase-in-2022-amidst-rd-growth-and-product-expansion/2024-12-29T15:40:01+08:00https://flcube.com/astellas-pharma-executive-arrested-in-china-on-spying-allegations/2024-12-29T15:37:07+08:00https://flcube.com/chinas-nhsa-introduces-tiered-pricing-for-covid-19-therapies-a-b-and-c-categories/2024-12-29T15:35:08+08:00https://flcube.com/shanghai-pharmaceuticals-sph4336-earns-orphan-drug-status-for-liposarcoma-treatment/2024-12-29T15:33:34+08:00https://flcube.com/junshi-biosciences-and-rxilient-biotech-form-jv-to-commercialize-tuoyi-in-southeast-asia/2024-12-29T15:31:09+08:00https://flcube.com/novartis-kisqali-demonstrates-improved-idfs-in-phase-iii-natalee-study-for-early-breast-cancer/2024-12-29T15:22:53+08:00https://flcube.com/keymed-biosciences-cm310-achieves-primary-endpoints-in-phase-iii-atopic-dermatitis-study/2024-12-29T15:20:48+08:00https://flcube.com/broncus-medical-and-venus-medtech-establish-joint-venture-fund-for-digital-medical-equipment/2024-12-29T15:18:05+08:00https://flcube.com/astrazeneca-plans-tripled-rd-investment-in-china-aims-for-15-new-drugs-by-2030/2024-12-29T15:10:22+08:00https://flcube.com/burning-rock-reports-q4-2022-revenue-dip-but-10-9-full-year-growth/2024-12-29T15:03:20+08:00https://flcube.com/cde-grants-priority-review-status-to-tqb3454-hlx208-and-infigratinib-for-cancer-treatments/2024-12-29T14:54:45+08:00https://flcube.com/genfleet-therapeutics-submits-ipo-application-to-hkex-backed-by-citic-securities/2024-12-29T14:47:35+08:00https://flcube.com/overwhelming-shareholder-support-for-hengrui-pharmaceuticals-h-share-ipo/2024-12-29T14:09:39+08:00https://flcube.com/beijings-ql-bio-secures-tens-of-millions-in-funding-for-proteomics-platform-upgrade/2024-12-29T00:36:10+08:00https://flcube.com/round-8-vbp-tender-results-announced-with-rmb-21-6-billion-market/2024-12-29T00:27:43+08:00https://flcube.com/harbour-biomed-reports-846-5-yoy-revenue-increase-and-expands-rd-in-2022-financials/2024-12-29T00:26:10+08:00https://flcube.com/janssen-to-halt-rsv-adult-vaccine-development-impacting-phase-iii-trial/2024-12-29T00:23:55+08:00https://flcube.com/luye-pharma-group-reports-15-revenue-growth-in-2022-financial-results/2024-12-29T00:21:51+08:00https://flcube.com/pfizers-ritlecitinib-heads-for-priority-review-in-china-for-vitiligo-treatment/2024-12-29T00:19:30+08:00https://flcube.com/boston-scientific-partners-with-scivita-medtech-for-disposable-electronic-cholangioscope/2024-12-29T00:17:09+08:00https://flcube.com/transcentas-osemitamab-receives-fda-orphan-drug-designation-for-pancreatic-cancer/2024-12-29T00:12:46+08:00https://flcube.com/cnbg-partners-with-china-cdc-to-strengthen-disease-prevention-and-public-health/2024-12-29T00:10:26+08:00https://flcube.com/immuneonco-achieves-full-enrollment-in-phase-ii-study-of-imm01-for-cmml/2024-12-29T00:08:22+08:00https://flcube.com/everest-medicines-reports-2022-revenue-growth-and-pipeline-updates/2024-12-28T23:50:24+08:00https://flcube.com/cloudr-partners-with-banbiantian-to-digitalize-medicine-and-medical-device-sector/2024-12-28T23:48:14+08:00https://flcube.com/pharmaron-secures-uk-government-grant-to-expand-viral-vector-manufacturing-facility/2024-12-28T23:42:00+08:00https://flcube.com/hutchmed-completes-nda-submission-to-us-fda-for-frquintinib-in-metastatic-crc/2024-12-28T23:37:35+08:00https://flcube.com/apollomics-inc-completes-merger-with-maxpro-capital-lists-on-nasdaq-as-aplm/2024-12-28T23:27:44+08:00https://flcube.com/huadong-medicine-wins-nmpa-approval-for-liraglutide-biosimilar-for-type-2-diabetes/2024-12-28T23:22:58+08:00https://flcube.com/ablaze-pharma-charts-path-for-gpc3-targeted-polypeptide-with-rayzebio-partnership/2024-12-28T23:20:46+08:00https://flcube.com/fosun-pharmaceutical-gets-nmpa-approval-for-fcn-159-phase-ii-study-in-lch/2024-12-28T23:18:29+08:00https://flcube.com/shanghai-fosun-pharma-commences-phase-iii-trial-for-her2-targeted-fs-1502/2024-12-28T23:15:42+08:00https://flcube.com/kangtai-bio-partners-with-astrazeneca-and-combiphar-to-expand-vaccine-collaboration/2024-12-28T23:13:14+08:00https://flcube.com/cstone-pharmaceuticals-sugemalimab-study-published-in-jco-for-r-r-enktl-treatment/2024-12-28T23:08:00+08:00https://flcube.com/icecure-medical-gains-nmpa-approval-for-cryoablation-technology-in-china/2024-12-28T23:05:55+08:00https://flcube.com/scineuro-pharmaceuticals-and-secarna-pharmaceuticals-ink-cns-disease-research-deal/2024-12-28T22:54:38+08:00https://flcube.com/regimmune-and-san-fu-biotech-ink-deal-for-rgi-2001-development-in-asia/2024-12-28T22:47:12+08:00https://flcube.com/chinas-life-expectancy-on-track-to-surpass-81-3-years-by-2035-study-reveals/2024-12-28T22:39:32+08:00https://flcube.com/willingmed-secures-series-b-funding-to-advance-clinical-infection-diagnostics/2024-12-28T22:37:33+08:00https://flcube.com/cde-launches-guidelines-to-expedite-pediatric-and-rare-disease-drug-reviews/2024-12-28T22:33:25+08:00https://flcube.com/johnson-johnsons-talquetamab-on-track-for-breakthrough-therapy-designation-in-multiple-myeloma/2024-12-28T22:27:56+08:00https://flcube.com/cspc-pharmaceutical-receives-fda-approval-for-phase-i-study-of-cpo301-in-lung-cancer/2024-12-28T22:25:18+08:00https://flcube.com/shanghai-fosun-pharmaceutical-gets-nmpa-approval-for-fcn-338-phase-ii-study/2024-12-28T22:21:49+08:00https://flcube.com/mabwell-bioscience-receives-nmpa-approval-for-biosimilar-version-of-amgens-prolia/2024-12-28T22:17:10+08:00https://flcube.com/roches-cosentyx-300mg-dosage-approved-by-nmpa-for-ankylosing-spondylitis-treatment/2024-12-28T22:14:29+08:00https://flcube.com/changzhou-qianhong-bio-pharma-receives-nmpa-approval-for-qhrd107-phase-ii-aml-study/2024-12-28T22:11:45+08:00https://flcube.com/konruns-pharmaceutical-reports-positive-efficacy-results-for-kc1036-in-advanced-escc/2024-12-28T22:04:09+08:00https://flcube.com/healthstar-medical-commences-phase-iii-clinical-trial-for-kc1036-in-esophageal-cancer/2024-12-28T21:55:52+08:00https://flcube.com/healthstar-medical-receives-nmpa-go-ahead-for-kc1036-esophageal-cancer-study/2024-12-28T21:53:42+08:00https://flcube.com/healthstar-medical-gets-nmpa-approval-for-kc1036-clinical-study-in-juventus-sarcoma/2024-12-28T21:51:45+08:00https://flcube.com/healthstar-medical-launches-phase-iii-study-for-kc1036-in-advanced-esophageal-cancer/2024-12-28T21:49:51+08:00https://flcube.com/healthstar-medicals-kc1036-pediatric-indication-accepted-for-nmpa-review/2024-12-28T21:47:35+08:00https://flcube.com/boao-lecheng-medical-tourism-zone-partners-with-eye-valley-to-advance-ophthalmology-innovation/2024-12-28T21:35:21+08:00https://flcube.com/cellular-biomedicine-group-initiates-phase-iii-study-for-allojoin-in-knee-osteoarthritis/2024-12-28T21:30:58+08:00https://flcube.com/abbisko-therapeutics-secures-orphan-drug-designation-for-fgfr4-inhibitor-absk012/2024-12-28T21:07:16+08:00https://flcube.com/henlius-reports-91-1-revenue-growth-in-2022-driven-by-product-commercialization/2024-12-28T21:01:32+08:00https://flcube.com/dynamiker-biotechnology-receives-approval-for-ipo-on-beijing-stock-exchange/2024-12-28T20:54:19+08:00https://flcube.com/microport-endovascular-medtechs-castor-branched-stent-wins-china-patent-gold-award/2024-12-28T12:05:22+08:00https://flcube.com/oncosec-medicals-tavo-ep-combo-misses-primary-endpoint-in-melanoma-trial/2024-12-27T23:54:13+08:00https://flcube.com/legend-biotech-corporation-appoints-industry-veterans-to-strategic-advisory-board/2024-12-27T23:49:38+08:00https://flcube.com/beijing-tianjin-hebei-alliance-completes-vbp-tender-for-coronary-intervention-devices-with-78-29-price-cut/2024-12-27T23:27:49+08:00https://flcube.com/jacobio-pharma-receives-approval-for-phase-i-iia-study-of-lif-mab-in-advanced-solid-tumors/2024-12-27T23:26:00+08:00https://flcube.com/nanjing-zenshine-pharmaceuticals-zx-7101a-meets-primary-endpoint-in-phase-ii-influenza-study/2024-12-27T23:23:06+08:00https://flcube.com/wuxi-advanced-therapies-closes-manufacturing-facilities-in-shanghai-due-to-market-changes/2024-12-27T23:18:34+08:00https://flcube.com/sph-cansinobio-suspends-covid-19-vaccine-production-for-180-days-amid-market-shifts/2024-12-27T23:08:55+08:00https://flcube.com/cnbg-and-sinopharm-form-partnership-to-integrate-medical-industries/2024-12-27T23:01:37+08:00https://flcube.com/beijings-surgerii-secures-series-c3-financing-to-advance-endoscopic-surgical-robot-technology/2024-12-27T22:54:40+08:00https://flcube.com/lynk-pharmaceuticals-concludes-phase-i-study-for-jak-inhibitor-lnk01003-with-positive-results/2024-12-27T22:46:33+08:00https://flcube.com/sanofi-partners-with-shenzhens-pingshan-district-to-boost-innovative-vaccines-in-china/2024-12-27T22:41:38+08:00https://flcube.com/haisco-pharmaceutical-gets-cde-approval-for-hsk38008-prostate-cancer-clinical-study/2024-12-27T22:39:25+08:00https://flcube.com/yiling-pharmaceuticals-g201-na-receives-cde-approval-for-phase-ia-study-in-prostate-cancer-treatment/2024-12-27T22:36:52+08:00https://flcube.com/mabwells-9mw2821-adc-shows-positive-signals-in-solid-tumor-clinical-data/2024-12-27T22:34:40+08:00https://flcube.com/gates-foundation-and-nsfc-launch-partnership-to-boost-regulatory-science-in-vaccine-development/2024-12-27T22:32:22+08:00https://flcube.com/affamed-digital-initiates-clinical-study-for-amd201-at-beijing-tiantan-hospital/2024-12-27T22:29:47+08:00https://flcube.com/provincial-budgets-highlight-top-earning-hospitals-in-china-for-2023/2024-12-27T22:19:38+08:00https://flcube.com/corxel-pharmaceuticals-oc-01-nasal-spray-approved-as-urgently-needed-drug-in-hainan/2024-12-27T22:17:51+08:00https://flcube.com/harbour-biomeds-nona-biosciences-partners-with-exevir-bio-to-explore-infectious-disease-sector/2024-12-27T22:10:53+08:00https://flcube.com/abbvies-china-general-manager-ou-silang-steps-down-intercons-colzi-to-take-interim-role/2024-12-27T22:06:26+08:00https://flcube.com/allist-pharmaceuticals-furmonertinib-receives-nmpa-approval-for-two-clinical-trials/2024-12-27T22:04:07+08:00https://flcube.com/everest-medicines-nefecon-nda-accepted-for-review-by-singapores-hsa/2024-12-27T22:01:44+08:00https://flcube.com/hutchison-china-meditech-initiates-two-phase-ii-studies-for-hmpl-453-and-orpathys/2024-12-27T21:59:29+08:00https://flcube.com/evopoint-biosciences-partners-with-merck-for-phase-ib-ii-study-combining-xnw5004-and-keytruda/2024-12-27T21:55:55+08:00https://flcube.com/astrazeneca-and-hkstp-expand-collaboration-with-mou-to-support-start-ups/2024-12-27T21:52:40+08:00https://flcube.com/cstone-pharmaceuticals-sugemalimab-files-for-new-indication-with-nmpa-for-esophageal-cancer/2024-12-27T21:48:01+08:00https://flcube.com/biosion-receives-fda-approval-for-phase-ii-study-of-tslp-mab-bsi-045b/2024-12-27T21:46:00+08:00https://flcube.com/shanghai-best-link-bioscience-secures-29-million-in-series-a-financing-for-nano-drug-innovation/2024-12-27T21:43:41+08:00https://flcube.com/astrazeneca-china-announces-structural-adjustments-to-oncology-business-divisions/2024-12-27T17:25:55+08:00https://flcube.com/daiichi-sankyo-and-astrazeneca-withdraw-eu-application-for-datopotamab-deruxtecan-in-lung-cancer/2024-12-27T17:20:55+08:00https://flcube.com/beijing-releases-list-of-novel-drugs-and-technologies-exempt-from-chs-drg-payment-scheme/2024-12-27T16:49:21+08:00https://flcube.com/johnson-johnson-secures-licensing-deal-with-kaken-pharmaceutical-for-stat6-program/2024-12-27T16:39:10+08:00https://flcube.com/ascentage-pharma-announces-secondary-offering-on-nasdaq-expanding-global-reach/2024-12-27T16:24:08+08:00https://flcube.com/auzone-submits-nda-for-oral-edaravone-ttyp01-to-treat-als/2024-12-27T16:02:34+08:00https://flcube.com/pediatrix-therapeutics-neffy-nda-accepted-by-nmpa-for-allergy-treatment/2024-12-27T15:43:45+08:00https://flcube.com/immunochina-pharmaceuticals-and-cell-store-partner-to-advance-cell-therapy-commercialization-in-china/2024-12-27T15:25:41+08:00https://flcube.com/hinova-pharmaceuticals-enrolls-first-patient-in-phase-ii-study-for-hp518-in-mcrpc/2024-12-27T14:51:42+08:00https://flcube.com/xbiome-partners-with-zohealth-to-advance-microbiome-drug-development-and-precision-nutrition/2024-12-27T14:32:58+08:00https://flcube.com/astellas-pharma-partners-with-axcelead-ddp-for-targeted-protein-degraders-discovery/2024-12-27T14:20:38+08:00https://flcube.com/ausperbio-secures-73-million-in-series-b-financing-to-advance-hepatitis-b-therapy/2024-12-27T13:51:56+08:00https://flcube.com/advaccine-biotechnologys-microepad-receives-fda-registration-approval/2024-12-27T13:32:06+08:00https://flcube.com/shandong-buchang-pharmaceuticals-terminates-agreement-with-novast-laboratories/2024-12-27T13:19:51+08:00https://flcube.com/chia-tai-tianqings-benmelstobart-and-anlotinib-combo-meets-primary-endpoint-in-phase-iii-study/2024-12-27T13:03:19+08:00https://flcube.com/china-isotope-radiation-corporations-18f-piramide-receives-nmpa-clinical-trial-approval/2024-12-27T12:54:22+08:00https://flcube.com/circ-unveils-fuzhi-1-0-smart-nuclear-medicine-system-at-chinese-medical-association-meeting/2024-12-27T12:26:27+08:00https://flcube.com/china-isotope-radiation-corporation-to-establish-cancer-treatment-center-in-nigeria/2024-12-27T12:26:26+08:00https://flcube.com/china-isotope-radiation-corporation-secures-nmpa-license-for-innovative-radiotherapy-system/2024-12-27T12:26:25+08:00https://flcube.com/circs-subsidiary-hta-co-ltd-secures-nmpa-approval-for-sodium-fluoride-18f-for-bone-imaging/2024-12-27T12:26:24+08:00https://flcube.com/junshi-biosciences-challenges-alynlams-pcsk9-sirna-patent-with-cnipa/2024-12-26T21:49:39+08:00https://flcube.com/apollobio-partners-with-baidu-health-to-enhance-marketing-of-igm-nano-immunoglobulin-spray/2024-12-26T21:42:58+08:00https://flcube.com/chinas-provincial-governments-implement-second-batch-of-national-drug-use-monitoring-policy/2024-12-26T21:39:09+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-gets-singapore-regulatory-approval-for-177lu-lnc1004-phase-i-study/2024-12-26T21:37:21+08:00https://flcube.com/acostream-second-generation-receives-nmpa-marketing-approval-for-peripheral-vascular-use/2024-12-26T21:34:34+08:00https://flcube.com/shenzhen-kangtai-biological-partners-with-biotis-for-13-valent-pneumococcal-vaccine-in-indonesia/2024-12-26T21:32:08+08:00https://flcube.com/harbour-biomed-and-astrazeneca-partner-to-advance-pharmaceutical-innovation-in-yangtze-river-delta/2024-12-26T21:17:47+08:00https://flcube.com/shuwen-biotechs-subsidiary-signs-promotion-agreement-with-sysmex-europe-for-breast-cancer-detection-product/2024-12-26T21:00:50+08:00https://flcube.com/vcanbio-receives-cde-approval-for-vum02-clinical-trial-in-idiopathic-pulmonary-fibrosis/2024-12-26T20:54:02+08:00https://flcube.com/luye-pharma-group-partners-with-duopharma-for-exclusive-marketing-rights-of-tcm-in-malaysia/2024-12-26T20:51:25+08:00https://flcube.com/scorpion-therapeutics-and-pierre-fabre-collaborate-on-nsclc-therapies-stx-721-and-stx-241/2024-12-26T20:46:14+08:00https://flcube.com/hybio-pharmaceutical-receives-us-fda-approval-for-biosimilar-victoza-liraglutide/2024-12-26T17:36:24+08:00https://flcube.com/shanxi-cy-pharmaceutical-initiates-clinical-study-for-generic-ferric-maltol-with-nmpa-approval/2024-12-26T17:10:54+08:00https://flcube.com/boji-medical-technology-receives-nmpa-approval-for-tba-clinical-study-in-drug-resistant-tuberculosis/2024-12-26T16:45:25+08:00https://flcube.com/guangzhou-boji-medical-and-capitalbio-pharma-form-joint-venture-to-innovate-in-traditional-chinese-medicine/2024-12-26T16:33:34+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-secures-nmpa-approvals-for-prostate-cancer-and-solid-tumor-clinical-trials/2024-12-26T16:27:39+08:00https://flcube.com/sichuan-biokins-bl-m08d1-and-cspcs-sys6010-eye-breakthrough-therapy-designations-in-china/2024-12-26T14:31:40+08:00https://flcube.com/cde-indicates-priority-review-for-boehringer-ingelheims-zongertinib-and-peers/2024-12-26T14:14:18+08:00https://flcube.com/zelgen-biopharmaceuticals-zg005-gets-nmpa-green-light-for-solid-tumor-and-lymphoma-clinical-trial/2024-12-26T13:52:55+08:00https://flcube.com/western-chongqing-southern-sichuan-precision-medicine-center-digital-platform-launches-in-rongchang-district/2024-12-26T13:41:55+08:00https://flcube.com/innovent-biologics-partners-with-suzhou-forlong-to-explore-sintilimab-and-fl115-combination-in-solid-tumors/2024-12-26T13:11:22+08:00https://flcube.com/zhejiang-huahai-pharmaceuticals-subsidiary-huaota-bio-secures-27-4-million-investment/2024-12-26T10:59:31+08:00https://flcube.com/cstone-pharmaceuticals-reduces-ayvakit-price-to-boost-accessibility-in-china/2024-12-26T01:26:20+08:00https://flcube.com/bioyond-robotics-secures-29-million-in-series-a-and-a-financing-rounds/2024-12-26T01:25:24+08:00https://flcube.com/henan-province-sees-53-6-price-reduction-in-neuro-and-peripheral-intervention-consumables-tender/2024-12-26T01:17:10+08:00https://flcube.com/jiangsu-hillgene-biopharma-secures-tens-of-millions-in-series-a-financing-for-cell-therapy-rd/2024-12-26T01:14:36+08:00https://flcube.com/forecyte-bio-expands-with-new-cell-and-gene-therapy-gmp-facility-in-shanghai/2024-12-26T01:08:26+08:00https://flcube.com/yiling-pharmaceuticals-xy0206-advances-to-phase-iii-trial-for-flt3-itd-aml/2024-12-26T01:03:15+08:00https://flcube.com/jiangsu-yuyue-medical-secures-nmpa-approval-for-semi-automatic-external-defibrillator/2024-12-26T01:00:45+08:00https://flcube.com/jiangsu-yuyue-medical-teams-up-with-china-unicom-for-digital-healthcare-innovation/2024-12-26T00:57:21+08:00https://flcube.com/jiangsu-yuyue-medical-equipment-partners-with-tuv-sud-to-boost-medical-device-market-access/2024-12-26T00:57:20+08:00https://flcube.com/micurx-pharmaceuticals-initiates-phase-iii-study-for-mrx-4-in-diabetic-foot-infection-treatment/2024-12-26T00:52:01+08:00https://flcube.com/astrazeneca-partners-with-guangzhou-institute-to-advance-respiratory-medicine-research/2024-12-26T00:49:58+08:00https://flcube.com/indonesia-and-china-deepen-healthcare-ties-with-high-level-dialogue-and-new-agreements/2024-12-26T00:47:31+08:00https://flcube.com/shanxi-province-begins-historical-procurement-data-collection-for-pacemaker-vbp-round/2024-12-26T00:40:34+08:00https://flcube.com/tyk-medicines-secures-fda-approval-for-next-generation-tki-clinical-trial/2024-12-26T00:39:05+08:00https://flcube.com/sequanta-technologies-partners-with-element-biosciences-to-expand-single-cell-applications/2024-12-26T00:37:03+08:00https://flcube.com/fujian-healthcare-security-bureau-updates-sunshine-procurement-mechanism-for-drugs/2024-12-26T00:32:12+08:00https://flcube.com/yifan-pharmaceutical-receives-nmpa-approval-for-hyruan-one-in-knee-osteoarthritis-treatment/2024-12-26T00:30:02+08:00https://flcube.com/fda-issues-complete-response-letters-to-six-novel-drugs-in-q1-2023/2024-12-26T00:24:53+08:00https://flcube.com/bristol-myers-squibbs-sotyktu-meets-primary-endpoints-in-poetyk-psa-studies/2024-12-25T23:36:59+08:00https://flcube.com/bio-thera-solutions-enters-licensing-agreement-with-tabuk-pharmaceutical-for-bat2206-in-saudi-arabia/2024-12-25T23:29:19+08:00https://flcube.com/achilles-therapeutics-and-astrazeneca-seal-12-billion-deal-for-tracerx-nsclc-study-data/2024-12-25T22:52:58+08:00https://flcube.com/nuvation-bios-taletrectinib-nda-for-ros1-nsclc-receives-fda-priority-review/2024-12-25T15:33:06+08:00https://flcube.com/shanghai-henlius-biotech-initiates-patient-dosing-in-global-phase-iii-elaine-3-study-for-lasofoxifene/2024-12-25T15:15:39+08:00https://flcube.com/bristol-myers-squibb-launches-zeposia-in-china-for-multiple-sclerosis-treatment/2024-12-25T15:00:57+08:00https://flcube.com/hubei-implements-inter-provincial-vbp-tender-results-for-pacemakers/2024-12-25T14:57:48+08:00https://flcube.com/zelgen-biopharmaceuticals-zg006-earns-fda-approval-for-small-cell-lung-cancer-trial/2024-12-25T14:56:10+08:00https://flcube.com/jw-therapeutics-carteyva-receives-nmpa-approval-for-moderate-to-severe-sle-clinical-trial/2024-12-25T14:52:06+08:00https://flcube.com/hua-medicine-partners-with-111-inc-for-dorzagliatin-sales-and-distribution-in-china/2024-12-25T14:41:38+08:00https://flcube.com/hangzhou-baikai-biomedical-and-leads-biolabs-partner-to-develop-innovative-adcs/2024-12-25T14:28:56+08:00https://flcube.com/nhc-report-performance-assessment-of-national-class-2-public-hospitals-in-2021/2024-12-25T14:18:07+08:00https://flcube.com/cuban-chinese-biotechnology-center-showcases-drug-and-vaccine-progress-to-cuban-delegation/2024-12-25T14:15:43+08:00https://flcube.com/takeda-pharmas-iclusig-poised-for-priority-review-by-cde-for-leukemia-treatments/2024-12-25T14:08:09+08:00https://flcube.com/arctic-vision-partners-with-sinopharm-group-for-ophthalmic-product-distribution-in-china/2024-12-25T14:04:01+08:00https://flcube.com/raysightmeds-angioqfa-100-receives-nmpa-approval-for-coronary-artery-function-measurement/2024-12-25T13:33:29+08:00https://flcube.com/ubrigene-secures-rmb-200-million-in-pre-series-d-financing-to-expand-atmps-cdmo-services/2024-12-25T12:57:01+08:00https://flcube.com/wuxi-apptec-to-divest-wuxi-advanced-therapies-and-oxford-genetics-to-altaris-llc/2024-12-25T12:36:32+08:00https://flcube.com/basecare-medical-and-solarcare-form-alliance-to-advance-ai-in-ivf-services/2024-12-25T12:06:35+08:00https://flcube.com/alphamab-oncologys-jskn033-gets-green-light-for-phase-i-ii-study-from-chinas-cde/2024-12-25T11:14:56+08:00https://flcube.com/shanghai-bio-hearts-iberis-rdn-system-meets-primary-endpoint-in-iberis-htn-study/2024-12-25T00:01:03+08:00https://flcube.com/grand-pharmaceuticals-app13007-achieves-clinical-endpoints-in-us-trials-for-post-operative-treatment/2024-12-24T23:58:09+08:00https://flcube.com/sirnaomics-commences-phase-i-clinical-trial-for-factor-xl-rnai-drug-stp122g/2024-12-24T23:46:15+08:00https://flcube.com/shanghai-fosun-pharmaceutical-submits-market-approval-filing-for-daxibotulinumtoxin-a-in-china/2024-12-24T21:38:16+08:00https://flcube.com/junshi-biosciences-senaparib-meets-primary-endpoint-in-phase-iii-ovarian-cancer-study/2024-12-24T21:36:06+08:00https://flcube.com/porton-pharma-solutions-expands-with-biomacromolecules-rd-and-manufacturing-center-in-shanghai/2024-12-24T21:32:49+08:00https://flcube.com/blueray-med-secures-tens-of-millions-in-series-a-financing-for-advanced-laser-medicine-devices/2024-12-24T21:29:42+08:00https://flcube.com/specialised-therapeutics-to-commercialize-akesos-pd-1-inhibitor-penpulimab-in-apac/2024-12-24T21:24:45+08:00https://flcube.com/legend-biotech-appoints-dr-mythili-koneru-as-chief-medical-officer-to-lead-clinical-development/2024-12-24T21:19:35+08:00https://flcube.com/luye-pharmas-bevacizumab-biosimilar-accepted-for-review-in-brazil-by-anvisa/2024-12-24T21:17:43+08:00https://flcube.com/round-8-vbp-tender-results-rmb-3-775-billion-awarded-across-152-manufacturers/2024-12-24T21:14:52+08:00https://flcube.com/priority-review-status-anticipated-for-hh-003-bi655130-vis649-and-remternetug-by-cde/2024-12-24T20:43:57+08:00https://flcube.com/diapin-therapeutics-announces-breakthrough-preclinical-results-for-dt-109-in-nash-treatment/2024-12-24T20:36:35+08:00https://flcube.com/convalife-pharmaceuticals-mefuparib-earns-orphan-drug-designation-for-cholangiocarcinoma/2024-12-24T20:32:02+08:00https://flcube.com/vintabio-secures-64m-funding-to-revolutionize-viral-vectors-for-cell-and-gene-therapy/2024-12-24T20:29:48+08:00https://flcube.com/alebund-pharmaceuticals-secures-29m-in-pre-series-c-funding-and-116m-loan-for-rd-and-manufacturing/2024-12-24T20:24:49+08:00https://flcube.com/overland-adct-biopharma-achieves-primary-endpoint-in-zynlonta-phase-ii-study-for-r-r-dlbcl/2024-12-24T20:20:57+08:00https://flcube.com/novartis-jakavi-secures-nmpa-approval-for-acute-gvhd-treatment-in-china/2024-12-24T20:17:04+08:00https://flcube.com/chengdu-hyperway-pharmaceuticals-hbw-004285-gets-nmpa-tacit-approval-for-pain-treatment/2024-12-24T20:14:36+08:00https://flcube.com/cspc-pharmaceuticals-syh2062-receives-nmpa-clearance-for-hypertension-treatment/2024-12-24T17:38:48+08:00https://flcube.com/keymed-biosciences-kangyueda-approved-for-crswnp-treatment-in-china/2024-12-24T17:27:19+08:00https://flcube.com/sichuan-biokins-gnc-038-tetra-specific-antibody-clears-for-clinical-trials-in-autoimmune-diseases/2024-12-24T17:03:51+08:00https://flcube.com/changchun-high-new-technology-industries-receives-fda-approval-for-menopausal-vms-drug-trial/2024-12-24T16:53:06+08:00https://flcube.com/changchun-high-new-technology-industries-to-launch-gensci125-phase-i-trial-in-us/2024-12-24T16:38:05+08:00https://flcube.com/changchun-high-new-technology-to-transfer-7-42-stake-to-ex-wife-in-divorce-settlement/2024-12-24T16:38:05+08:00https://flcube.com/changchun-high-new-technology-industries-gets-green-light-for-jinnamab-clinical-trial/2024-12-24T16:38:04+08:00https://flcube.com/changchun-high-new-technology-secures-nmpa-approval-for-turner-syndrome-treatment/2024-12-24T16:38:03+08:00https://flcube.com/changchun-high-new-technology-industries-receives-fda-approval-for-gensci098-clinical-trial-in-thyroid-eye-disease/2024-12-24T16:38:03+08:00https://flcube.com/changchun-high-new-technology-industries-receives-fda-tacit-approval-for-gensci122-clinical-study/2024-12-24T16:38:02+08:00https://flcube.com/changchun-high-new-technology-industries-receives-nmpa-approval-for-long-acting-somatropin/2024-12-24T16:38:01+08:00https://flcube.com/astrazenecas-tagrisso-secures-eu-approval-for-egfr-mutated-locally-advanced-nsclc/2024-12-24T16:23:49+08:00https://flcube.com/ikena-oncology-and-inmagene-biopharmaceuticals-to-merge-into-imagenebio-listed-on-nasdaq-as-ima/2024-12-24T16:07:06+08:00https://flcube.com/sanofi-and-sk-bioscience-broaden-partnership-to-develop-next-gen-pneumococcal-vaccines/2024-12-24T15:53:52+08:00https://flcube.com/corxel-pharmaceuticals-secures-global-rights-to-cx11-a-novel-oral-glp-1-ra-in-licensing-deal-with-vincentage/2024-12-24T15:39:43+08:00https://flcube.com/etern-therapeutics-yap-tead-inhibitor-ets-006-wins-fda-clinical-approval-for-advanced-solid-tumors/2024-12-24T15:12:57+08:00https://flcube.com/bristol-myers-squibbs-opdivo-yervoy-combo-approved-by-ec-for-msi-h-mcrc/2024-12-24T14:47:08+08:00https://flcube.com/porton-pharma-and-dragon-sail-join-forces-to-enhance-adc-drug-development/2024-12-24T14:30:28+08:00https://flcube.com/rapt-therapeutics-secures-ex-china-rights-to-jemincare-groups-anti-ige-antibody-jyb1904/2024-12-24T14:29:32+08:00https://flcube.com/beigene-rebrands-to-beone-medicines-ltd-ticker-symbol-changes-to-onc/2024-12-24T14:27:31+08:00https://flcube.com/roches-lunsumio-receives-nmpa-approval-for-r-r-follicular-lymphoma-treatment/2024-12-24T14:24:04+08:00https://flcube.com/remegens-disitamab-vedotin-rc48-clears-for-phase-i-study-in-her2-positive-tumors/2024-12-24T13:24:32+08:00https://flcube.com/junshi-biosciences-js401-receives-nmpa-approval-for-hyperlipidemia-clinical-trial/2024-12-24T13:21:37+08:00https://flcube.com/jiangxi-jemincare-group-secures-exclusive-rights-to-promote-mabpharms-biosimilar-cmab007/2024-12-24T13:18:49+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-meituan-for-digital-healthcare-services-expansion/2024-12-24T13:15:05+08:00https://flcube.com/ocumension-therapeutics-zerviate-nda-accepted-for-review-by-chinas-nmpa/2024-12-24T13:08:59+08:00https://flcube.com/pfizer-and-sinopharm-expand-partnership-to-enhance-drug-distribution-and-lifecycle-solutions/2024-12-24T13:05:20+08:00https://flcube.com/fosun-pharmaceuticals-fcn-159-earns-breakthrough-therapy-designation-for-histiocyte-tumors/2024-12-24T13:01:56+08:00https://flcube.com/aosaikang-pharmaceutical-receives-nmpa-review-for-askc200-liniment-from-propella-therapeutics/2024-12-24T12:58:50+08:00https://flcube.com/huidagene-therapeutics-enhances-crispr-cas12f-system-with-higher-editing-efficiency/2024-12-24T12:55:38+08:00https://flcube.com/shanghais-pharmalegacy-files-for-ipo-on-star-targets-pre-clinical-rd-expansion/2024-12-24T12:42:08+08:00https://flcube.com/huadong-medicine-reports-9-12-yoy-revenue-growth-and-13-24-increase-in-net-profits-for-2022/2024-12-24T12:21:53+08:00https://flcube.com/neurophth-biotechnology-receives-nmpa-approval-for-phase-i-ii-gene-therapy-study/2024-12-24T12:14:45+08:00https://flcube.com/shenzhen-core-medical-technology-secures-rmb-200-million-in-series-c-financing-for-artificial-heart-tech/2024-12-24T12:12:15+08:00https://flcube.com/hainan-poly-pharm-wins-health-canada-approval-for-generic-cytovene-iv-ganciclovir/2024-12-24T12:05:15+08:00https://flcube.com/zephyrm-bioscience-secures-over-rmb-200-million-in-series-b-financing-for-stem-cell-drug-development/2024-12-24T11:35:38+08:00https://flcube.com/zephyrm-bioscience-limited-files-for-ipo-on-hong-kong-stock-exchange/2024-12-24T11:31:49+08:00https://flcube.com/zephyrm-biotechnologies-aims-for-hkex-main-board-with-innovative-cell-therapy-products/2024-12-24T11:31:01+08:00https://flcube.com/legend-biotech-and-janssen-partner-with-novartis-on-carvykti-manufacturing-and-clinical-supply/2024-12-24T11:21:49+08:00https://flcube.com/cansino-biologics-receives-nmpa-approval-for-bivalent-covid-19-mrna-vaccine/2024-12-24T11:17:45+08:00https://flcube.com/js-innopharm-initiates-phase-ib-study-of-aurka-inhibitor-vic-1911-for-egfr-tki-resistant-nsclc/2024-12-24T11:12:43+08:00https://flcube.com/simcere-pharmaceutical-group-reports-26-4-yoy-revenue-growth-in-2022-financials/2024-12-24T11:05:49+08:00https://flcube.com/henlius-reports-97-2-yoy-revenue-growth-in-q1-2023-highlighted-by-strong-sales-of-hanquyou-and-haisizhuang/2024-12-24T11:02:44+08:00https://flcube.com/hainan-introduces-management-regulations-for-urgently-needed-import-drugs-and-devices-in-boao-lecheng/2024-12-24T10:59:42+08:00https://flcube.com/minghui-pharmaceuticals-mh004-cream-shows-positive-results-in-atopic-dermatitis-phase-ii-trial/2024-12-24T10:57:45+08:00https://flcube.com/affamed-therapeutics-gets-nmpa-approval-for-phase-iii-dextenza-study-in-post-ophthalmic-surgery/2024-12-24T10:55:43+08:00https://flcube.com/nhc-proposes-updates-to-access-standards-for-class-a-and-b-medical-equipment/2024-12-24T10:53:09+08:00https://flcube.com/harbour-biomed-to-present-early-clinical-data-for-ctla-4-antibody-combo-at-aacr-2023/2024-12-24T10:47:32+08:00https://flcube.com/merck-and-xtalpi-leverage-molecular-dynamics-to-enhance-small-molecule-crystallization/2024-12-24T10:43:00+08:00https://flcube.com/hanchorbio-receives-fda-approval-for-multi-region-clinical-study-of-hcb101-fusion-protein/2024-12-23T23:37:32+08:00https://flcube.com/hainans-boao-lecheng-partners-with-sonova-to-advance-hearing-health-solutions-in-china/2024-12-23T23:35:13+08:00https://flcube.com/nanjing-chamlion-laser-technology-secures-rmb-236-million-in-series-b-financing-for-dental-3d-printing/2024-12-23T23:30:43+08:00https://flcube.com/hutchmeds-elunate-receives-nmpa-review-for-second-line-gastric-cancer-treatment/2024-12-23T23:25:18+08:00https://flcube.com/huidagene-receives-cde-ind-approval-for-ophthalmology-gene-therapy-hg004/2024-12-23T23:21:44+08:00https://flcube.com/cbmgs-c-car031-shows-promising-results-in-phase-i-study-for-hepatocellular-carcinoma/2024-12-23T23:19:17+08:00https://flcube.com/cansino-biologics-reports-2022-revenue-drop-and-increased-losses-amid-covid-19-vaccine-market-shifts/2024-12-23T23:17:00+08:00https://flcube.com/packgene-secures-series-c-financing-to-boost-aav-innovation-and-global-expansion/2024-12-23T22:46:27+08:00https://flcube.com/bioworkshops-secures-rmb-100-million-in-series-a-financing-for-biologic-drug-development/2024-12-23T22:42:13+08:00https://flcube.com/sinovation-medicals-sinolitt-system-and-fiber-kit-gain-nmpa-approval-for-epilepsy-treatment/2024-12-23T22:37:51+08:00https://flcube.com/biosyngen-receives-us-fda-ind-approval-for-t-cell-redirection-therapy-for-ebv-positive-lymphoma/2024-12-23T22:33:09+08:00https://flcube.com/eoc-pharma-group-partners-with-china-national-accord-medicines-for-distribution-rights/2024-12-23T22:30:56+08:00https://flcube.com/ubrigene-secures-rmb-150-million-in-series-c-financing-to-expand-global-cgt-cdmo-platform/2024-12-23T22:25:08+08:00https://flcube.com/shanghai-huikai-medical-technology-secures-series-a-funding-for-prostate-stent-system/2024-12-23T21:54:24+08:00https://flcube.com/shandong-jincheng-pharmaceutical-initiates-phase-ii-study-for-lt-01-antibacterial-drug/2024-12-23T21:48:52+08:00https://flcube.com/apollobios-hpv-therapeutic-vaccine-vgx-3100-gets-nmpa-green-light-for-clinical-trial/2024-12-23T21:44:47+08:00https://flcube.com/remegen-ltd-partners-with-shandong-cancer-hospital-for-adc-development-and-integrated-system/2024-12-23T21:39:37+08:00https://flcube.com/nona-biosciences-partners-with-dr-michael-s-diamond-for-viral-disease-monoclonal-antibody-research/2024-12-23T21:35:40+08:00https://flcube.com/everest-medicines-and-sph-keyuan-ink-mou-to-expand-xerava-distribution-in-china/2024-12-23T21:29:52+08:00https://flcube.com/innovent-biologics-presents-ibi351-phase-i-results-at-aacr-annual-meeting/2024-12-23T21:20:24+08:00https://flcube.com/national-center-reports-increase-in-medical-device-adverse-event-reports-for-2022/2024-12-23T21:18:07+08:00https://flcube.com/chinas-nmpa-mps-and-nhc-announce-updates-to-narcotics-and-psychotropic-substances-catalog/2024-12-23T21:16:23+08:00https://flcube.com/china-resources-biopharmaceutical-partners-with-hefei-institute-and-afana-bio-for-joint-lab/2024-12-23T21:13:53+08:00https://flcube.com/xzenith-biopharm-completes-enrollment-in-phase-ii-study-for-proton-pump-inhibitor/2024-12-23T21:04:59+08:00https://flcube.com/adagene-inc-presents-positive-interim-results-for-adg126-at-aacr-annual-meeting/2024-12-23T21:00:30+08:00https://flcube.com/legend-biotechs-carvykti-data-boosts-stock-price-by-19-64-on-positive-phase-iii-results/2024-12-23T19:01:10+08:00https://flcube.com/acotec-scientific-holdings-receives-nmpa-approval-for-paclitaxel-coated-balloon-dilation-catheter/2024-12-23T18:58:55+08:00https://flcube.com/carsgen-therapeutics-ct041-receives-nmpa-approval-for-post-operative-pancreatic-cancer-therapy/2024-12-23T18:56:32+08:00https://flcube.com/zelgen-biopharmaceuticals-zg2001-receives-nmpa-approval-for-clinical-trials/2024-12-23T18:53:57+08:00https://flcube.com/beijing-aosaikangs-askg915-receives-nmpa-approval-for-clinical-trials-in-advanced-solid-tumors/2024-12-23T18:51:09+08:00https://flcube.com/innocare-pharmas-orelabrutinib-gains-nmpa-approval-for-recurrent-refractory-mzl-treatment/2024-12-23T18:48:10+08:00https://flcube.com/walvax-biotechnologys-rq3013-mrna-vaccine-shows-efficacy-in-phase-iii-study/2024-12-23T18:45:31+08:00https://flcube.com/nmpas-2022-drug-supervision-report-clinical-trials-and-market-filings-on-the-rise/2024-12-23T18:42:48+08:00https://flcube.com/alcon-laboratories-innovative-intraocular-lens-approved-by-chinas-nmpa/2024-12-23T18:40:45+08:00https://flcube.com/gsks-jemperli-combo-shows-improved-pfs-in-phase-iii-ovarian-cancer-trial/2024-12-23T17:41:46+08:00https://flcube.com/pfizers-braftovi-receives-fda-approval-for-metastatic-colorectal-cancer-treatment/2024-12-23T17:01:51+08:00https://flcube.com/shenzhen-chipscreen-biosciences-gets-nmpa-approval-for-cs231295-solid-tumor-study/2024-12-23T16:42:02+08:00https://flcube.com/eli-lillys-zepbound-receives-fda-approval-for-moderate-to-severe-osa-and-obesity/2024-12-23T16:40:55+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-gets-nmpa-approval-to-test-shr-1681-in-clinical-trials/2024-12-23T16:39:47+08:00https://flcube.com/cspc-pharmaceuticals-syh9017-receives-nmpa-clearance-for-weight-management-clinical-trial/2024-12-23T16:36:20+08:00https://flcube.com/cspc-pharmaceutical-group-receives-nmpa-approval-for-two-antibody-drug-conjugates/2024-12-23T16:35:12+08:00https://flcube.com/cansino-biologics-initiates-phase-i-ii-study-for-cs-2036-polio-vaccine-with-gates-foundation-support/2024-12-23T16:34:28+08:00https://flcube.com/innovent-biologics-taletrectinib-wins-nmpa-approval-for-ros1-nsclc-treatment/2024-12-23T16:33:22+08:00https://flcube.com/microport-scientific-corp-receives-nmpa-approval-for-fireraptor-coronary-atherectomy-system/2024-12-23T16:32:29+08:00https://flcube.com/changchun-bcht-biotechnology-receives-nmpa-approval-for-hsv-2-mrna-vaccine-lvrna101/2024-12-23T16:30:59+08:00https://flcube.com/yifan-pharmaceuticals-evive-biotech-receives-anvisa-approval-for-ryzneuta/2024-12-23T16:30:09+08:00https://flcube.com/c-q-pharmaceutical-holding-to-come-under-sasacs-indirect-control-via-genertec-acquisition/2024-12-23T16:29:27+08:00https://flcube.com/becton-dickinson-and-co-launches-rmb1-332-billion-factory-in-jiangsu-for-pre-filled-syringes/2024-12-23T16:28:44+08:00https://flcube.com/cstone-pharmaceuticals-initiates-first-in-human-trial-for-pd-1-vegf-ctla-4-trispecific-antibody-cs2009/2024-12-23T16:28:04+08:00https://flcube.com/boehringer-ingelheim-sec-joint-incubator-launches-in-shenzhens-luohu-district/2024-12-23T16:27:23+08:00https://flcube.com/novo-nordisks-alhemo-receives-fda-approval-for-hemophilia-a-and-b-prophylaxis/2024-12-23T16:26:53+08:00https://flcube.com/cansino-biotechnology-leads-rmb-500-million-private-equity-fund-for-vaccine-investments/2024-12-23T13:11:39+08:00https://flcube.com/cansino-biologics-granted-approval-by-health-canada-for-zoster-vaccine-candidate-cs-2032/2024-12-23T13:11:38+08:00https://flcube.com/cansino-biotechnology-receives-nmpa-approval-for-tetanus-vaccine-cs-2047/2024-12-23T13:11:09+08:00https://flcube.com/cansino-biologicslaunches-phase-iii-trial-for-dtcp-vaccine-in-infants-and-young-children/2024-12-23T13:11:08+08:00https://flcube.com/cansino-biotechnology-partners-with-astrazeneca-for-mrna-vaccine-development-and-manufacturing/2024-12-23T13:11:08+08:00https://flcube.com/cansino-biologics-receives-halal-certificate-for-covid-19-vaccine-in-indonesia/2024-12-23T13:11:07+08:00https://flcube.com/cansino-biologics-to-expand-southeast-asian-presence-with-solution-group-berhad-stake/2024-12-23T13:11:06+08:00https://flcube.com/cansino-biologics-reports-h1-2023-revenues-down-96-7-yoy-covid-19-demand-decreases/2024-12-23T13:11:06+08:00https://flcube.com/gates-foundation-funds-cansinos-innovative-polio-vaccine-development/2024-12-23T13:11:05+08:00https://flcube.com/cansino-biologics-enrolls-first-patient-in-phase-i-trial-of-innovative-polio-vaccine/2024-12-23T13:11:04+08:00https://flcube.com/chinese-firms-secure-euas-for-omicron-xbb-vaccines-amid-dominant-variant-surge/2024-12-23T13:11:04+08:00https://flcube.com/cansino-biologics-13-valent-pneumococcal-vaccine-crm197-accepted-for-nmpa-review/2024-12-23T13:11:03+08:00https://flcube.com/cansino-biologics-partners-with-asymchem-laboratories-to-innovate-biopharmaceutical-development/2024-12-23T13:11:02+08:00https://flcube.com/cansino-biologics-launches-phase-iii-study-for-menhycia-vaccine-in-indonesia/2024-12-23T13:11:02+08:00https://flcube.com/cansino-biologics-reports-2023-revenue-dip-amid-reduced-covid-19-vaccine-demand/2024-12-23T13:11:01+08:00https://flcube.com/cansino-biologics-partners-with-malaysias-nibm-to-develop-mrna-influenza-vaccine/2024-12-23T13:11:00+08:00https://flcube.com/cansino-biologics-receives-nmpa-approval-for-haemophilus-influenzae-type-b-hib-conjugate-vaccine-clinical-trial/2024-12-23T13:11:00+08:00https://flcube.com/bill-melinda-gates-foundation-invests-17-million-in-cansino-biologics-recombinant-polio-vaccine/2024-12-23T13:10:59+08:00https://flcube.com/cansino-biologics-initiates-phase-i-clinical-trial-for-freeze-dried-hib-conjugate-vaccine/2024-12-23T13:10:58+08:00https://flcube.com/cansino-biologics-menhycia-vaccine-aims-to-expand-age-range-with-nmpa-filing/2024-12-23T13:10:58+08:00https://flcube.com/cansino-biologics-partners-with-etana-for-inhaled-tuberculosis-vaccine-development/2024-12-23T13:10:57+08:00https://flcube.com/cansino-biologics-dtcp-vaccine-for-infants-and-young-children-accepted-by-nmpa-for-review/2024-12-23T13:10:56+08:00https://flcube.com/hasten-biopharmaceutical-secures-315-million-investment-for-pipeline-expansion/2024-12-23T01:26:39+08:00https://flcube.com/staidson-pharmaceutical-plans-rmb-580-million-private-placement-for-drug-rd/2024-12-23T01:17:36+08:00https://flcube.com/sangon-biotech-secures-rmb-2-billion-in-first-financing-round-to-boost-life-science-services/2024-12-23T01:15:21+08:00https://flcube.com/shenzhen-01-life-science-secures-rmb-100-million-in-series-b1-financing-for-microecology-platform/2024-12-23T01:10:04+08:00https://flcube.com/pfizers-prevenar-13-receives-expanded-age-range-approval-in-china/2024-12-23T01:05:34+08:00https://flcube.com/zylox-tonbridge-medical-teams-up-with-hicicare-science-for-guide-wire-product-sales-in-china/2024-12-23T01:00:43+08:00https://flcube.com/shanghai-ark-biopharmaceuticals-star-market-ipo-filing-accepted-aims-to-raise-289-6-million/2024-12-23T00:52:03+08:00https://flcube.com/hunan-warrant-pharmaceutical-receives-nmpa-approval-for-generic-brivudine/2024-12-23T00:49:52+08:00https://flcube.com/junshi-biosciences-tuoyi-combo-shows-promise-in-phase-iii-neotorch-study-for-nsclc/2024-12-23T00:43:54+08:00https://flcube.com/jiangsu-aidea-pharmaceutical-secures-global-licensing-deal-for-kainos-medicines-hiv-drugs/2024-12-23T00:40:42+08:00https://flcube.com/acotec-scientifics-vericor-14-microcatheter-receives-nmpa-approval-for-vascular-surgeries/2024-12-23T00:33:48+08:00https://flcube.com/janssens-spravato-approved-by-nmpa-for-adult-depression-and-suicidal-ideation-treatment/2024-12-23T00:31:41+08:00https://flcube.com/jiangxi-jemincare-group-secures-clinical-trial-approvals-for-four-innovative-drugs/2024-12-23T00:29:38+08:00https://flcube.com/cspc-pharmaceutical-group-gets-nmpa-approval-for-sys6010-adc-clinical-trial/2024-12-23T00:27:25+08:00https://flcube.com/healzen-therapeutics-and-neushen-seal-deal-for-global-rights-to-cns-drug-programs/2024-12-23T00:25:22+08:00https://flcube.com/aacr-2023-highlights-car-t-therapies-and-monoclonal-antibody-combinations-in-cancer-research/2024-12-22T22:54:34+08:00https://flcube.com/lianbio-appoints-pascal-qian-as-coo-in-anticipation-of-mavacamten-market-launch/2024-12-22T22:50:26+08:00https://flcube.com/suzhou-basecare-medical-and-qitan-tech-partner-to-advance-nanopore-sequencing-in-pgt/2024-12-22T22:46:05+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-pyrotinib-gains-nmpa-approval-for-her2-breast-cancer-treatment/2024-12-22T22:40:29+08:00https://flcube.com/evopoint-biosciences-gets-cde-approval-for-phase-i-ii-study-of-xnw27011-adc/2024-12-22T22:01:57+08:00https://flcube.com/sinovent-enrolls-first-patient-in-phase-iii-trial-for-gout-drug-xnw3009/2024-12-22T21:57:58+08:00https://flcube.com/sinovent-secures-usd-97-2-million-in-series-e-financing-to-boost-clinical-trials-and-commercialization/2024-12-22T21:55:52+08:00https://flcube.com/chinas-sinovent-and-uks-gsk-eye-breakthrough-therapy-designations-for-cancer-therapies/2024-12-22T20:13:50+08:00https://flcube.com/sinovent-inc-submits-pre-nda-for-funobactam-imipenem-and-cilastatin-to-nmpa/2024-12-22T20:11:59+08:00https://flcube.com/chinas-nhc-advances-enhanced-recovery-after-surgery-eras-protocols-nationwide/2024-12-22T19:50:28+08:00https://flcube.com/chengdu-shengnuo-biotech-secures-nmpa-approval-for-generic-firazyr-equivalent/2024-12-22T19:46:32+08:00https://flcube.com/pharmaessentia-corporation-completes-secondary-offering-of-gdr-shares-on-luxembourg-exchange/2024-12-22T19:13:29+08:00https://flcube.com/lees-pharmaceutical-holdings-ltd-reports-2022-revenues-and-pipeline-updates/2024-12-22T19:07:11+08:00https://flcube.com/reistone-biopharmas-rss0343-receives-nmpa-approval-for-non-cystic-fibrosis-bronchiectasis/2024-12-22T17:23:44+08:00https://flcube.com/siemens-healthineers-and-china-chest-pain-center-launch-smart-training-program/2024-12-22T17:19:22+08:00https://flcube.com/neurodawn-pharmaceuticals-y-1-receives-nmpa-approval-for-primary-intracranial-tumor-treatment/2024-12-22T17:14:42+08:00https://flcube.com/biosion-secures-series-b-financing-to-advance-antibody-based-therapies-pipeline/2024-12-22T17:10:48+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-reports-2022-revenue-dip-and-increased-rd-investment/2024-12-22T17:07:04+08:00https://flcube.com/genscript-biotechs-subsidiary-legend-biotech-announces-positive-car-t-therapy-results/2024-12-22T17:03:46+08:00https://flcube.com/gsks-cervarix-receives-approval-for-two-dose-schedule-in-china-for-ages-9-to-14/2024-12-22T16:59:21+08:00https://flcube.com/everest-medicines-nefecon-for-igan-approved-for-clinical-use-in-hainan/2024-12-22T16:52:27+08:00https://flcube.com/grand-pharmaceutical-group-to-acquire-majority-stake-in-blackswan-vascular-inc-for-37-5-million/2024-12-22T16:50:07+08:00https://flcube.com/zelgen-biopharmaceuticals-zg2001-receives-us-fda-clinical-trial-approval-for-pan-kras-inhibitor/2024-12-22T16:47:36+08:00https://flcube.com/sichuan-biokin-pharmaceutical-gets-nmpa-approval-for-two-clinical-studies-on-cancer-therapies/2024-12-22T16:45:09+08:00https://flcube.com/yichang-hec-changjiang-pharmaceutical-reports-309-83-yoy-revenue-growth-in-2022-financials/2024-12-22T16:42:43+08:00https://flcube.com/olympus-corp-to-invest-40-6-million-in-new-endoscope-factory-in-suzhou-china/2024-12-22T16:40:02+08:00https://flcube.com/beijing-based-holox-secures-tens-of-millions-in-series-a-financing-for-healthcare-software/2024-12-22T16:34:39+08:00https://flcube.com/shanghai-kingstar-winning-secures-43-39-million-in-series-c-financing-for-digital-healthcare-solutions/2024-12-22T16:25:30+08:00https://flcube.com/luzhu-biotech-prepares-for-hkd-433-million-ipo-with-focus-on-vaccines-and-biologics/2024-12-22T16:20:32+08:00https://flcube.com/gan-lee-pharmaceuticals-receives-marketing-approval-for-insulin-glargine-in-bolivia/2024-12-22T16:17:19+08:00https://flcube.com/rainmed-medicals-caimr-system-receives-nmpa-approval-for-coronary-artery-function-measurement/2024-12-22T16:09:39+08:00https://flcube.com/wuxi-apptec-reports-5-77-yoy-revenue-growth-and-31-97-increase-in-net-profits-for-2023q1/2024-12-22T16:04:16+08:00https://flcube.com/smpa-suspends-procurement-of-levornidazole-by-warrant-pharmaceutical-over-ip-concerns/2024-12-22T16:00:29+08:00https://flcube.com/tot-biopharmaceutical-partners-with-suzhou-smart-nuclide-on-radioactive-drug-development/2024-12-22T15:52:36+08:00https://flcube.com/biopharma-company-transthera-sciences-nanjing-gets-green-light-for-hk-ipo/2024-12-22T14:09:53+08:00https://flcube.com/zhaoke-ophthalmologys-us-partner-visus-therapeutics-reports-positive-phase-iii-results/2024-12-21T23:52:29+08:00https://flcube.com/lanova-medicines-and-legochem-biosciences-partner-to-develop-innovative-adc-product/2024-12-21T23:46:54+08:00https://flcube.com/sunshine-guojian-pharmaceutical-and-shenyang-3sbio-secure-exclusive-licensing-agreement-for-antitumor-programs/2024-12-21T23:39:45+08:00https://flcube.com/junshi-biosciences-submits-market-filings-for-pcsk9-mab-ongericimab-to-nmpa/2024-12-21T23:33:01+08:00https://flcube.com/jiangsu-initiates-price-negotiations-for-provincial-stock-drugs-addresses-shortages/2024-12-21T23:28:43+08:00https://flcube.com/ping-an-healthcare-and-technology-partners-with-chugai-pharmaceutical-to-establish-angina-pectoris-center/2024-12-21T23:15:09+08:00https://flcube.com/ping-an-good-doctor-partners-with-vcanbio-to-pioneer-cell-health-management-services-in-china/2024-12-21T23:07:32+08:00https://flcube.com/belief-biomed-completes-patient-dosing-in-phase-iii-hemophilia-b-gene-therapy-trial/2024-12-21T23:01:05+08:00https://flcube.com/tot-biopharmaceutical-and-shanghai-escugen-partner-on-adc-development-and-commercialization/2024-12-21T22:56:04+08:00https://flcube.com/meilitech-secures-series-a-funding-led-by-autobio-diagnostics-for-cancer-detection-tech/2024-12-21T22:44:15+08:00https://flcube.com/sable-therapeutics-and-liuqiang-medical-ink-licensing-deal-for-aesthetic-fat-reduction-patch/2024-12-21T22:36:52+08:00https://flcube.com/cspc-pharmaceutical-group-reports-11-yoy-revenue-growth-in-2022-financial-results/2024-12-21T21:12:18+08:00https://flcube.com/roches-q1-2023-report-3-dip-in-revenues-with-strong-growth-in-pharmaceuticals/2024-12-21T21:09:40+08:00https://flcube.com/gsk-reports-q1-2023-revenue-dip-amid-covid-19-treatment-decline-underlying-growth/2024-12-21T21:06:08+08:00https://flcube.com/sinomabs-sm03-meets-primary-endpoint-in-phase-iii-rheumatoid-arthritis-trial/2024-12-21T21:03:22+08:00https://flcube.com/junshi-biosciences-renotorch-study-meets-endpoints-for-rcc-treatment/2024-12-21T20:59:17+08:00https://flcube.com/sihuan-pharmaceuticals-birociclib-meets-primary-endpoint-in-phase-iii-breast-cancer-study/2024-12-21T20:56:32+08:00https://flcube.com/microport-scientific-corp-reports-8-revenue-growth-and-increased-rd-investment-in-2022/2024-12-21T20:53:57+08:00https://flcube.com/cspc-pharmaceuticals-prusogliptin-for-type-2-diabetes-accepted-for-nmpa-review/2024-12-21T20:50:50+08:00https://flcube.com/ocumension-therapeutics-zerviate-receives-nmpa-priority-review-for-ophthalmology-treatment/2024-12-21T20:48:05+08:00https://flcube.com/dizal-pharma-plans-to-raise-376-1-million-for-drug-rd-and-industrialization/2024-12-21T20:42:24+08:00https://flcube.com/nmpa-mandates-label-updates-for-11-drug-varieties-including-black-box-warnings/2024-12-21T20:38:51+08:00https://flcube.com/shanghai-fosun-pharmaceutical-reported-to-halt-sale-of-stake-in-gland-pharma/2024-12-21T20:36:17+08:00https://flcube.com/q1-2023-financial-report-astrazeneca-leads-innovation-in-china-sanofis-sales-in-china-decline/2024-12-21T20:28:51+08:00https://flcube.com/cms-receives-nmpa-approval-for-clinical-study-of-tetravalent-bsab-for-namd/2024-12-21T20:18:35+08:00https://flcube.com/sirnaomics-rv-1730-receives-fda-clearance-for-phase-i-covid-19-vaccine-booster-trial/2024-12-21T20:14:32+08:00https://flcube.com/reforgene-medicine-secures-pre-series-b-funding-to-advance-thalassemia-gene-therapy/2024-12-21T20:08:09+08:00https://flcube.com/zai-lab-partners-with-medilink-therapeutics-to-develop-yl212-dll3-adc/2024-12-21T20:02:25+08:00https://flcube.com/jiangsu-hengruis-vunakizumab-for-plaque-psoriasis-accepted-for-review-by-nmpa/2024-12-21T19:58:16+08:00https://flcube.com/synerk-achieves-milestone-with-first-patient-dosing-in-phase-i-sirna-clinical-trial/2024-12-21T19:27:44+08:00https://flcube.com/yoltech-therapeutics-yolt-201-advances-in-attr-treatment-clinical-trial/2024-12-21T19:15:07+08:00https://flcube.com/wuhan-weike-medical-technology-secures-series-c-funding-to-boost-cardiovascular-innovation/2024-12-21T14:50:12+08:00https://flcube.com/medisan-pharmaceutical-secures-ppar-agonist-technology-from-china-pharmaceutical-university/2024-12-21T01:55:06+08:00https://flcube.com/meihua-international-medical-expands-with-new-healthcare-industrial-park-in-hainan/2024-12-21T01:49:39+08:00https://flcube.com/ascletis-pharmas-asc40-meets-acne-treatment-goals-in-phase-ii-trial/2024-12-21T01:43:22+08:00https://flcube.com/bdgene-technologys-bd111-receives-tacit-approval-for-hsv-1-keratitis-trial/2024-12-21T01:41:03+08:00https://flcube.com/sanreno-therapeutics-completes-dosing-in-kidney-disease-trial-for-bion-1301/2024-12-21T01:38:46+08:00https://flcube.com/qilu-pharmaceutical-launches-first-generic-iressa-in-the-us-market/2024-12-21T01:34:52+08:00https://flcube.com/neuexcell-therapeutics-secures-over-14-5-million-in-pre-series-a-funding-for-neurological-treatments/2024-12-21T01:31:37+08:00https://flcube.com/transcentas-osemitamab-achieves-full-enrollment-in-phase-ii-gastric-cancer-study/2024-12-21T01:26:18+08:00https://flcube.com/tyk-medicines-ty-9591-gains-cde-green-light-for-pivotal-phase-ii-study-in-nsclc-with-brain-metastases/2024-12-21T01:20:37+08:00https://flcube.com/nmpa-transitions-desloratadine-loratadine-ambroxol-and-naproxen-to-otc-status/2024-12-21T01:18:08+08:00https://flcube.com/skyline-therapeutics-reports-positive-preclinical-results-for-skg0106-and-skg0201-gene-therapies/2024-12-21T01:16:10+08:00https://flcube.com/cellular-biomedicine-group-inc-and-janssen-biotech-inc-announce-global-collaboration-for-car-t-therapies/2024-12-21T01:12:58+08:00https://flcube.com/chinese-authorities-launch-special-campaign-to-combat-fraud-in-medical-insurance/2024-12-21T01:08:18+08:00https://flcube.com/johnson-johnsons-kenvue-ipo-raises-usd-3-8-billion-marking-years-largest-us-ipo/2024-12-21T01:05:50+08:00https://flcube.com/full-life-technologies-ltd-to-establish-gmp-compliant-radiopharmaceutical-plant-in-belgiums-wallonie-region/2024-12-21T01:00:17+08:00https://flcube.com/chinas-cde-unveils-technical-guidelines-for-stem-cell-products-and-immunotherapy-in-chronic-hepatitis-b/2024-12-21T00:54:48+08:00https://flcube.com/yantai-dongcheng-pharmas-177lu-lnc1003-cleared-for-us-fda-phase-i-study/2024-12-21T00:52:45+08:00https://flcube.com/abm-therapeutics-abm-168-begins-phase-i-dosing-in-the-us-for-advanced-solid-tumors/2024-12-21T00:50:04+08:00https://flcube.com/kangrui-health-partners-with-west-china-second-university-hospital-for-pediatric-care-innovation/2024-12-21T00:47:43+08:00https://flcube.com/chinas-cde-releases-69th-batch-of-generic-chemical-reference-preparations-for-public-review/2024-12-21T00:27:34+08:00https://flcube.com/innovent-biologics-gfh925-earns-breakthrough-therapy-designation-for-krasg12c-crc-treatment/2024-12-21T00:24:44+08:00https://flcube.com/carsgen-therapeutics-ab011-and-tecentriq-combo-gets-nmpa-approval-for-gastric-cancer-treatment/2024-12-21T00:19:25+08:00https://flcube.com/fujian-cosunter-pharmaceutical-completes-enrollment-in-phase-ii-iii-trial-for-gst-hg171-ritonavir/2024-12-21T00:16:39+08:00https://flcube.com/beigene-reports-q1-2023-financial-growth-advances-pipeline-with-global-expansion-plans/2024-12-21T00:14:11+08:00https://flcube.com/chinas-regulatory-bodies-unveil-guidelines-to-strengthen-supervision-of-medical-aesthetic-industry/2024-12-21T00:04:09+08:00https://flcube.com/vivavision-biotech-secures-over-rmb-100-million-in-series-d2-financing-for-ophthalmology-pipeline-expansion/2024-12-21T00:02:00+08:00https://flcube.com/sumitomo-pharma-expands-collaboration-with-shanghai-pharmaceuticals-for-prescription-drug-co-marketing/2024-12-20T22:26:50+08:00https://flcube.com/boston-scientifics-next-gen-ivus-system-avvigo-approved-by-chinas-nmpa-for-coronary-disease-use/2024-12-20T22:20:11+08:00https://flcube.com/guardant-health-and-boehringer-ingelheim-join-forces-to-develop-guardant360-cdx-for-zongertinib-companion-diagnostic/2024-12-20T22:08:47+08:00https://flcube.com/roches-prasinezumab-shows-promise-in-phase-iib-padova-study-for-early-stage-parkinsons-disease/2024-12-20T21:43:37+08:00https://flcube.com/hainan-boao-lecheng-and-sanofi-partner-with-paris-saclay-cancer-cluster-for-advanced-cancer-treatments/2024-12-20T21:36:09+08:00https://flcube.com/sichuan-kelun-biotech-launches-sacituzumab-tirumotecan-for-triple-negative-breast-cancer-in-china/2024-12-20T21:30:28+08:00https://flcube.com/wuxi-biologics-enters-licensing-deal-with-hangzhou-dac-and-aadi-bio-for-preclinical-adc-portfolio/2024-12-20T17:43:40+08:00https://flcube.com/mgi-tech-co-ltd-partners-with-sabin-group-to-enhance-genetic-sequencing-in-brazil/2024-12-20T17:26:16+08:00https://flcube.com/rejukon-biopharms-rjk002-earns-tacit-approval-for-amyotrophic-lateral-sclerosis-clinical-trial/2024-12-20T17:25:49+08:00https://flcube.com/astellas-pharma-inks-licensing-deal-with-sangamo-therapeutics-for-neurological-av-capsid-stac-bbb/2024-12-20T16:53:08+08:00https://flcube.com/fangzhou-inc-partners-with-bms-to-innovate-digital-medicine-platform/2024-12-20T16:07:30+08:00https://flcube.com/sanofi-and-corxel-pharmaceuticals-partner-for-aficamten-in-greater-china-rights/2024-12-20T15:48:30+08:00https://flcube.com/hob-biotech-group-corp-acquired-by-sino-biopharmaceutical-ltd-for-ivd-synergies/2024-12-20T15:26:56+08:00https://flcube.com/joincare-pharmaceuticals-jkn2403-gains-nmpa-approval-for-copd-clinical-trials/2024-12-20T15:07:55+08:00https://flcube.com/sino-biopharmaceutical-ltd-files-for-benmelstobart-and-anlotinib-combination-therapy-in-asps-treatment/2024-12-20T14:40:40+08:00https://flcube.com/hightide-therapeutics-and-ssy-group-ltd-join-forces-to-tackle-metabolic-and-aging-diseases/2024-12-20T14:29:43+08:00https://flcube.com/aim-vaccine-co-ltd-receives-nmpa-clearance-for-innovative-cell-based-influenza-vaccine/2024-12-20T14:09:07+08:00https://flcube.com/henlius-biotech-expands-partnership-with-palleon-pharmaceuticals-for-autoimmune-disease-treatment/2024-12-20T13:56:21+08:00https://flcube.com/aim-vaccine-co-ltd-receives-nmpa-approval-for-second-gen-tetanus-vaccine-clinical-trial/2024-12-20T13:36:56+08:00https://flcube.com/lingyi-biotechnology-secures-rmb-100-million-in-series-a-funding-for-gene-therapy-pipeline/2024-12-20T13:26:37+08:00https://flcube.com/henlius-biotechs-hlx26-and-haisizhuang-combo-for-nsclc-gets-nmpa-phase-ii-approval/2024-12-20T13:18:35+08:00https://flcube.com/shanghai-junshi-biosciences-inks-exclusive-license-deal-with-dr-reddys-laboratories-for-tuoyi/2024-12-20T13:04:49+08:00https://flcube.com/sinopharm-partners-with-shenzhen-to-boost-high-end-medical-device-and-pharmaceutical-innovation/2024-12-20T12:50:59+08:00https://flcube.com/xtalpi-inc-and-china-pharmaceutical-university-launch-joint-ai-research-center-in-china/2024-12-20T12:38:49+08:00https://flcube.com/omega-medical-imagings-soteria-ai-receives-fda-approval-for-interventional-cardiology/2024-12-20T12:34:43+08:00https://flcube.com/nmpa-extends-public-feedback-period-for-drug-standardization-management-measures-in-china/2024-12-20T12:05:51+08:00https://flcube.com/hasten-biopharm-acquires-commercial-rights-to-rocephin-in-china-from-roche/2024-12-20T11:48:28+08:00https://flcube.com/mindray-reports-strong-yoy-growth-in-2022-and-q1-2023-financial-results/2024-12-20T11:44:07+08:00https://flcube.com/anhui-and-qinghai-provinces-update-bmi-chronic-disease-drug-lists-for-outpatient-reimbursement/2024-12-20T10:43:45+08:00https://flcube.com/huadong-medicines-mefatinib-poised-for-breakthrough-therapy-designation-by-cde/2024-12-20T10:41:27+08:00https://flcube.com/shunxi-holding-group-secures-licensing-deal-for-cartherics-cth-004-in-greater-china/2024-12-20T10:38:31+08:00https://flcube.com/astrazenecas-mek-inhibitor-koselugo-approved-in-china-for-pediatric-nf1-related-pn/2024-12-20T10:29:32+08:00https://flcube.com/shenzhens-angio8-secures-tens-of-millions-in-series-a-financing-for-surgical-robot-development/2024-12-20T10:26:11+08:00https://flcube.com/beigenes-brukinsa-receives-nmpa-approval-for-expanded-use-in-leukemia-and-lymphoma/2024-12-20T10:19:55+08:00https://flcube.com/shanghai-junshi-biosciences-tuoyi-shows-promise-in-phase-iii-study-for-es-sclc/2024-12-20T10:11:24+08:00https://flcube.com/tianjin-shandong-and-hainan-provinces-announce-vbp-backup-suppliers-for-round-8/2024-12-20T10:07:48+08:00https://flcube.com/suzhou-genassists-gen6050-receives-us-fda-pre-ind-acceptance-for-duchenne-muscular-dystrophy-treatment/2024-12-20T10:02:17+08:00https://flcube.com/sinopharm-partners-with-fudan-university-to-establish-national-innovation-platform/2024-12-20T09:56:45+08:00https://flcube.com/reistone-biopharmas-edralbrutinib-earns-orphan-drug-designation-for-nmosd-from-us-fda/2024-12-20T09:52:00+08:00https://flcube.com/grand-pharmaceutical-group-files-nda-for-ophthalmic-analgesic-app13007-with-us-fda/2024-12-20T01:07:39+08:00https://flcube.com/neuro3-therapeutics-secures-exclusive-license-deal-with-lundbeck-for-kcnq2-activator-programs/2024-12-20T01:04:07+08:00https://flcube.com/organon-reports-q1-2023-revenue-growth-highlights-womens-health-and-biosimilars-progress/2024-12-20T00:58:00+08:00https://flcube.com/us-fda-nears-regulatory-decision-on-junshi-biosciences-pd-1-inhibitor-tuoyi/2024-12-20T00:50:26+08:00https://flcube.com/acorda-therapeutics-strikes-deal-with-hangzhou-chance-for-inbrija-distribution-in-china/2024-12-20T00:46:41+08:00https://flcube.com/remegen-ltd-receives-approval-for-phase-i-clinical-study-of-rc198-in-solid-tumors/2024-12-20T00:38:55+08:00https://flcube.com/grand-pharmaceutical-group-completes-enrollment-in-phase-iii-study-for-ryaltris-nasal-spray/2024-12-20T00:36:33+08:00https://flcube.com/alphamab-oncology-and-cspc-pharma-get-green-light-for-kn026-phase-iii-study-in-breast-cancer/2024-12-20T00:33:48+08:00https://flcube.com/jiangsu-alphamab-biopharmaceuticals-partners-with-shanghai-jinmant-biotech-for-jskn003-adc/2024-12-20T00:30:42+08:00https://flcube.com/eyenovia-inc-receives-fda-approval-for-mydcombi-a-first-of-its-kind-ophthalmic-spray/2024-12-20T00:24:45+08:00https://flcube.com/nmpa-releases-67th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2024-12-20T00:17:46+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-advances-shr-1819-shr-2002-and-adebrelimab-into-new-clinical-trials/2024-12-20T00:14:47+08:00https://flcube.com/ascletis-pharma-receives-approval-for-phase-iia-study-of-asc10-for-rsv-infection/2024-12-20T00:11:36+08:00https://flcube.com/eqrx-inc-abandons-plans-for-low-cost-drugs-terminates-development-of-three-china-sourced-products/2024-12-20T00:08:57+08:00https://flcube.com/zion-pharmas-zn-a-1041-acquired-by-roche-for-global-development-and-commercialization/2024-12-20T00:02:15+08:00https://flcube.com/suzhou-porton-biologics-and-synbio-technologies-partner-to-advance-cell-and-gene-therapy-in-china/2024-12-19T23:55:11+08:00https://flcube.com/mabwell-biosciences-9mw3911-receives-nmpa-approval-for-clinical-trial-in-advanced-tumors/2024-12-19T23:48:54+08:00https://flcube.com/akeso-biopharma-initiates-phase-iii-study-for-ivonescimab-in-non-small-cell-lung-cancer/2024-12-19T23:46:18+08:00https://flcube.com/zai-lab-limited-reports-q1-2023-financial-results-and-product-highlights/2024-12-19T23:42:47+08:00https://flcube.com/yifan-pharmaceuticals-f-627-receives-nmpa-approval-for-neutropenia-treatment-in-cancer-patients/2024-12-19T23:38:37+08:00https://flcube.com/jiangsu-nhwa-pharmaceutical-receives-nmpa-approval-for-olinvyk-oliceridine-injection/2024-12-19T23:30:00+08:00https://flcube.com/innovent-biologics-tyvyt-secures-nmpa-approval-for-egfr-mutated-nsclc-treatment/2024-12-19T23:24:17+08:00https://flcube.com/chinas-nhc-releases-draft-guidelines-for-somatic-cell-clinical-research-seeks-public-input/2024-12-19T23:16:17+08:00https://flcube.com/msds-clesrovimab-for-infant-rsv-protection-fda-accepts-bla-for-review/2024-12-19T22:16:09+08:00https://flcube.com/photys-therapeutics-and-novo-nordisk-partner-to-develop-proximity-based-therapies-for-cardiometabolic-diseases/2024-12-19T22:06:44+08:00https://flcube.com/merck-to-acquire-hub-organoids-holding-b-v-advancing-organoid-technology-in-drug-development/2024-12-19T21:30:45+08:00https://flcube.com/bioage-labs-and-novartis-partner-to-discover-aging-related-therapeutic-targets/2024-12-19T21:18:14+08:00https://flcube.com/daan-gene-co-ltd-receives-nmpa-approval-for-genetic-deafness-gene-detection-kit/2024-12-19T21:07:05+08:00https://flcube.com/medilink-therapeutics-yl201-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer/2024-12-19T20:54:53+08:00https://flcube.com/bms-regains-exclusive-rights-to-abz-706-in-greater-china/2024-12-19T20:42:26+08:00https://flcube.com/ucbs-minzasolmin-fails-to-meet-endpoints-in-orchestra-study-for-early-parkinsons/2024-12-19T17:16:52+08:00https://flcube.com/ascletis-pharmas-asc47-outperforms-semaglutide-in-weight-loss-study/2024-12-19T17:16:07+08:00https://flcube.com/hansoh-pharmaceutical-secures-global-licensing-deal-with-merck-for-hs-10535/2024-12-19T17:15:27+08:00https://flcube.com/sino-biopharmaceuticals-benmelstobart-meets-primary-endpoint-in-phase-iii-nsclc-study/2024-12-19T17:14:37+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-gets-nmpa-approval-for-shr-1501-combo-in-bladder-cancer/2024-12-19T17:14:07+08:00https://flcube.com/huadong-medicines-hdm1005-receives-fda-clearance-for-heart-failure-and-obesity-clinical-trial/2024-12-19T17:13:27+08:00https://flcube.com/sinocare-incs-true-vie-cgms-advances-to-510k-substantive-review-stage-at-fda/2024-12-19T17:12:51+08:00https://flcube.com/chengdu-kanghua-biological-receives-nmpa-approval-for-recombinant-norovirus-vaccine/2024-12-19T17:12:12+08:00https://flcube.com/iflyteks-subsidiary-xunfei-healthcare-technologies-lists-on-hkex-raises-over-hkd-580-million/2024-12-19T17:11:25+08:00https://flcube.com/int-medical-instruments-to-acquire-controlling-stake-in-weiqiang-medical-technology-for-rmb-230-million/2024-12-19T17:10:52+08:00https://flcube.com/fda-approves-xcovery-holdings-ensartinib-for-untreated-alk-positive-nsclc-patients/2024-12-19T17:10:03+08:00https://flcube.com/everest-medicines-nefecon-receives-first-prescription-for-igan-treatment-in-adults/2024-12-19T17:08:36+08:00https://flcube.com/janssen-cilag-submits-for-imbruvica-indication-extension-in-untreated-mantle-cell-lymphoma/2024-12-19T15:56:58+08:00https://flcube.com/healthyway-inc-completes-hkd-220-million-ipo-on-the-hong-kong-stock-exchange/2024-12-19T13:00:47+08:00https://flcube.com/cnipa-releases-patent-linkage-decisions-paving-way-for-generic-drugs-in-china/2024-12-19T11:58:40+08:00https://flcube.com/guangdong-taienkangs-ckba-ointment-for-vitiligo-accepted-for-review-by-chinas-nmpa/2024-12-19T11:54:40+08:00https://flcube.com/mabwells-b7-h3-targeting-adc-7mw3711-accepted-for-review-by-chinas-nmpa/2024-12-19T11:47:52+08:00https://flcube.com/cstone-pharmaceuticals-partner-servier-secures-eu-approvals-for-idh1-inhibitor-tibsovo/2024-12-19T11:43:23+08:00https://flcube.com/innovent-biologics-mazdutide-showcases-weight-loss-efficacy-in-phase-ii-study-for-chinese-adults/2024-12-19T11:39:37+08:00https://flcube.com/beijing-medical-insurance-bureau-announces-key-healthcare-initiatives-and-bmi-expansion/2024-12-19T11:35:42+08:00https://flcube.com/joincare-pharmaceutical-receives-nmpa-approval-for-triptorelin-microspheres-for-prostate-cancer/2024-12-19T11:30:37+08:00https://flcube.com/zai-labs-repotrectinib-on-track-for-priority-review-by-chinas-cde-for-ros1-nsclc/2024-12-19T11:27:04+08:00https://flcube.com/sichuan-kelun-pharmaceuticals-a166-anti-her2-adc-nda-accepted-for-review-by-nmpa/2024-12-19T11:20:36+08:00https://flcube.com/nona-biosciences-partners-with-pharmaessentia-for-harnessing-harbor-mice-technology/2024-12-19T11:16:59+08:00https://flcube.com/first-condor-biotechnology-secures-tens-of-millions-in-pre-series-a-financing-for-car-t-cell-trials/2024-12-19T11:08:04+08:00https://flcube.com/chinas-nhc-and-13-bureaus-launch-campaign-to-rectify-pharmaceutical-and-medical-services-practices/2024-12-19T10:56:59+08:00https://flcube.com/bayer-q1-2023-financial-report-sales-dip-amid-regional-challenges-and-covid-19-impact/2024-12-19T10:41:52+08:00https://flcube.com/wuhan-institutes-hexavalent-rotavirus-vaccine-on-track-for-priority-review-by-cde/2024-12-19T10:39:01+08:00https://flcube.com/kintor-pharmaceuticals-kx-826-shows-promise-in-phase-ii-study-for-male-androgenetic-alopecia/2024-12-19T10:24:57+08:00https://flcube.com/zhenge-biotech-partners-with-nnit-for-advanced-digitalization-in-drug-development/2024-12-19T10:19:11+08:00https://flcube.com/rona-therapeutics-and-keymed-biosciences-collaborate-on-sirna-therapeutics-for-glomerulonephritis/2024-12-19T00:04:53+08:00https://flcube.com/omron-healthcare-and-jd-healthcare-form-partnership-to-innovate-chronic-disease-management/2024-12-18T23:56:45+08:00https://flcube.com/lanova-medicines-and-astrazeneca-ink-global-licensing-deal-for-gprc5d-targeting-adc-lm-305/2024-12-18T23:49:33+08:00https://flcube.com/exorna-bio-secures-tens-of-millions-in-financing-to-advance-huntingtons-disease-pipeline/2024-12-18T23:42:42+08:00https://flcube.com/luye-pharmas-boan-biotechnology-partners-with-genscript-on-gencircle-dsdna-development/2024-12-18T23:38:12+08:00https://flcube.com/betta-pharmaceuticals-and-eyepoint-pharmaceuticals-submit-eyp-1901-for-nmpa-review/2024-12-18T23:29:28+08:00https://flcube.com/nmpa-releases-68th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2024-12-18T23:22:34+08:00https://flcube.com/basecare-medical-to-acquire-bmx-holdco-for-40-million-expanding-ivf-portfolio/2024-12-18T23:17:34+08:00https://flcube.com/zelgen-biopharmaceuticals-zg0895-receives-fda-approval-for-clinical-trials-in-advanced-solid-tumors/2024-12-18T23:11:19+08:00https://flcube.com/coherent-biopharma-secures-100-million-in-series-b-and-b-financings-for-clinical-pipeline/2024-12-18T23:08:45+08:00https://flcube.com/philips-agrees-to-62-million-settlement-with-sec-over-china-marketing-practices/2024-12-18T23:05:55+08:00https://flcube.com/drug-farm-secures-27-million-in-series-c-financing-to-advance-hbv-treatments/2024-12-18T23:00:27+08:00https://flcube.com/peijia-medical-achieves-milestone-with-first-commercial-implants-of-trilogy-tavr-system-in-hong-kong/2024-12-18T22:55:37+08:00https://flcube.com/bionecure-therapeutics-and-nanjing-leads-biolabs-collaborate-on-innovative-adcs-for-solid-tumors/2024-12-18T22:51:12+08:00https://flcube.com/lynk-pharmaceuticals-lnk01001-demonstrates-efficacy-in-phase-ii-rheumatoid-arthritis-study/2024-12-18T22:45:24+08:00https://flcube.com/skyline-therapeutics-initiates-clinical-study-with-first-patient-dosing-of-skg0106-for-wamd/2024-12-18T22:43:09+08:00https://flcube.com/gracell-biotechnologies-initiates-trial-for-gc012f-in-refractory-sle-with-dual-target-fastcar-therapy/2024-12-18T22:39:20+08:00https://flcube.com/aligos-therapeutics-partners-with-amoytop-biotech-for-oligonucleotide-compound-rd/2024-12-18T22:24:08+08:00https://flcube.com/cims-cancer-vaccine-cimavax-confirmed-immunogenic-in-us-study-cuba-announces/2024-12-18T22:18:15+08:00https://flcube.com/covid-19-disruptions-lead-to-soaring-lab-monkey-prices-impacting-us-drug-development/2024-12-18T22:14:58+08:00https://flcube.com/roc-rock-biotechnology-secures-ethical-approval-for-car-m-therapy-in-ovarian-cancer/2024-12-18T22:12:44+08:00https://flcube.com/huadong-medicines-hdm1002-receives-fda-approval-for-clinical-trials/2024-12-18T22:04:53+08:00https://flcube.com/sino-biopharmaceutical-and-sinopharm-group-collaborate-to-expand-retail-pharmacy-network/2024-12-18T21:12:57+08:00https://flcube.com/everest-medicines-velsipity-etrasimod-receives-first-prescription-in-foshan-under-gba-policy/2024-12-18T20:58:24+08:00https://flcube.com/immuneonco-biopharmaceuticals-initiates-phase-ib-study-for-amulirafusp-alfa-in-nmosd/2024-12-18T20:50:27+08:00https://flcube.com/henlius-biotech-joins-biosimilars-forum-to-expand-global-biosimilars-access/2024-12-18T17:26:11+08:00https://flcube.com/microport-cardioflow-medtechs-vitaflow-liberty-flex-receives-nmpa-approval/2024-12-18T17:15:23+08:00https://flcube.com/lepu-scientechs-scienccrown-tavr-system-earns-nmpa-medical-device-license/2024-12-18T17:02:07+08:00https://flcube.com/eli-lillys-kisunla-receives-nmpa-approval-for-early-alzheimers-disease-treatment/2024-12-18T16:38:40+08:00https://flcube.com/bionova-pharmaceuticals-bn104-receives-breakthrough-therapy-designation-in-china/2024-12-18T16:28:11+08:00https://flcube.com/xtalpi-inc-partners-with-gnosis-neurodynamics-to-develop-neural-drug-screening-platform/2024-12-18T15:49:24+08:00https://flcube.com/gsks-blenrep-and-star-pharmas-topiramate-solution-target-priority-review-in-china/2024-12-18T15:27:18+08:00https://flcube.com/sciwind-biosciences-ecnoglutide-accepted-for-review-by-nmpa-for-weight-management/2024-12-18T15:02:47+08:00https://flcube.com/blackstone-and-bain-capital-submit-final-bids-for-mitsubishi-tanabe-pharma/2024-12-18T14:45:38+08:00https://flcube.com/everest-medicines-completes-patient-enrollment-in-etrasimod-phase-iii-uc-trial/2024-12-18T14:12:09+08:00https://flcube.com/huidagene-secures-us-patent-for-high-efficiency-cas12max-dna-editing-system/2024-12-18T14:09:30+08:00https://flcube.com/jiangsu-hengruis-shr0302-secures-clinical-trial-approval-for-gvhd-treatment/2024-12-18T14:05:45+08:00https://flcube.com/sanofis-vaxigriptetra-expands-influenza-vaccine-access-to-all-ages-in-china/2024-12-18T14:01:59+08:00https://flcube.com/astrazenecas-nirsevimab-on-track-for-priority-review-for-rsv-prevention-in-infants/2024-12-18T13:54:22+08:00https://flcube.com/antengene-submits-market-approval-filing-for-xpovio-in-indonesia-for-multiple-myeloma-and-lymphoma/2024-12-18T13:43:42+08:00https://flcube.com/tyk-medicines-receives-cde-approval-for-cdk7-inhibitor-ty-2699a-clinical-study/2024-12-18T13:38:18+08:00https://flcube.com/transcenta-holdings-tst002-shows-positive-phase-i-results-for-bone-density-in-china/2024-12-18T13:35:52+08:00https://flcube.com/yizun-biomedicines-cnk-ut-cell-therapy-initiates-patient-enrollment-for-solid-tumor-trial/2024-12-18T13:28:37+08:00https://flcube.com/zelgen-biopharmaceuticals-jacktinib-studies-selected-for-eha-annual-meeting/2024-12-18T13:20:23+08:00https://flcube.com/bioray-pharmaceuticals-zuberitamab-approved-by-nmpa-for-cd20-positive-dlbcl-treatment/2024-12-18T13:10:26+08:00https://flcube.com/nmpa-approves-nanjing-sanhomes-alfosbuvir-for-chronic-hepatitis-c-treatment/2024-12-18T12:54:29+08:00https://flcube.com/betta-pharmaceuticals-initiates-phase-i-ii-study-for-first-in-class-bsab-bpb-101/2024-12-18T12:49:26+08:00https://flcube.com/antengenes-first-in-class-cd24-mab-atg-031-gets-us-fda-approval-for-phase-i-study/2024-12-18T12:47:26+08:00https://flcube.com/westvac-biopharma-receives-fda-approval-for-covid-19-protein-vaccines-targeting-xbb-variants/2024-12-18T12:36:40+08:00https://flcube.com/carsgen-therapeutics-initiates-phase-ii-study-for-ct041-in-advanced-gastric-cancer/2024-12-18T12:25:29+08:00https://flcube.com/national-vaccine-serum-institute-partners-with-corning-life-sciences-to-foster-innovation/2024-12-18T12:19:40+08:00https://flcube.com/cde-lists-three-home-grown-drugs-for-priority-review-including-myopia-treatment/2024-12-18T12:12:10+08:00https://flcube.com/grand-pharmaceuticals-novasight-hybrid-system-receives-marketing-approval-in-china/2024-12-18T11:37:58+08:00https://flcube.com/hitgen-inc-enters-research-agreement-with-arase-therapeutics-to-discover-oncology-inhibitors/2024-12-18T11:34:58+08:00https://flcube.com/huadong-medicines-hdm1002-receives-nmpa-approval-for-type-2-diabetes-clinical-trial/2024-12-18T11:24:36+08:00https://flcube.com/cabaletta-bios-caba-201-clears-fda-for-phase-i-ii-study-in-idiopathic-inflammatory-myopathy/2024-12-18T11:14:09+08:00https://flcube.com/microport-scientific-plans-ipo-for-subsidiary-microport-crm-on-hong-kong-stock-exchange/2024-12-18T11:08:01+08:00https://flcube.com/mustang-bio-inc-enters-strategic-partnership-with-ubrigene-for-cell-and-gene-therapy/2024-12-18T11:02:47+08:00https://flcube.com/beijing-sun-novo-secures-exclusive-rights-to-kanekas-skin-patch-drugs-in-licensing-deal/2024-12-18T10:56:09+08:00https://flcube.com/international-vaccine-institute-and-nankai-university-establish-joint-research-center-for-vaccine-advancements/2024-12-18T10:49:18+08:00https://flcube.com/microport-medbot-receives-nmpa-approval-for-mona-lisa-prostate-puncture-robot-system/2024-12-18T10:47:08+08:00https://flcube.com/asieris-pharmaceuticals-secures-exclusive-global-rights-to-urovius-fluorescent-imaging-cystoscope/2024-12-18T10:39:04+08:00https://flcube.com/abbisko-therapeutics-and-x4-pharmaceuticals-announce-positive-phase-iii-results-for-mavorixafor-in-whim-syndrome/2024-12-18T10:29:40+08:00https://flcube.com/shenzhen-kangtai-biological-partners-with-saudi-importer-for-pneumonia-vaccine-distribution/2024-12-18T10:23:14+08:00https://flcube.com/fibrogens-roxadustat-shows-positive-results-in-phase-iii-chemotherapy-induced-anemia-trial/2024-12-18T10:20:02+08:00https://flcube.com/genscipt-biotech-corp-expands-oligonucleotide-and-peptide-manufacturing-in-zhenjiang/2024-12-18T10:13:54+08:00https://flcube.com/jw-therapeutics-secures-supply-agreement-with-juno-to-advance-car-t-therapy-commercialization/2024-12-18T00:42:40+08:00https://flcube.com/hightide-therapeutics-htd1801-meets-primary-and-secondary-endpoints-in-type-2-diabetes-phase-ii-study/2024-12-18T00:38:18+08:00https://flcube.com/genscript-biotechs-legend-biotech-secures-private-placement-with-hillhouse-investment/2024-12-18T00:32:38+08:00https://flcube.com/zhejiang-conba-pharmaceuticals-inhalable-pirfenidone-for-ipf-clears-for-chinese-clinical-trials/2024-12-18T00:27:34+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-receives-nmpa-approval-for-two-autoimmune-disease-drug-candidates/2024-12-18T00:23:11+08:00https://flcube.com/beijing-hospitals-to-pilot-drg-vbp-reforms-for-medical-consumables-procurement/2024-12-18T00:17:09+08:00https://flcube.com/lundbeck-a-s-reports-record-quarterly-revenue-in-q1-2023-with-11-yoy-increase/2024-12-18T00:15:12+08:00https://flcube.com/sinomab-biosciences-sm17-ind-accepted-by-nmpa-for-potential-global-first-in-class-monoclonal-antibody/2024-12-18T00:12:06+08:00https://flcube.com/china-aims-to-establish-basic-elderly-care-system-by-2025-outlines-comprehensive-plan/2024-12-18T00:07:18+08:00https://flcube.com/azenta-life-sciences-and-vazyme-biotech-form-global-partnership-for-comprehensive-services/2024-12-18T00:05:06+08:00https://flcube.com/3sbio-inc-initiates-phase-iii-clinical-study-for-thrombopoietin-in-chronic-liver-disease-patients/2024-12-17T23:59:00+08:00https://flcube.com/shanghai-junshi-biosciences-tuoyi-combo-for-triple-negative-breast-cancer-accepted-for-review/2024-12-17T23:56:11+08:00https://flcube.com/oculis-ocs-01-achieves-primary-efficacy-endpoint-in-phase-iii-diamond-trial-for-dme/2024-12-17T23:37:38+08:00https://flcube.com/nona-biosciences-and-modex-therapeutics-partner-to-develop-polyspecific-antibodies/2024-12-17T23:31:01+08:00https://flcube.com/nhsa-proposes-draft-to-enhance-basic-medical-insurance-payment-management-for-consumables/2024-12-17T23:23:41+08:00https://flcube.com/antengenes-atg-022-earns-fda-orphan-drug-designations-for-gastric-and-pancreatic-cancers/2024-12-17T23:21:52+08:00https://flcube.com/cde-drafts-proposal-on-generic-drug-studies-for-varieties-without-reference-preparations/2024-12-17T23:19:37+08:00https://flcube.com/mural-health-partners-with-clinflash-to-enhance-patient-payments-in-clinical-trials/2024-12-17T23:17:39+08:00https://flcube.com/hanx-biopharmaceuticals-hx009-receives-us-ind-approval-for-lymphoma-treatment/2024-12-17T23:11:20+08:00https://flcube.com/clover-biopharmaceuticals-partners-with-kyuan-trade-for-commercial-launch-of-adimflu-s-qis-in-china/2024-12-17T23:04:30+08:00https://flcube.com/minghui-pharmaceutical-initiates-first-in-human-trial-for-igf-1r-antibody-fusion-protein-mhb018a/2024-12-17T22:58:21+08:00https://flcube.com/chinas-nmpa-and-nhc-tighten-regulations-on-tramadol-compound-preparations/2024-12-17T22:47:31+08:00https://flcube.com/sino-biopharmaceuticals-tq-b3525-files-for-market-approval-with-cde/2024-12-17T22:45:32+08:00https://flcube.com/mabpharms-cmab007-receives-nmpa-approval-for-ige-mediated-asthma-treatment/2024-12-17T22:40:03+08:00https://flcube.com/alibaba-health-reports-30-1-revenue-growth-in-2022-financial-report/2024-12-17T22:35:40+08:00https://flcube.com/enhertu-her2-targeted-adc-officially-launched-in-china-for-breast-cancer-treatment/2024-12-17T22:00:10+08:00https://flcube.com/bayers-copanlisib-aliqopa-approved-by-nmpa-for-recurrent-follicular-lymphoma/2024-12-17T21:55:01+08:00https://flcube.com/everest-medicines-velsipity-nda-for-ulcerative-colitis-accepted-by-chinas-nmpa/2024-12-17T20:48:09+08:00https://flcube.com/astrazenecas-alxn2350-selected-for-cdes-rare-disease-drug-development-program/2024-12-17T20:42:05+08:00https://flcube.com/nmpas-cde-releases-draft-proposal-for-benefit-risk-assessment-in-global-drug-development/2024-12-17T20:36:38+08:00https://flcube.com/perennial-real-estate-holdings-tianjin-hospital-earns-medical-practice-license/2024-12-17T20:31:25+08:00https://flcube.com/msd-halts-development-of-vibostolimab-and-favezelimab-due-to-trial-setbacks/2024-12-17T16:38:17+08:00https://flcube.com/adcendo-aps-expands-partnership-with-biocytogen-to-enhance-adc-pipeline/2024-12-17T16:31:10+08:00https://flcube.com/microport-cardioflows-vitaflow-liberty-receives-marketing-approval-in-turkey/2024-12-17T16:09:46+08:00https://flcube.com/vcanbios-vum02-secures-nmpa-approval-and-fda-odd-for-cirrhosis-and-agvhd/2024-12-17T15:53:30+08:00https://flcube.com/novo-nordisk-invests-dkk-8-5-billion-in-new-odense-manufacturing-facility/2024-12-17T15:40:25+08:00https://flcube.com/johnson-johnson-submits-sbla-to-fda-for-simponi-in-pediatric-ulcerative-colitis/2024-12-17T15:29:34+08:00https://flcube.com/jjs-sc-amivantamab-faces-complete-response-letter-from-fda-for-nsclc-treatment/2024-12-17T15:19:56+08:00https://flcube.com/grand-pharmaceuticals-gpn01768-accepted-for-review-by-nmpa-for-demodex-blepharitis-treatment/2024-12-17T15:10:51+08:00https://flcube.com/jiangsu-hengruis-trastuzumab-rezetecan-on-track-for-nmpas-breakthrough-therapy-designation/2024-12-17T14:54:54+08:00https://flcube.com/abbisko-therapeutics-receives-nmpa-approval-for-irpagratinib-regulatory-study/2024-12-17T14:44:14+08:00https://flcube.com/vocabria-receives-positive-chmp-opinion-for-hiv-treatment-in-adolescents/2024-12-17T14:33:38+08:00https://flcube.com/gsks-jemperli-receives-positive-chmp-opinion-for-endometrial-cancer-indication-extension/2024-12-17T14:22:23+08:00https://flcube.com/gsks-jemperli-receives-fda-breakthrough-therapy-designation-for-rectal-cancer-treatment/2024-12-17T14:07:48+08:00https://flcube.com/microport-neurotech-leads-investment-fund-to-advance-brain-science-industry/2024-12-17T13:43:48+08:00https://flcube.com/candid-therapeutics-expands-tce-portfolio-with-strategic-partnerships-in-autoimmune-disease-treatment/2024-12-17T13:32:45+08:00https://flcube.com/ema-grants-prime-designation-to-hansoh-pharmaceuticals-hs-20093-in-collaboration-with-gsk/2024-12-17T13:18:27+08:00https://flcube.com/bio-thera-solutions-expands-license-deal-with-steincares-for-latin-american-market/2024-12-17T13:06:48+08:00https://flcube.com/lancet-study-reveals-dalians-cancer-survival-rates-compared-to-us/2024-12-17T12:04:51+08:00https://flcube.com/bioray-pharmaceuticals-liv-1-targeted-adc-bry812-files-ind-in-china/2024-12-17T12:02:34+08:00https://flcube.com/vcanbio-initiates-phase-ii-clinical-study-for-dental-pulp-stem-cell-injection-in-periodontitis/2024-12-17T11:51:13+08:00https://flcube.com/mabwell-biosciences-9mw3811-receives-nmpa-approval-for-clinical-trials-in-oncology-and-fibrosis/2024-12-17T11:48:05+08:00https://flcube.com/roches-rozlytrek-on-track-for-priority-review-for-pediatric-ntrk-fusion-tumor-treatment/2024-12-17T11:45:32+08:00https://flcube.com/zelixir-biotech-secures-over-rmb-100-million-in-series-a-financing-for-synthetic-biology-pipeline/2024-12-17T11:14:08+08:00https://flcube.com/pathoai-secures-tens-of-millions-in-angel-financing-for-ai-powered-pathology-solutions/2024-12-17T11:08:23+08:00https://flcube.com/microport-endovascular-medtech-announces-private-placement-to-fund-innovation-and-expansion/2024-12-17T10:54:45+08:00https://flcube.com/hainan-province-and-nhsa-partner-to-enhance-medical-insurance-industry-with-real-world-data/2024-12-17T10:43:05+08:00https://flcube.com/shanghai-market-regulation-bureau-targets-unfair-competition-in-pharmaceutical-sector/2024-12-17T10:37:09+08:00https://flcube.com/tianlong-science-and-technology-expands-into-northern-thailand-with-hepatitis-diagnostics/2024-12-17T10:34:17+08:00https://flcube.com/chia-tai-tianqings-tq-b3525-heads-for-priority-review-for-recurrent-follicular-lymphoma/2024-12-17T10:25:36+08:00https://flcube.com/sanofi-launches-soliqua-for-type-2-diabetes-treatment-in-china/2024-12-17T10:20:42+08:00https://flcube.com/genscripts-legend-biotech-files-type-ii-variation-application-for-carvykti-with-ema/2024-12-17T10:17:39+08:00https://flcube.com/takeda-and-hutchmeds-fruquintinib-receives-priority-review-status-from-fda/2024-12-17T09:55:26+08:00https://flcube.com/chinas-nhc-releases-fourth-list-of-pediatric-priority-drugs-to-boost-development/2024-12-17T09:50:06+08:00https://flcube.com/sichuan-kelun-pharmaceutical-to-present-clinical-data-on-ret-inhibitor-and-adc-at-asco/2024-12-17T09:47:02+08:00https://flcube.com/moderna-establishes-usd-100-million-subsidiary-in-shanghai-to-expand-mrna-technology/2024-12-16T23:56:55+08:00https://flcube.com/hubei-leads-national-volume-based-procurement-of-patented-traditional-chinese-medicines/2024-12-16T23:52:18+08:00https://flcube.com/harbour-biomeds-porustobart-combo-shows-promise-in-hcc-treatment-asco-presentation-reveals/2024-12-16T23:50:06+08:00https://flcube.com/ascentage-pharmas-olverembatinib-earns-breakthrough-designation-for-sdh-deficient-gist/2024-12-16T23:45:54+08:00https://flcube.com/abbisko-therapeutics-reports-positive-phase-ib-results-for-absk021-at-asco/2024-12-16T23:37:32+08:00https://flcube.com/shanghai-yizhongs-paclitaxel-micelles-data-to-be-presented-at-asco-annual-meeting/2024-12-16T23:34:41+08:00https://flcube.com/samr-imposes-penalties-on-grand-pharma-and-wuhan-huihai-for-monopoly-agreements/2024-12-16T23:29:13+08:00https://flcube.com/ascentage-pharma-to-present-clinical-results-of-four-oncology-drugs-at-medical-conference/2024-12-16T23:14:15+08:00https://flcube.com/astrazeneca-launches-calquence-in-china-for-mantle-cell-lymphoma-treatment/2024-12-16T23:10:15+08:00https://flcube.com/kangtai-biological-partners-with-indian-pharmaceutical-giant-for-13-valent-pneumonia-vaccine/2024-12-16T22:57:49+08:00https://flcube.com/medtronic-launches-aible-orthopedic-ecosystem-and-partners-with-allinmd-orthopedics-in-china/2024-12-16T22:51:09+08:00https://flcube.com/tyk-medicines-partners-with-wuxi-sta-for-comprehensive-cmc-services/2024-12-16T22:48:26+08:00https://flcube.com/beijings-e-health-now-secures-tens-of-millions-in-series-b-financing/2024-12-16T22:43:01+08:00https://flcube.com/boyi-biotech-secures-over-rmb100-million-in-series-a-financing-led-by-jolmo/2024-12-16T22:19:58+08:00https://flcube.com/mindray-partners-with-vazyme-biotech-to-develop-automated-infection-screening-solutions/2024-12-16T22:15:10+08:00https://flcube.com/hisun-pharmaceuticals-shp2-inhibitor-hs336-gets-nmpa-clinical-trial-approval/2024-12-16T22:06:33+08:00https://flcube.com/hainan-boao-lecheng-introduces-319-overseas-drugs-and-devices-reports-significant-growth/2024-12-16T22:04:21+08:00https://flcube.com/european-chmp-supports-conditional-approval-of-msds-welireg-for-vhl-disease-and-rcc/2024-12-16T16:43:46+08:00https://flcube.com/emas-chmp-recommends-approval-of-bayers-acoramidis-for-attr-cm-treatment/2024-12-16T16:32:54+08:00https://flcube.com/guangdong-province-releases-list-of-urgent-clinical-drugs-and-devices-for-gba-cities/2024-12-16T16:25:32+08:00https://flcube.com/sanofis-tolebrutinib-earns-fda-breakthrough-designation-for-non-relapsing-secondary-progressive-ms/2024-12-16T16:08:15+08:00https://flcube.com/roches-cobas-6800-8800-systems-2-0-earn-ce-certification-set-for-us-market-entry/2024-12-16T15:57:24+08:00https://flcube.com/ars-pharmaceuticals-neffy-receives-market-filings-in-asia-pacific-region/2024-12-16T15:44:51+08:00https://flcube.com/fujian-cosunter-pharmaceuticals-gst-hg141-earns-breakthrough-designation-for-chronic-hepatitis-b/2024-12-16T15:33:29+08:00https://flcube.com/beijing-conference-outlines-2025-healthcare-security-goals-and-2024-progress/2024-12-16T15:19:32+08:00https://flcube.com/quantum-hi-tech-chempartner-plans-to-raise-over-rmb-930-million-in-private-placement/2024-12-16T15:03:54+08:00https://flcube.com/chempartner-and-meta-bright-to-jointly-develop-a-pharmaceutical-and-biotech-hub-in-malaysia/2024-12-16T14:59:46+08:00https://flcube.com/chempartner-pharmatech-enters-strategic-partnership-with-malaysian-entities-to-develop-innovative-drugs/2024-12-16T14:59:45+08:00https://flcube.com/quantum-hi-tech-partners-with-east-china-normal-university-to-establish-advanced-drug-research-lab/2024-12-16T14:32:32+08:00https://flcube.com/abbvie-acquires-roches-nimble-therapeutics-to-boost-immunology-pipeline/2024-12-16T14:27:57+08:00https://flcube.com/iflyteks-xunfei-healthcare-passes-hkex-hearing-for-ai-powered-medical-ipo/2024-12-16T13:56:22+08:00https://flcube.com/innovent-biologics-partners-with-eli-lilly-for-distribution-of-jaypirca-in-china/2024-12-16T13:11:15+08:00https://flcube.com/emas-chmp-supports-approval-of-eli-lillys-omvoh-mirikizumab-for-crohns-disease/2024-12-16T12:51:36+08:00https://flcube.com/wepon-medicals-wp107-for-myasthenia-gravis-accepted-for-fda-review/2024-12-16T11:34:02+08:00https://flcube.com/mabwell-bioscience-plans-secondary-listing-in-hong-kong-secures-funding-for-bone-health-project/2024-12-16T11:19:18+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-receives-nmpa-approval-for-lupus-nephritis-clinical-trial/2024-12-16T10:56:28+08:00https://flcube.com/neusoft-medical-systems-and-xiamen-university-launch-mri-rd-center-partnership/2024-12-16T10:49:59+08:00https://flcube.com/neusoft-medical-systems-and-nmpa-collaborate-on-ai-enhanced-drug-administration/2024-12-16T10:41:33+08:00https://flcube.com/grand-pharmaceuticals-stc3141-sepsis-therapy-completes-phase-ii-patient-enrollment/2024-12-16T10:23:33+08:00https://flcube.com/digital-china-development-report-highlights-growth-of-digital-healthcare-ecosystem/2024-12-16T00:51:45+08:00https://flcube.com/sanofis-commitment-to-china-expansion-digital-innovation-and-local-rd/2024-12-16T00:45:39+08:00https://flcube.com/xtalpi-partners-with-eli-lilly-for-ai-driven-drug-discovery-services/2024-12-16T00:42:58+08:00https://flcube.com/chia-tai-tianqings-biosimilar-rituximab-approved-by-chinas-nmpa-for-lymphoma-treatments/2024-12-16T00:38:26+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-secures-nmpa-approvals-for-shr-2106-and-hrs-1893-clinical-trials/2024-12-16T00:35:52+08:00https://flcube.com/galvanize-therapeutics-partners-with-energenx-medical-for-greater-china-expansion/2024-12-16T00:32:55+08:00https://flcube.com/luzhu-biotechnologys-herpes-zoster-vaccine-lz901-concludes-phase-ii-study/2024-12-16T00:26:04+08:00https://flcube.com/cms-receives-nmpa-approval-for-tildrakizumab-for-plaque-psoriasis-treatment/2024-12-15T23:34:42+08:00https://flcube.com/cutia-therapeutics-lists-on-hkex-with-hkd527-million-ipo-for-dermatology-therapies/2024-12-15T23:28:28+08:00https://flcube.com/cspc-pharmaceuticals-alamab-therapeutics-presents-positive-almb-0168-data-at-asco/2024-12-15T23:25:58+08:00https://flcube.com/betta-pharmaceuticals-secures-exclusive-rights-to-c4-therapeutics-cft8919-in-greater-china/2024-12-15T23:20:49+08:00https://flcube.com/lynk-pharmaceuticals-secures-rmb-200-million-in-series-c1-financing-round/2024-12-15T23:17:44+08:00https://flcube.com/state-council-mandates-enhanced-oversight-of-medical-insurance-funds-utilization/2024-12-15T23:13:45+08:00https://flcube.com/nmpa-issues-procedures-for-enhancing-childrens-medication-information-in-drug-inserts/2024-12-15T23:11:10+08:00https://flcube.com/jiangsu-hengrui-medicines-shr-1905-and-shr7280-receive-nmpa-clinical-trial-approvals/2024-12-15T23:07:01+08:00https://flcube.com/brii-biosciences-initiates-phase-i-study-for-brii-297-in-australia/2024-12-15T23:04:37+08:00https://flcube.com/aim-vaccines-omicron-ba-5-mrna-vaccine-shows-73-16-efficacy-in-china-trial/2024-12-15T23:01:36+08:00https://flcube.com/aiming-med-partners-with-becton-dickinson-and-co-to-advance-tumor-precision-medicine/2024-12-15T22:59:54+08:00https://flcube.com/national-health-commission-unveils-action-plan-for-medical-quality-improvement-2023-2025/2024-12-15T22:48:18+08:00https://flcube.com/coherus-and-junshi-biosciences-await-fda-decision-on-toripalimab-after-inspection/2024-12-15T22:46:21+08:00https://flcube.com/betta-pharmaceuticals-befotertinib-approved-by-chinas-nmpa-for-egfr-mutated-nsclc/2024-12-15T22:42:42+08:00https://flcube.com/antengenes-xpovio-combination-therapy-approved-for-reimbursement-in-australia-for-r-r-mm/2024-12-15T22:38:07+08:00https://flcube.com/amoytop-biotech-and-fosun-pharmaceutical-ink-licensing-deal-for-pegfilgrastim-in-china/2024-12-15T22:34:54+08:00https://flcube.com/highfield-biopharmaceuticals-presents-promising-hf1k16-data-at-asco-annual-meeting/2024-12-15T22:31:45+08:00https://flcube.com/sirnaomics-initiates-phase-i-clinical-trial-for-anticoagulant-drug-candidate-stp122g/2024-12-15T22:29:48+08:00https://flcube.com/canbridge-pharmaceuticals-maralixibat-approved-by-nmpa-for-alagille-syndrome/2024-12-15T22:25:53+08:00https://flcube.com/innovent-biologics-partners-with-merck-kgaa-to-test-kras-inhibitor-combo-in-nsclc/2024-12-15T22:23:15+08:00https://flcube.com/shenzhen-abrobo-medical-robot-secures-rmb-100-million-in-series-a-financing-for-robotic-development/2024-12-15T22:12:46+08:00https://flcube.com/akeso-biopharmas-ebronucimab-nda-accepted-for-review-by-chinas-nmpa/2024-12-15T22:00:47+08:00https://flcube.com/eikon-therapeutics-inks-licensing-deals-and-raises-funds-for-drug-pipeline-expansion/2024-12-15T21:56:01+08:00https://flcube.com/sino-biopharmaceuticals-subsidiary-invox-completes-additional-investment-in-phion-therapeutics/2024-12-15T21:45:49+08:00https://flcube.com/ucello-therapeutics-secures-rmb-150-million-in-series-a-financing-for-car-t-cell-therapy/2024-12-15T21:40:00+08:00https://flcube.com/eversana-forms-strategic-alliance-with-china-resource-pharmaceutical-for-healthcare-expansion/2024-12-15T21:35:03+08:00https://flcube.com/biosyngens-brg01-earns-orphan-drug-designation-from-us-fda-for-nasopharyngeal-carcinoma/2024-12-15T21:25:28+08:00https://flcube.com/nmpa-clears-medtronics-corindus-for-marketing-of-advanced-coronary-surgery-systems/2024-12-15T21:20:51+08:00https://flcube.com/nmpa-grants-market-approval-for-lanzhou-kejin-taijis-carbon-ion-therapy-system/2024-12-15T21:11:17+08:00https://flcube.com/hightide-therapeutics-inc-plans-hong-kong-ipo-to-fund-clinical-development/2024-12-15T20:31:22+08:00https://flcube.com/shanghai-duoning-biotechnology-partners-with-wuhan-kaide-jinuo-for-gene-therapy-rd/2024-12-15T20:29:16+08:00https://flcube.com/guangdong-zhongsheng-pharma-initiates-phase-iib-study-for-zsp1601-in-nash/2024-12-15T20:24:27+08:00https://flcube.com/novartiss-iptacopan-on-track-for-priority-review-status-in-china-for-pnh-treatment/2024-12-15T20:21:39+08:00https://flcube.com/cspc-pharmaceutical-group-partners-with-china-unicom-for-digital-transformation/2024-12-15T20:19:13+08:00https://flcube.com/novo-nordisks-semaglutide-for-weight-loss-accepted-for-review-by-chinas-nmpa/2024-12-15T20:16:28+08:00https://flcube.com/qilu-pharmaceutical-gains-temporary-fda-approval-to-import-cisplatin-amid-us-shortage/2024-12-15T20:13:51+08:00https://flcube.com/cde-releases-70th-batch-of-generic-reference-preparations-for-public-feedback/2024-12-15T20:02:53+08:00https://flcube.com/cstone-pharmaceuticals-and-blueprint-medicines-ayvakit-wins-fda-approval-for-ism-treatment/2024-12-15T20:00:44+08:00https://flcube.com/neurophth-biotechnology-partners-with-sinopharm-group-to-commercialize-gene-therapy-nfs-01/2024-12-15T19:57:57+08:00https://flcube.com/shanghai-junshi-biosciences-to-list-gdrs-on-swiss-exchange-raising-rmb-3-4-billion/2024-12-15T19:54:20+08:00https://flcube.com/cstone-pharmaceuticals-presents-ayvakit-data-for-advanced-gist-at-asco-2023/2024-12-15T19:50:27+08:00https://flcube.com/hansoh-pharmaceutical-gets-nmpa-approval-for-hs-20117-bispecific-antibody-clinical-study/2024-12-15T19:48:12+08:00https://flcube.com/chinese-pharma-companies-update-pipelines-at-asco-2023-annual-meeting/2024-12-15T19:42:30+08:00https://flcube.com/sinovac-biotech-partners-with-bogota-to-establish-bogotabio-for-vaccine-production/2024-12-15T19:39:05+08:00https://flcube.com/longreach-group-puts-quasar-medical-on-the-block-attracting-major-bidders/2024-12-15T19:36:14+08:00https://flcube.com/gracell-biotechnologies-gc012f-showcases-positive-data-at-asco-annual-meeting/2024-12-15T19:29:40+08:00https://flcube.com/cstone-pharmaceuticals-and-servier-report-positive-agile-study-results-for-tibsovo-at-asco/2024-12-15T19:22:34+08:00https://flcube.com/gileads-kite-announces-breakthrough-phase-iii-results-for-yescarta-in-r-r-lbcl/2024-12-15T19:16:06+08:00https://flcube.com/itabmed-ltd-receives-nmpa-ind-approval-for-a-337-a-cd3-activating-bsab-targeting-epcam/2024-12-15T19:12:24+08:00https://flcube.com/chinas-most-issues-updated-hgr-rules-impacting-foreign-collaborations-in-genetic-research/2024-12-15T19:00:53+08:00https://flcube.com/luye-pharmas-lurbinectedin-for-metastatic-sclc-accepted-for-review-by-chinas-nmpa/2024-12-15T18:56:23+08:00https://flcube.com/lees-pharmaceutical-subsidiary-zhaoke-ophthalmology-announces-fda-review-of-nvk002-for-pediatric-myopia/2024-12-15T18:23:26+08:00https://flcube.com/legend-biotech-submits-sbla-to-expand-carvykti-label-for-relapsed-multiple-myeloma/2024-12-15T18:20:39+08:00https://flcube.com/zai-lab-and-novocures-ttfields-show-survival-benefit-in-nsclc-despite-stock-plunge/2024-12-15T16:33:45+08:00https://flcube.com/sequoia-capital-to-split-into-three-units-including-independent-china-and-india-sea-divisions/2024-12-15T16:29:15+08:00https://flcube.com/jacobio-pharma-gets-green-light-for-phase-i-iia-study-of-parp7-inhibitor-jab-26766/2024-12-15T16:23:24+08:00https://flcube.com/biomarin-pharmaceutical-to-discontinue-vimizim-import-license-in-china/2024-12-15T16:16:46+08:00https://flcube.com/biomarin-to-cut-225-jobs-amid-challenges-in-gene-therapy-commercialization/2024-12-15T16:13:49+08:00https://flcube.com/vcanbio-receives-nmpa-approval-for-vum02-stem-cell-therapy-in-liver-failure-and-ards/2024-12-15T16:10:57+08:00https://flcube.com/dizal-pharmaceutical-presents-updates-on-sunvozertinib-and-golidocitinib-at-asco-2023/2024-12-15T15:25:29+08:00https://flcube.com/abbisko-therapeutics-pimicotinib-earns-prime-status-for-tgct-from-ema/2024-12-15T15:22:57+08:00https://flcube.com/nmpa-approves-shenzhen-core-medicals-implantable-left-ventricular-assist-system/2024-12-15T15:20:14+08:00https://flcube.com/ubrigene-partners-with-everlife-biomed-to-advance-ipsc-therapy-preparation/2024-12-15T14:52:54+08:00https://flcube.com/epimab-biotherapeutics-appoints-dr-zhu-yonghong-as-chief-medical-officer/2024-12-15T14:45:15+08:00https://flcube.com/innovent-biologics-initiates-phase-i-trial-for-ibi3009-in-small-cell-lung-cancer-and-neuroendocrine-tumors/2024-12-15T14:32:31+08:00https://flcube.com/janssen-submits-additional-indication-application-to-fda-for-carvykti-in-multiple-myeloma/2024-12-15T01:21:57+08:00https://flcube.com/reistone-biopharmas-ivarmacitinib-accepted-for-review-by-chinas-cde-for-atopic-dermatitis/2024-12-15T01:12:50+08:00https://flcube.com/lees-pharmaceutical-secures-rights-to-eyedetecs-dry-eye-device-in-asia-pacific/2024-12-15T00:47:56+08:00https://flcube.com/nmpa-approves-betta-pharmaceuticals-vorolanib-for-second-line-rcc-treatment-in-combination-with-everolimus/2024-12-15T00:41:48+08:00https://flcube.com/zelgen-biopharmaceuticals-zggs15-earns-fda-approval-for-advanced-solid-tumor-clinical-trial/2024-12-15T00:36:49+08:00https://flcube.com/cspc-pharmaceuticals-cpo301-receives-health-canada-approval-for-phase-i-study/2024-12-15T00:32:19+08:00https://flcube.com/shanghai-fosun-high-technology-partners-with-nice-for-joint-innovation-centers/2024-12-15T00:29:36+08:00https://flcube.com/samyang-holdings-partners-with-yxintent-for-lafullen-dermal-filler-in-china/2024-12-15T00:21:00+08:00https://flcube.com/keymed-biosciences-cm313-monoclonal-antibody-shows-promise-in-phase-i-study-for-multiple-myeloma/2024-12-15T00:12:33+08:00https://flcube.com/eccogene-secures-25-million-in-series-b-financing-to-advance-metabolic-disease-therapies/2024-12-15T00:09:21+08:00https://flcube.com/hutchmed-presents-updated-data-on-hematological-malignancy-therapies-at-eha-and-icml/2024-12-15T00:05:02+08:00https://flcube.com/abbisko-therapeutics-initiates-phase-ii-study-for-pimicotinib-in-chronic-graft-versus-host-disease/2024-12-15T00:02:14+08:00https://flcube.com/nhsa-launches-2023-nrdl-update-process-with-new-work-plan-and-public-feedback-period/2024-12-14T23:59:33+08:00https://flcube.com/genor-biopharmas-geptanolimab-nda-for-ptcl-rejected-by-chinas-nmpa/2024-12-14T23:57:17+08:00https://flcube.com/cspc-pharmaceuticals-cpo301-earns-fast-track-status-for-egfr-mutant-nsclc-treatment/2024-12-14T23:54:37+08:00https://flcube.com/salubris-pharmaceuticals-enarodustat-gains-nmpa-approval-for-renal-anemia-treatment/2024-12-14T23:52:08+08:00https://flcube.com/baheal-pharmaceutical-partners-with-rabpharma-for-commercialization-of-rab001-in-china/2024-12-14T23:47:24+08:00https://flcube.com/cde-releases-71st-batch-of-generic-reference-preparations-with-updates-and-new-injecables/2024-12-14T23:37:47+08:00https://flcube.com/hainan-boao-lecheng-partners-with-recordati-on-rare-disease-drug-development/2024-12-14T23:36:00+08:00https://flcube.com/nmpa-approves-shanghai-magic-medicines-innovative-multimodal-tumor-treatment-system/2024-12-14T23:30:10+08:00https://flcube.com/croma-pharma-initiates-phase-iii-clinical-trial-in-china-for-hyaluronic-acid-dermal-filler/2024-12-14T23:22:11+08:00https://flcube.com/mass-general-brigham-partners-with-simcere-pharmaceutical-for-cancer-and-autoimmune-disease-research/2024-12-14T23:16:57+08:00https://flcube.com/apeloa-pharmaceutical-partners-with-zelgen-biopharmaceuticals-for-cdmo-programs/2024-12-14T23:14:14+08:00https://flcube.com/sinocelltech-group-receives-nmpa-approval-for-biosimilar-version-of-humira/2024-12-14T23:11:30+08:00https://flcube.com/bio-thera-solutions-bat6026-receives-nmpa-approval-for-atopic-dermatitis-clinical-trials/2024-12-14T23:08:25+08:00https://flcube.com/dizal-pharmaceuticals-sunvozertinib-gets-eu-approval-for-global-phase-iii-study/2024-12-14T23:05:59+08:00https://flcube.com/cspc-pharmaceutical-gets-nmpa-approval-for-atm-inhibitor-syh2051-clinical-study/2024-12-14T23:03:41+08:00https://flcube.com/viva-biotech-holdings-divests-stake-in-shanghai-unit-to-temasek-backed-entities/2024-12-14T23:01:14+08:00https://flcube.com/china-medical-systems-diazepam-nasal-spray-receives-nmpa-approval-for-cluster-seizures/2024-12-14T22:58:21+08:00https://flcube.com/dizal-pharmaceutical-presents-updates-on-dzd8586-and-golidocitinib-at-icml/2024-12-14T22:46:54+08:00https://flcube.com/astrazenecas-soliris-secures-third-indication-for-myasthenia-gravis-in-china/2024-12-14T22:43:42+08:00https://flcube.com/nhsa-report-highlights-flying-inspections-impact-on-medical-insurance-fund-use-in-2022/2024-12-14T22:41:23+08:00https://flcube.com/hansoh-pharmaceutical-gets-nmpa-approval-for-hif-2%ce%b1-inhibitor-hs-10516-clinical-study/2024-12-14T22:39:24+08:00https://flcube.com/sino-biopharmaceutical-secures-exclusive-rights-to-gmax-biopharms-gma106-in-greater-china/2024-12-14T22:31:41+08:00https://flcube.com/huahai-pharmaceuticals-adalimumab-biosimilar-accepted-by-chinas-cde-for-review/2024-12-14T22:07:24+08:00https://flcube.com/insilico-medicine-receives-10-million-milestone-payment-for-xl309-clinical-progress/2024-12-14T21:43:53+08:00https://flcube.com/uih-surgical-to-invest-rmb-2-5-billion-in-wuhan-medical-innovation-and-robotics-base/2024-12-14T02:36:44+08:00https://flcube.com/jjets-ipo-on-star-market-accepted-aims-to-raise-rmb-2-691-billion-for-medical-device-expansion/2024-12-14T02:30:59+08:00https://flcube.com/genevector-initiates-clinical-study-for-jwk001-in-neovascular-age-related-macular-degeneration/2024-12-14T02:24:17+08:00https://flcube.com/dartsbio-pharmaceuticals-and-simm-receive-nmpa-approval-for-adc-ds001-clinical-trial/2024-12-14T02:00:16+08:00https://flcube.com/hubei-guangji-pharmaceutical-partners-with-jiangnan-university-for-green-manufacturing-innovation-lab/2024-12-14T01:53:21+08:00https://flcube.com/hybio-pharmaceuticals-semaglutide-api-receives-fda-review-acceptance/2024-12-14T01:48:33+08:00https://flcube.com/ysb-inc-lists-on-hkse-with-hkd-363-6-million-ipo-targeting-digital-pharma-services/2024-12-14T01:42:39+08:00https://flcube.com/ascletis-pharma-inc-ceases-promotion-of-hepatitis-c-products-and-halts-development-of-asc06-and-asc09/2024-12-14T01:39:12+08:00https://flcube.com/mabwell-biosciences-il-11-mab-9mw3811-receives-us-fda-clinical-trial-approval/2024-12-14T01:36:08+08:00https://flcube.com/ascendis-pharmas-transcon-hgh-sbla-for-adult-ghd-accepted-by-fda/2024-12-13T15:42:51+08:00https://flcube.com/alibaba-health-reports-10-2-revenue-growth-and-72-8-profit-increase-in-2024-h1-financials/2024-12-13T15:29:25+08:00https://flcube.com/novo-nordisks-ozempic-receives-positive-chmp-opinion-for-kidney-disease-indication/2024-12-13T15:20:25+08:00https://flcube.com/bayer-ag-initiates-phase-i-study-combining-bay3498264-with-sotorasib-for-kras-mutated-tumors/2024-12-13T15:13:23+08:00https://flcube.com/curegene-pharmaceutical-gets-nmpa-approval-for-antiplatelet-drug-cg-0255/2024-12-13T14:59:34+08:00https://flcube.com/johnson-johnson-medtechs-impella-heart-pumps-gain-fda-approval-for-pediatric-heart-failure/2024-12-13T14:50:33+08:00https://flcube.com/pfizers-ibrance-demonstrates-significant-pfs-improvement-in-phase-iii-patina-trial/2024-12-13T14:33:28+08:00https://flcube.com/gan-lee-pharmaceuticals-gets-fda-approval-for-gzr18-obesity-overweight-phase-ii-study/2024-12-13T14:10:03+08:00https://flcube.com/hutchmeds-orpathys-receives-breakthrough-therapy-designation-in-china-for-advanced-lung-cancer/2024-12-13T13:42:28+08:00https://flcube.com/hutchmed-to-receive-milestone-payment-as-takedas-fruzaqla-gets-reimbursement-nod-in-spain/2024-12-13T13:19:29+08:00https://flcube.com/national-vbp-program-round-10-195-manufacturers-secure-winning-bids-for-62-drugs/2024-12-13T13:02:33+08:00https://flcube.com/nanjing-leads-biolabs-receives-fda-ind-approval-for-lbl-033-phase-i-ii-clinical-trial/2024-12-13T12:55:16+08:00https://flcube.com/jiangxi-jemincares-jyb1907-receives-nmpa-approval-for-clinical-study-in-solid-tumors/2024-12-13T12:54:30+08:00https://flcube.com/takeda-and-hutchmeds-elunate-study-results-published-in-the-lancet/2024-12-13T12:54:02+08:00https://flcube.com/transcentas-liv-1-adcs-show-promising-results-in-pre-clinical-breast-cancer-study/2024-12-13T12:51:41+08:00https://flcube.com/sunshine-lake-pharma-files-for-hkex-ipo-expanding-global-pharmaceutical-reach/2024-12-13T12:51:02+08:00https://flcube.com/huidagene-therapeutics-launches-muscle-study-for-crispr-therapy-in-duchenne-muscular-dystrophy/2024-12-13T12:50:27+08:00https://flcube.com/grand-pharmaceutical-group-receives-nmpa-approval-for-novasync-hybrid-systm/2024-12-13T12:49:51+08:00https://flcube.com/fosun-pharma-initiates-phase-ii-study-of-hlx26-and-serplulimab-combo-for-metastatic-crc/2024-12-13T10:58:16+08:00https://flcube.com/cstones-sugemalimab-shows-promising-survival-rates-in-stage-iv-nsclc-treatment/2024-12-13T10:50:49+08:00https://flcube.com/gates-foundation-renews-partnership-with-beijing-and-tsinghua-to-boost-infectious-disease-research/2024-12-13T10:41:55+08:00https://flcube.com/sperogenix-therapeutics-and-luca-healthcare-join-forces-to-advance-digital-therapy-for-myasthenia-gravis/2024-12-13T10:26:38+08:00https://flcube.com/nmpa-approves-suzhou-microport-joint-medical-technologys-zirconium-niobium-alloy-femoral-head-for-hip-replacement/2024-12-13T10:14:35+08:00https://flcube.com/cytocraft-biotechs-sdt-t002-cell-therapy-approved-for-advanced-liver-cancer-by-nmpa/2024-12-13T10:01:55+08:00https://flcube.com/grand-pharmaceuticals-stc3141-achieves-clinical-endpoint-in-sepsis-study/2024-12-13T09:53:57+08:00https://flcube.com/everest-medicines-appoints-dr-mike-berry-as-chief-technology-officer-to-drive-innovation/2024-12-13T09:50:45+08:00https://flcube.com/siemens-healthineers-ag-acquires-advanced-accelerator-applications-to-boost-petnet-solutions/2024-12-13T00:03:38+08:00https://flcube.com/astrazeneca-weighs-spinning-off-china-business-to-shield-against-geopolitical-tensions/2024-12-12T23:53:28+08:00https://flcube.com/tg-immunopharma-receives-fda-approval-for-phase-i-clinical-study-of-tgi-6-bispecific-antibody/2024-12-12T23:50:28+08:00https://flcube.com/iaso-bio-receives-fda-ind-approval-for-iaso-782-for-autoimmune-disorders/2024-12-12T23:46:38+08:00https://flcube.com/adicon-holdings-ltd-ipo-a-strategic-move-for-growth-in-diagnostics/2024-12-12T23:43:24+08:00https://flcube.com/acotec-scientific-holdings-and-boston-scientific-group-plc-sign-mou-to-broaden-collaboration/2024-12-12T23:38:37+08:00https://flcube.com/aosaikang-pharmaceuticals-askb589-shows-promising-results-in-solid-tumor-treatment-study/2024-12-12T23:34:05+08:00https://flcube.com/jiangsu-hengrui-medicine-cancels-licensing-agreement-with-mabworks-citing-market-changes/2024-12-12T23:29:54+08:00https://flcube.com/roches-evrysdi-receives-nmpa-approval-for-wider-sma-patient-age-range/2024-12-12T23:27:31+08:00https://flcube.com/micurx-pharmaceuticals-mrx-4-contezolid-combo-receives-clinical-trial-approvals-for-diabetic-foot-infection/2024-12-12T23:24:57+08:00https://flcube.com/astrazeneca-enters-three-year-collaboration-with-cholesgen-for-metabolic-disease-therapies/2024-12-12T22:55:54+08:00https://flcube.com/mabwell-bioscience-secures-licensing-deal-with-tabuk-pharmaceutical-for-mena-region/2024-12-12T20:48:53+08:00https://flcube.com/immunotech-biopharms-car-t-19-earns-breakthrough-therapy-designation-for-b-all-treatment/2024-12-12T17:03:00+08:00https://flcube.com/grand-pharmaceutical-group-secures-licensing-agreement-for-corxels-nasal-sprays-in-greater-china/2024-12-12T16:40:43+08:00https://flcube.com/eosvision-ltd-secures-series-a-funding-to-advance-ophthalmic-implant-development/2024-12-12T15:53:50+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-receives-nmpa-clearance-for-hrs-4729-peptide-drug/2024-12-12T15:38:18+08:00https://flcube.com/viva-biotech-expands-global-footprint-with-new-boston-branch/2024-12-12T15:25:43+08:00https://flcube.com/angitia-biopharmaceuticals-secures-usd-120-million-in-series-c-financing-for-musculoskeletal-treatments/2024-12-12T14:53:07+08:00https://flcube.com/mdhc-life-technologies-secures-series-c-funding-to-boost-consumer-healthcare-and-life-sciences/2024-12-12T14:40:33+08:00https://flcube.com/bayer-ags-shanghai-co-lab-to-host-epigenic-therapeutics-and-peers-for-cgt-innovation/2024-12-12T14:28:33+08:00https://flcube.com/astrazenecas-lynparza-shows-sustained-improvements-in-olympia-phase-iii-study/2024-12-12T14:13:52+08:00https://flcube.com/sanofi-receives-fda-fast-track-designation-for-influenza-and-covid-19-combo-vaccine-candidates/2024-12-12T13:58:55+08:00https://flcube.com/youjia-biomedical-and-livzon-pharmaceutical-group-ink-licensing-deal-for-sirna-drug/2024-12-12T13:47:30+08:00https://flcube.com/bayer-ag-to-acquire-hidoc-technologies-and-launch-digital-health-app-cara-care/2024-12-12T13:31:30+08:00https://flcube.com/eli-lillys-imlunestrant-reduces-disease-progression-in-er-her2-advanced-breast-cancer-ember-3-study/2024-12-12T13:12:24+08:00https://flcube.com/pfizer-to-establish-smart-medical-innovation-center-in-hangzhous-qiantang-district/2024-12-12T12:02:33+08:00https://flcube.com/medivir-ab-receives-chinese-patent-approval-for-liver-cancer-treatment-fostroxacitabine-bralpamide/2024-12-12T11:57:03+08:00https://flcube.com/shanghai-cell-therapy-group-partners-with-nantong-federation-for-comprehensive-health-services-platform/2024-12-12T11:53:43+08:00https://flcube.com/huadong-medicines-subsidiary-perfect-mrna-biotechnology-partners-with-yoltech-therapeutics/2024-12-12T11:47:49+08:00https://flcube.com/merck-appoints-marc-horn-as-china-unit-president-succeeding-allan-gabor/2024-12-12T11:35:44+08:00https://flcube.com/sinocelltech-group-launches-biosimilar-version-of-abbvies-humira-in-china/2024-12-12T11:32:54+08:00https://flcube.com/grand-pharmaceutical-initiates-phase-ii-starburst-study-for-tlx250-cdx-in-indication-expansion/2024-12-12T11:28:59+08:00https://flcube.com/novlead-biotech-secures-rmb-100-million-in-series-b-financing-for-nitric-oxide-therapy-innovations/2024-12-12T11:22:57+08:00https://flcube.com/guangdong-zhongsheng-pharmaceutical-plans-to-raise-rmb-600-million-via-private-placement/2024-12-12T11:17:43+08:00https://flcube.com/shanghai-pharmaceuticals-sph3127-for-hypertension-gets-mnpa-review-acceptance/2024-12-12T11:13:10+08:00https://flcube.com/united-imaging-healthcare-acquires-stake-in-apactron-for-high-end-particle-therapy-technology/2024-12-12T11:04:38+08:00https://flcube.com/sequanta-technologies-partners-with-darkjade-sciences-to-establish-organoid-bank-and-glioma-project/2024-12-12T10:43:39+08:00https://flcube.com/insilico-medicine-partners-with-shanghaitech-university-for-tumor-drug-rd-advancement/2024-12-12T10:19:33+08:00https://flcube.com/winhealth-pharma-receives-nmpa-approval-for-glycerol-phenylbutyrate-for-urea-cycle-disorders/2024-12-12T10:15:27+08:00https://flcube.com/jiangsu-hengrui-pharmaceutials-shr-1209-for-hypercholesterolemia-accepted-for-nmpa-review/2024-12-12T00:57:58+08:00https://flcube.com/minghui-pharmaceutical-achieves-first-dosing-milestone-in-phase-i-studies-for-adc-candidates/2024-12-12T00:54:35+08:00https://flcube.com/xiamen-itg-group-and-fosun-health-collaborate-on-big-health-industry-fund-and-medical-device-commercialization/2024-12-12T00:49:15+08:00https://flcube.com/australian-scleral-lens-epicon-a-approved-by-chinas-nmpa-as-10th-novel-product/2024-12-12T00:33:53+08:00https://flcube.com/cde-considers-breakthrough-therapy-designation-for-beijing-mabworks-mil162-and-amgens-amg-890/2024-12-12T00:16:22+08:00https://flcube.com/fujian-cosunter-pharmaceuticals-covid-19-drug-gst-hg171-meets-primary-endpoint-in-phase-ii-iii-study/2024-12-12T00:12:23+08:00https://flcube.com/boehringer-ingelheims-spevigo-on-track-for-priority-review-for-gpp-flare-prevention-in-china/2024-12-12T00:08:24+08:00https://flcube.com/bio-thera-solutions-pd-1-inhibitor-bat1308-approved-for-cervical-cancer-clinical-trials-in-china/2024-12-12T00:03:25+08:00https://flcube.com/jiangsu-hengruis-camrelizumab-earns-full-approval-for-advanced-hepatocellular-carcinoma-in-china/2024-12-12T00:01:07+08:00https://flcube.com/biocytogen-pharmaceuticals-receives-cnipa-patent-for-renmab-human-antibody-mice-platform/2024-12-11T23:57:47+08:00https://flcube.com/sino-cuban-jv-biotech-pharmaceutical-receives-nmpa-approval-for-nimotuzumab-in-pancreatic-cancer/2024-12-11T23:46:45+08:00https://flcube.com/sarepta-therapeutics-elevidys-receives-fda-accelerated-approval-for-duchenne-muscular-dystrophy/2024-12-11T22:54:53+08:00https://flcube.com/s-evans-biosciences-receives-nmpa-tacit-approval-for-stem-cell-therapy-in-ards/2024-12-11T22:13:47+08:00https://flcube.com/kite-pharmas-yescarta-marketing-rights-transferred-to-gilead-sciences-k-k-in-japan/2024-12-11T22:07:45+08:00https://flcube.com/hopstem-biotechnologys-hnpc01-receives-tacit-approval-for-stroke-sequelae-treatment-from-cde/2024-12-11T22:01:32+08:00https://flcube.com/edding-pharma-aims-for-fifth-ipo-attempt-on-hong-kong-stock-exchange/2024-12-11T21:52:00+08:00https://flcube.com/cde-releases-guidelines-for-clinical-trials-of-stem-cell-therapies-and-derived-products/2024-12-11T21:44:01+08:00https://flcube.com/sciwind-biosciences-leads-chinas-anti-obesity-drug-market-with-glp-1-analog-ecnoglutide/2024-12-11T21:41:29+08:00https://flcube.com/cde-releases-draft-guidelines-for-antibody-drug-conjugate-research-and-evaluation/2024-12-11T21:37:06+08:00https://flcube.com/aureka-biotechnologies-secures-10-million-in-seed-funding-for-ai-driven-biotechnology/2024-12-11T21:35:05+08:00https://flcube.com/shanghai-unveils-action-plan-and-fund-for-biopharma-ma-activities/2024-12-11T20:19:58+08:00https://flcube.com/fresenius-kabi-partners-with-ori-biotech-to-integrate-iro-platform-with-cell-processing-systems/2024-12-11T17:24:26+08:00https://flcube.com/arvinas-and-pfizer-present-positive-tactive-u-sub-study-data-at-sabcs-2024/2024-12-11T17:13:59+08:00https://flcube.com/gsk-enters-multi-program-partnerships-with-relation-therapeutics-for-fibrotic-diseases-and-osteoarthritis/2024-12-11T16:58:10+08:00https://flcube.com/novartis-kisqali-shows-sustained-efficacy-in-natalee-study-at-sabcs-2024/2024-12-11T16:45:32+08:00https://flcube.com/legend-biotechs-carvykti-demonstrates-high-mrd-negativity-rates-in-phase-iii-cartitude-4-trial/2024-12-11T16:37:35+08:00https://flcube.com/huadong-medicines-arcalyst-receives-nmpa-approval-for-recurrent-pericarditis-treatment/2024-12-11T16:27:15+08:00https://flcube.com/imeik-technology-receives-nmpa-approval-for-recombinant-human-hyaluronidase-clinical-study/2024-12-11T16:12:33+08:00https://flcube.com/patronus-biotechs-rsv-vaccine-lyb005-receives-nmpa-approval-for-clinical-study/2024-12-11T15:55:54+08:00https://flcube.com/shanghai-pharmaceuticals-srd4610-receives-fda-orphan-drug-designation-for-als-treatment/2024-12-11T15:04:47+08:00https://flcube.com/sperogenix-therapeutics-agamree-receives-nmpa-approval-for-duchenne-muscular-dystrophy-treatment/2024-12-11T14:52:56+08:00https://flcube.com/beijing-expands-medical-insurance-sharing-to-near-relatives-with-new-policy/2024-12-11T14:22:47+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-secures-nmpa-approvals-for-shr-4394-and-hrs-3802-clinical-trials/2024-12-11T14:16:02+08:00https://flcube.com/mercks-pd-1-inhibitor-keytruda-approved-by-nmpa-for-cervical-cancer-treatment-in-china/2024-12-11T13:52:42+08:00https://flcube.com/msds-noxafil-receives-nmpa-approval-for-pediatric-use-in-antifungal-treatment/2024-12-11T13:44:19+08:00https://flcube.com/nmpa-approves-zynlonta-for-relapsed-or-refractory-large-b-cell-lymphoma-treatment/2024-12-11T13:33:21+08:00https://flcube.com/wuhan-yzy-biopharmas-m701-shows-promise-in-phase-ii-study-for-malignant-pleural-effusion-at-esmo-asia-2024/2024-12-11T12:48:29+08:00https://flcube.com/porton-pharma-solutions-and-od-kingsley-life-sciences-form-partnership-for-bio-conjugated-drug-development/2024-12-11T12:22:21+08:00https://flcube.com/stereotaxis-and-microport-ep-receive-nmpa-approval-for-magbot-magnetic-navigation-ablation-catheter/2024-12-10T22:56:37+08:00https://flcube.com/immunofocos-imc002-earns-fda-fast-track-designation-for-cldn-18-2-positive-gastric-cancer/2024-12-10T22:38:35+08:00https://flcube.com/innovec-biotherapeutics-ivb102-receives-fda-ind-approval-for-x-linked-retinoschisis-treatment/2024-12-10T22:28:20+08:00https://flcube.com/innovec-pharmas-ivb103-gene-therapy-for-namd-receives-clinical-trial-approval-from-chinas-cde/2024-12-10T22:21:47+08:00https://flcube.com/nona-biosciences-partners-with-kodiak-sciences-to-discover-multi-target-ophthalmic-antibodies/2024-12-10T22:13:16+08:00https://flcube.com/eisais-urece-dotinurad-approved-by-chinas-nmpa-for-gout-treatment-with-hyperuricemia/2024-12-10T20:51:27+08:00https://flcube.com/daiichi-sankyo-and-astrazenecas-datopotamab-deruxtecan-earns-fda-breakthrough-therapy-designation/2024-12-10T20:40:14+08:00https://flcube.com/shanghai-pharmaceuticals-and-sichuan-kelun-biotech-partner-to-expand-sacituzumab-tirumotecan-market-access/2024-12-10T20:28:50+08:00https://flcube.com/china-medical-systems-methylthioninium-tablets-receive-first-prescriptions-for-colonoscopy-use/2024-12-10T17:35:16+08:00https://flcube.com/dizal-pharmaceutical-unveils-promising-data-on-dzd8586-for-b-nhl-at-ash-annual-meeting/2024-12-10T17:20:06+08:00https://flcube.com/abbvies-tavapadon-shows-positive-results-in-phase-iii-tempo-2-study-for-parkinsons-disease/2024-12-10T17:03:27+08:00https://flcube.com/eli-lillys-jaypirca-demonstrates-superiority-in-bruin-cll-321-study-for-cll-sll-treatment/2024-12-10T16:55:06+08:00https://flcube.com/cde-releases-89th-batch-of-reference-preparations-for-generic-quality-consistency/2024-12-10T16:42:09+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-plans-secondary-listing-on-hong-kong-stock-exchange/2024-12-10T16:35:28+08:00https://flcube.com/keymed-biosciences-presents-cm336-data-for-relapsed-multiple-myeloma-at-ash-annual-meeting/2024-12-10T16:27:26+08:00https://flcube.com/antengenes-xpovio-showcases-positive-results-in-phase-iii-bench-and-phase-i-ii-touch-studies-at-ash-2024/2024-12-10T16:14:02+08:00https://flcube.com/lees-pharmaceutical-receives-nmpa-approval-for-generic-glaucoma-treatments/2024-12-10T15:53:27+08:00https://flcube.com/nmpa-proposes-draft-for-simplified-registration-of-traditional-chinese-medicines-from-hong-kong-and-macao/2024-12-10T15:40:12+08:00https://flcube.com/chinas-nhsa-and-nhc-issue-guidelines-to-enhance-volume-based-procurement-mechanism/2024-12-10T15:29:11+08:00https://flcube.com/cspc-pharmaceutical-groups-syhx2011-for-metastatic-breast-cancer-accepted-for-nmpa-review/2024-12-10T15:22:06+08:00https://flcube.com/gsks-nucala-receives-fda-review-for-copd-indication-based-on-matinee-study-data/2024-12-10T15:11:11+08:00https://flcube.com/hantech-medical-device-co-ltd-acquires-bds-villamarzana-factory-to-expand-manufacturing/2024-12-10T15:03:07+08:00https://flcube.com/novogene-and-becton-dickinson-partner-to-advance-single-cell-sequencing-technologies/2024-12-10T14:49:55+08:00https://flcube.com/precision-biotech-and-tl-biotechnology-form-partnership-to-advance-cell-and-gene-therapies/2024-12-10T14:34:22+08:00https://flcube.com/microport-scientific-corp-launches-firefalcon-balloon-for-coronary-interventions-with-nmpa-approval/2024-12-10T13:57:42+08:00https://flcube.com/huidagene-therapeutics-initiates-hero-trial-for-rna-editing-therapy-hg204-in-mecp2-duplication-syndrome/2024-12-10T13:37:05+08:00https://flcube.com/simcere-pharmaceuticals-sim0508-reaches-first-patient-dosing-in-global-clinical-study/2024-12-10T13:04:59+08:00https://flcube.com/livzon-pharmaceutical-group-inks-influenza-vaccine-patent-deal-with-south-china-vaccine-corporation/2024-12-10T12:44:19+08:00https://flcube.com/jiaxing-faber-xintian-pharma-secures-rmb-100-million-in-series-a2-financing-for-radiopharmaceuticals-expansion/2024-12-10T12:13:00+08:00https://flcube.com/cstone-pharmaceuticals-partners-with-pharmalink-for-suemalimab-commercialization-in-mena-and-south-africa/2024-12-10T12:10:58+08:00https://flcube.com/sinopharm-expands-partnership-with-guizhou-government-to-boost-health-industry/2024-12-10T12:09:48+08:00https://flcube.com/coherent-biopharma-and-c-ray-therapeutics-partner-to-advance-peptide-drug-conjugate-development/2024-12-10T11:55:30+08:00https://flcube.com/canbridge-pharmaceuticals-reports-positive-phase-ib-results-for-omoprubart-in-pnh-treatment/2024-12-10T11:43:28+08:00https://flcube.com/sino-medical-sciences-technology-secures-fda-thailand-approval-for-nc-rockstar-balloon-catheter/2024-12-10T11:29:36+08:00https://flcube.com/haisco-pharmaceuticals-hsk31679-receives-clinical-trial-approval-for-nash-treatment/2024-12-10T11:21:05+08:00https://flcube.com/nmpa-approves-xzenith-biopharms-anaprazole-for-duodenal-ulcer-treatment/2024-12-10T11:01:16+08:00https://flcube.com/sichuan-keluns-skb264-earns-breakthrough-therapy-designation-for-breast-cancer-treatment/2024-12-10T10:53:30+08:00https://flcube.com/sichuan-kelun-biotech-biopharmaceutical-prices-ipo-at-hkd-60-6-to-72-8-per-share/2024-12-10T10:50:25+08:00https://flcube.com/johnson-johnson-files-lawsuit-against-us-governments-drug-pricing-negotiation-authority/2024-12-10T10:50:23+08:00https://flcube.com/msds-v116-vaccine-shows-superior-immune-response-in-phase-iii-trials/2024-12-10T10:50:21+08:00https://flcube.com/msds-q2-2023-earnings-keytruda-and-gardasil-drive-growth-amid-covid-19-sales-decline/2024-12-10T10:50:19+08:00https://flcube.com/msds-welireg-meets-primary-endpoint-in-phase-iii-rcc-study-but-misses-os-milestone/2024-12-10T10:50:16+08:00https://flcube.com/astrazeneca-and-msds-lynparza-gets-green-light-for-prostate-cancer-treatment-in-japan/2024-12-10T10:50:14+08:00https://flcube.com/msd-initiates-phase-iii-trial-for-pcsk9-inhibitor-mk-0616-in-ldl-cholesterol-reduction/2024-12-10T10:50:12+08:00https://flcube.com/astrazeneca-challenges-us-governments-drug-price-negotiation-plan-for-medicare/2024-12-10T10:50:10+08:00https://flcube.com/hhs-releases-list-of-10-drugs-for-medicare-price-negotiations-starting-2026/2024-12-10T10:50:08+08:00https://flcube.com/bms-reblozyl-expands-indication-to-include-first-line-mds-related-anemia-treatment/2024-12-10T10:50:06+08:00https://flcube.com/msds-gardasil-9-hpv-vaccine-demonstrates-10-year-efficacy-in-adolescents/2024-12-10T10:50:05+08:00https://flcube.com/msd-plans-to-introduce-over-50-new-drugs-and-vaccines-to-china-in-the-next-five-years/2024-12-10T10:50:03+08:00https://flcube.com/mercks-keytruda-approved-in-china-for-msi-h-dmmr-advanced-solid-tumors-a-biomarker-driven-milestone/2024-12-10T10:50:02+08:00https://flcube.com/european-commission-approves-pediatric-indication-for-msds-ervebo-ebola-vaccine/2024-12-10T10:50:00+08:00https://flcube.com/gileads-trodelvy-combo-with-msds-keytruda-shows-promise-in-nsclc-phase-ii-trial/2024-12-10T10:49:59+08:00https://flcube.com/msds-sotatercept-demonstrates-positive-interim-results-in-phase-iii-pah-studies/2024-12-10T10:49:58+08:00https://flcube.com/emas-chmp-recommends-approval-of-keytruda-as-adjuvant-nsclc-treatment/2024-12-10T10:49:56+08:00https://flcube.com/fda-grants-priority-review-to-msds-welireg-for-advanced-rcc-indication-extension/2024-12-10T10:49:54+08:00https://flcube.com/msds-keytruda-meets-endpoints-in-urothelial-carcinoma-trial-but-misses-in-nsclc-study/2024-12-10T10:49:53+08:00https://flcube.com/msds-keytruda-achieves-primary-endpoint-in-late-stage-nsclc-trial/2024-12-10T10:49:51+08:00https://flcube.com/msd-partners-with-phanes-therapeutics-for-innovative-cancer-combo-therapy/2024-12-10T10:49:27+08:00https://flcube.com/msd-collaborates-with-daiichi-sankyo-on-development-of-innovative-adc-candidates/2024-12-10T10:49:25+08:00https://flcube.com/msd-halts-phase-ii-trials-for-glutamate-modulator-mk-1942-in-alzheimers-and-depression/2024-12-10T10:49:23+08:00https://flcube.com/merck-reports-9-global-sales-growth-in-q3-2023-boosted-by-keytruda-and-gardasil/2024-12-10T10:49:22+08:00https://flcube.com/seagens-adcetris-combo-with-keytruda-shows-promising-results-in-phase-ii-study/2024-12-10T10:49:21+08:00https://flcube.com/aurobindo-pharmas-china-plant-secures-eu-gmp-approval-eyes-revenue-generation/2024-12-10T10:49:18+08:00https://flcube.com/msd-to-acquire-caraway-therapeutics-for-usd-610-million-to-boost-neurodegenerative-disease-portfolio/2024-12-10T10:49:17+08:00https://flcube.com/mercks-v116-pneumococcal-vaccine-shows-promising-data-against-pfizers-prevnar-20/2024-12-10T10:49:14+08:00https://flcube.com/msd-to-migrate-it-systems-to-aws-aiming-for-faster-drug-discovery-and-clinical-trials/2024-12-10T10:49:11+08:00https://flcube.com/msd-halts-phase-iii-trial-of-keytruda-combo-in-nsclc-after-missing-primary-endpoints/2024-12-10T10:49:09+08:00https://flcube.com/msds-welireg-gains-fda-approval-for-advanced-renal-cell-carcinoma/2024-12-10T10:49:06+08:00https://flcube.com/fda-approves-pfizer-astellas-msd-combo-therapy-for-advanced-urothelial-cancer/2024-12-10T10:49:02+08:00https://flcube.com/keytruda-gains-12th-indication-approval-in-china-for-her2-negative-gastric-cancer/2024-12-10T10:49:00+08:00https://flcube.com/european-commission-expands-keytruda-indications-for-advanced-cancer-treatments/2024-12-10T10:48:57+08:00https://flcube.com/msd-partners-with-owkin-to-develop-msi-h-biomarker-screening-for-cancers/2024-12-10T10:48:54+08:00https://flcube.com/fda-rejects-msds-gefapixant-for-chronic-cough-treatment-over-efficacy-concerns/2024-12-10T10:48:52+08:00https://flcube.com/fda-grants-priority-review-to-msd-and-daiichi-sankyos-adc-for-lung-cancer/2024-12-10T10:48:50+08:00https://flcube.com/msd-advances-four-oncology-candidates-to-late-stage-trials-including-partnerships-with-kelun-biotech-and-orion/2024-12-10T10:48:49+08:00https://flcube.com/msd-to-acquire-harpoon-therapeutics-for-usd-680-million-expanding-its-oncology-pipeline/2024-12-10T10:48:46+08:00https://flcube.com/msds-gardasil-9-receives-nmpa-approval-for-two-dose-schedule-in-younger-females/2024-12-10T10:48:22+08:00https://flcube.com/c4-therapeutics-outlines-2024-focus-amid-30-workforce-reduction-prioritizes-key-oncology-trials/2024-12-10T10:48:20+08:00https://flcube.com/msds-keytruda-gains-fda-approval-for-advanced-cervical-cancer-treatment/2024-12-10T10:48:19+08:00https://flcube.com/gileads-trodelvy-misses-primary-endpoint-in-late-stage-nsclc-trial/2024-12-10T10:48:17+08:00https://flcube.com/msds-keytruda-combines-with-pharmabcines-pmc-309-in-phase-ia-b-solid-tumor-trial/2024-12-10T10:48:16+08:00https://flcube.com/bj-bioscience-inc-faces-bankruptcy-as-hangzhou-court-accepts-liquidation-application/2024-12-10T10:48:15+08:00https://flcube.com/msd-partners-with-variational-ai-to-harness-generative-ai-for-drug-discovery/2024-12-10T10:48:14+08:00https://flcube.com/merck-q4-sales-grow-6-yoy-driven-by-pharmaceutical-segment-and-hpv-vaccine-demand/2024-12-10T10:48:13+08:00https://flcube.com/msds-keytruda-secures-13th-indication-approval-in-china-for-biliary-carcinoma-treatment/2024-12-10T10:48:12+08:00https://flcube.com/mercks-keytruda-under-priority-review-for-new-indication-in-endometrial-carcinoma/2024-12-10T10:48:11+08:00https://flcube.com/msds-belzutifan-and-sperogenixs-vamorolone-targeted-for-priority-review-by-chinas-cde/2024-12-10T10:48:09+08:00https://flcube.com/kelun-biotech-launches-clinical-trials-for-skb264-triggering-75-million-milestone-payment-from-msd/2024-12-10T10:48:08+08:00https://flcube.com/gilead-and-msd-report-positive-interim-data-for-once-weekly-hiv-treatment-in-phase-ii-trial/2024-12-10T10:48:06+08:00https://flcube.com/msd-partners-with-ideaya-biosciences-to-develop-combination-therapy-for-endometrial-cancer/2024-12-10T10:48:04+08:00https://flcube.com/msd-strikes-deal-with-pearl-bio-to-tap-into-synthetic-biology-for-oncology-targets/2024-12-10T10:48:02+08:00https://flcube.com/merck-plans-broader-hpv-vaccine-development-targeting-african-and-asian-populations/2024-12-10T10:48:00+08:00https://flcube.com/msds-phase-iii-trial-of-keytruda-plus-lynparza-misses-primary-endpoints-in-nsclc/2024-12-10T10:47:58+08:00https://flcube.com/msds-winrevair-approved-by-fda-as-first-activin-signaling-inhibitor-for-pulmonary-arterial-hypertension/2024-12-10T10:47:55+08:00https://flcube.com/merck-sharp-dohme-acquires-abceutics-for-next-generation-adc-technology/2024-12-10T10:47:53+08:00https://flcube.com/msd-strikes-deal-with-gv20-therapeutics-to-test-anti-pd-1-combo-in-solid-tumor-therapies/2024-12-10T10:47:50+08:00https://flcube.com/msd-partners-with-hanmi-pharmaceutical-to-develop-combination-therapy-for-solid-tumors/2024-12-10T10:47:22+08:00https://flcube.com/msd-reports-usd-15-8-billion-in-q1-2024-sales-marked-by-11-yoy-growth-excluding-forex-impact/2024-12-10T10:47:19+08:00https://flcube.com/msds-keytruda-adjuvant-treatment-for-high-risk-endometrial-cancer-fails-to-meet-primary-endpoint/2024-12-10T10:47:16+08:00https://flcube.com/msd-discontinues-vibostolimab-and-keytruda-combo-trial-in-high-risk-melanoma/2024-12-10T10:47:14+08:00https://flcube.com/msd-partners-with-dragonfly-therapeutics-to-combine-keytruda-with-nk-cell-engager-in-cancer-treatment/2024-12-10T10:47:12+08:00https://flcube.com/msd-to-acquire-ophthalmology-specialist-eyebiotech-in-a-deal-valued-up-to-usd-3-billion/2024-12-10T10:47:09+08:00https://flcube.com/eli-lillys-kras-inhibitor-olomorasib-shows-promise-in-phase-i-ii-trial-for-advanced-solid-tumors/2024-12-10T10:47:07+08:00https://flcube.com/akeso-biopharmas-ivonescimab-outshines-keytruda-in-nsclc-trial-raises-fda-concerns/2024-12-10T10:47:05+08:00https://flcube.com/msd-chinas-vaccine-head-tang-xiaochun-departs-hutchmed-welcomes-msds-yuan-zezhi-as-executive-vice-president/2024-12-10T10:47:04+08:00https://flcube.com/msd-makes-undisclosed-equity-investment-in-cancer-diagnostics-firm-delfi-diagnostics/2024-12-10T10:47:01+08:00https://flcube.com/msds-keytruda-secures-fda-approval-for-advanced-or-recurrent-endometrial-carcinoma/2024-12-10T10:47:00+08:00https://flcube.com/msds-capvaxive-vaccine-targets-21-serotypes-of-streptococcus-pneumoniae/2024-12-10T10:46:58+08:00https://flcube.com/mercks-her3-targeted-adc-patritumab-deruxtecan-faces-fda-complete-response-letter/2024-12-10T10:46:55+08:00https://flcube.com/roches-tiragolumab-misses-primary-endpoints-in-nsclc-trial-study-halted/2024-12-10T10:46:53+08:00https://flcube.com/i-mab-shakes-up-leadership-with-new-chairman-and-interim-ceo-appointments/2024-12-10T10:46:51+08:00https://flcube.com/mercks-q2-2024-earnings-miss-estimates-as-china-market-downturn-surprises/2024-12-10T10:46:49+08:00https://flcube.com/daiichi-sankyo-and-msd-broaden-partnership-to-co-develop-t-cell-engager-mk-6079/2024-12-10T10:46:47+08:00https://flcube.com/msd-to-acquire-curon-biopharmaceuticals-cd3-x-cd19-bispecific-antibody-cn201-in-usd-1-3-billion-deal/2024-12-10T10:46:45+08:00https://flcube.com/merck-ends-phase-iii-keytruda-studies-in-nsclc-and-cscc-due-to-insufficient-results/2024-12-10T10:46:42+08:00https://flcube.com/henlius-biotechs-hlx17-biosimilar-to-msds-keytruda-wins-nmpa-clinical-trial-approval/2024-12-10T10:46:39+08:00https://flcube.com/kelun-biotechs-adc-for-cancer-gets-nmpa-review-expands-msd-collaboration/2024-12-10T10:46:09+08:00https://flcube.com/merck-and-daiichi-sankyos-ifinatamab-deruxtecan-shows-promising-results-in-phase-ii-es-sclc-trial/2024-12-10T10:46:07+08:00https://flcube.com/msd-and-daiichi-sankyos-patritumab-deruxtecan-achieves-milestone-in-phase-iii-lung-cancer-trial/2024-12-10T10:46:06+08:00https://flcube.com/msds-keytruda-secures-fda-approval-for-first-line-mesothelioma-treatment-in-combination-with-chemotherapy/2024-12-10T10:46:04+08:00https://flcube.com/sichuan-kelun-biotech-reports-32-2-revenue-growth-in-2024-h1-driven-by-msd-partnership/2024-12-10T10:46:02+08:00https://flcube.com/fda-panel-weighs-in-on-narrowing-use-of-pd-1-inhibitors-in-stomach-and-esophageal-cancers/2024-12-10T10:46:00+08:00https://flcube.com/westgene-biopharmas-pioneering-mrna-vaccine-for-ebv-related-tumors-clears-ind-hurdle-in-china/2024-12-10T10:45:58+08:00https://flcube.com/merck-acquires-modifi-biosciences-to-target-dna-repair-defects-in-cancer-therapies/2024-12-10T10:45:56+08:00https://flcube.com/mercks-keytruda-gains-two-additional-eu-indications-for-gynecologic-cancer-treatment/2024-12-10T10:45:54+08:00https://flcube.com/merck-and-moderna-launch-phase-iii-study-for-individualized-neoantigen-therapy-in-lung-cancer/2024-12-10T10:45:52+08:00https://flcube.com/msd-reports-4-yoy-revenue-increase-in-q3-2024-led-by-pharmaceutical-sector/2024-12-10T10:45:50+08:00https://flcube.com/merck-secures-exclusive-rights-to-lanovas-pd-1-vegf-bispecific-antibody-lm-299/2024-12-10T10:45:49+08:00https://flcube.com/emas-chmp-recommends-approval-for-msds-keytruda-combo-in-mesothelioma-treatment/2024-12-10T10:45:47+08:00https://flcube.com/lanova-medicines-inks-licensing-deal-with-sino-biopharmaceutical-for-cancer-therapies-in-china/2024-12-10T10:45:45+08:00https://flcube.com/msd-announces-positive-topline-results-from-phase-iii-subcutaneous-keytruda-trial/2024-12-10T10:45:42+08:00https://flcube.com/china-grants-marketing-approval-for-msds-welireg-for-von-hippel-lindau-disease-tumors/2024-12-10T10:45:41+08:00https://flcube.com/msd-china-to-streamline-diabetes-business-amid-volume-based-procurement-inclusion/2024-12-10T10:45:39+08:00https://flcube.com/msd-partners-with-cancer-foundation-of-china-for-hpv-vaccine-donation-program/2024-12-10T10:45:37+08:00https://flcube.com/mercks-recarbrio-approved-by-nmpa-for-hospital-acquired-infections-and-complicated-utis/2024-12-10T10:45:36+08:00https://flcube.com/sacituzumab-tirumotecan-earns-fda-breakthrough-therapy-designation-for-egfr-mutated-nsclc/2024-12-10T10:45:34+08:00https://flcube.com/brii-biosciences-partners-present-chronic-hepatitis-b-clinical-results-at-easl-2023/2024-12-10T10:36:42+08:00https://flcube.com/shionogis-acquisition-of-qpex-impacts-brii-biosciences-rights-to-anti-infective-drugs/2024-12-10T10:23:04+08:00https://flcube.com/innovent-biologics-and-remegen-partner-on-clinical-study-for-pd-1-inhibitor-and-adc-drugs/2024-12-10T10:11:48+08:00https://flcube.com/ascletis-pharmas-asc42-showcased-in-combination-therapy-for-chronic-hepatitis-b-at-easl-2023/2024-12-10T10:05:05+08:00https://flcube.com/wuxi-apptecs-subsidiary-invests-eur-20-million-in-jeito-ii-s-l-p-for-growth-expansion/2024-12-09T22:42:58+08:00https://flcube.com/tj-biopharma-and-jumpcan-pharmaceutical-announce-nmpa-review-of-eftansomatropin-alfa-bla/2024-12-09T22:27:17+08:00https://flcube.com/astrazenecas-imfinzi-receives-fda-priority-review-for-muscle-invasive-bladder-cancer/2024-12-09T21:34:39+08:00https://flcube.com/novartis-fabhalta-demonstrates-positive-results-in-appulse-pnh-phase-iiib-study/2024-12-09T21:03:53+08:00https://flcube.com/novo-holdings-acquisition-of-catalent-gets-eu-nod-paving-way-for-novo-nordisk-expansion/2024-12-09T17:22:44+08:00https://flcube.com/johnson-johnsons-darzalex-faspro-showcases-clinical-efficacy-in-multiple-myeloma-at-ash-2024/2024-12-09T17:05:35+08:00https://flcube.com/astrazenecas-imfinzi-demonstrates-positive-outcomes-in-pacific-5-iii-study-for-nsclc/2024-12-09T16:57:50+08:00https://flcube.com/innovent-biologics-ibi343-shows-promising-results-in-phase-i-study-for-pancreatic-cancer-at-esmo-asia/2024-12-09T16:37:32+08:00https://flcube.com/hainan-haiyao-secures-exclusive-rights-for-aft-pharmaceuticals-nutritional-products-in-china/2024-12-09T16:25:42+08:00https://flcube.com/novartis-scemblix-demonstrates-superior-mmr-rates-in-phase-iii-asc4first-study/2024-12-09T16:06:58+08:00https://flcube.com/tecvayli-teclistamab-demonstrates-positive-results-in-majestec-5-and-majestec-4-trials/2024-12-09T16:00:45+08:00https://flcube.com/sinopep-allsino-biopharmaceutical-partners-with-spraying-systems-co-for-peptide-api-manufacturing/2024-12-09T15:48:00+08:00https://flcube.com/sinopep-allsino-bio-pharmaceutical-cuts-fundraising-target-to-rmb434-million-via-convertible-bonds/2024-12-09T15:34:36+08:00https://flcube.com/chipscreen-biosciences-chiauranib-phase-iii-trial-results-for-sclc-announced/2024-12-09T15:26:18+08:00https://flcube.com/mercks-zilovertamab-vedotin-shows-100-cr-rate-in-phase-ii-study-for-dlbcl-ash-presentation/2024-12-09T15:23:26+08:00https://flcube.com/youcare-pharmaceutical-gets-fda-clearance-for-herpes-zoster-mrna-vaccine-ykyy026/2024-12-09T15:10:34+08:00https://flcube.com/jacobio-pharmas-bet-inhibitor-jab-8263-shows-promising-results-in-myelofibrosis-phase-i-study/2024-12-09T15:09:48+08:00https://flcube.com/abbisko-therapeutics-presents-positive-phase-ii-results-for-pimicotinib-in-cgvhd-at-ash/2024-12-09T15:09:15+08:00https://flcube.com/astrazenecas-calquence-combo-shows-35-reduced-risk-in-cll-amplify-phase-iii-results/2024-12-09T15:08:40+08:00https://flcube.com/medtide-inc-submits-second-ipo-application-to-hong-kong-stock-exchange/2024-12-09T15:07:39+08:00https://flcube.com/biomm-secures-late-stage-biosimilar-candidate-bat2206-from-bio-thera-solutions/2024-12-09T13:09:52+08:00https://flcube.com/cde-issues-guidelines-for-new-drug-benefit-risk-assessment-in-market-approval-filings/2024-12-09T13:02:50+08:00https://flcube.com/cnipa-launches-pilot-for-priority-patent-review-for-macau-applicants-in-mainland-china/2024-12-09T13:00:17+08:00https://flcube.com/astrazenecas-dapagliflozin-and-metformin-combo-approved-by-chinas-nmpa-for-type-2-diabetes/2024-12-09T12:58:26+08:00https://flcube.com/lion-tcr-secures-rmb-300-million-in-series-b2-financing-to-advance-clinical-studies-and-facility-construction/2024-12-09T12:54:02+08:00https://flcube.com/lianbios-mavacamten-receives-priority-review-status-from-chinas-cde-for-ohcm-treatment/2024-12-09T12:49:29+08:00https://flcube.com/cspc-pharmaceutical-group-gets-nmpa-approval-for-jmt203-cancer-cachexia-clinical-study/2024-12-09T12:39:53+08:00https://flcube.com/nmpa-releases-69th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2024-12-09T12:26:04+08:00https://flcube.com/bdgene-technology-secures-over-rmb-200-million-in-series-b-financing-led-by-lapam-capital/2024-12-09T12:23:58+08:00https://flcube.com/wuxi-biologics-partners-with-pharmadule-morimatsu-ab-for-crdmo-expansion-in-singapore/2024-12-09T12:19:23+08:00https://flcube.com/cstone-pharmaceuticals-gavreto-approved-for-first-line-ret-fusion-positive-nsclc-treatment-in-china/2024-12-09T12:10:21+08:00https://flcube.com/cspc-pharmaceuticals-biosimilar-omalizumab-accepted-for-review-by-chinas-nmpa/2024-12-09T11:59:18+08:00https://flcube.com/henlius-biotechs-hlx13-biosimilar-gets-nmpa-approval-for-liver-cancer-clinical-trial/2024-12-09T11:54:46+08:00https://flcube.com/chia-tai-tianqing-launches-first-batch-of-f-627-for-neutropenia-treatment-in-china/2024-12-09T11:47:55+08:00https://flcube.com/beijing-intellectual-property-court-upholds-validity-of-novartis-entresto-patent/2024-12-09T11:47:53+08:00https://flcube.com/eli-lillys-mirikizumab-and-chia-tai-tianqings-lanifibranor-enter-breakthrough-therapy-review/2024-12-09T11:47:52+08:00https://flcube.com/chia-tai-tianqing-secures-exclusive-rights-to-inventisbios-d-1553-in-china-licensing-deal/2024-12-09T11:47:51+08:00https://flcube.com/chia-tai-tianqings-generic-entresto-approved-by-nmpa-launch-expected-in-2026/2024-12-09T11:47:50+08:00https://flcube.com/akeso-biopharma-files-new-indication-for-penpulimab-in-first-line-npc-treatment/2024-12-09T11:47:48+08:00https://flcube.com/chia-tai-tianqing-and-fudan-university-shanghai-cancer-center-join-forces-for-innovative-drug-development/2024-12-09T11:47:47+08:00https://flcube.com/chia-tai-tianqings-anlotinib-benmelstobart-combo-therapy-receives-cde-review-for-endometrial-cancer/2024-12-09T11:47:46+08:00https://flcube.com/chia-tai-tianqings-rovadicitinib-meets-main-goal-in-myelofibrosis-trial-eyes-market-filing/2024-12-09T11:47:44+08:00https://flcube.com/chia-tai-tianqings-tqa3038-sirna-drug-completes-phase-i-clinical-trial-for-chronic-hepatitis-b/2024-12-09T11:47:42+08:00https://flcube.com/chia-tai-tianqings-pd-l1-antibody-benmelstobart-wins-nmpa-nod-for-es-sclc/2024-12-09T11:47:41+08:00https://flcube.com/xtalpi-inc-makes-a-splash-with-hkd-1-13-billion-ipo-on-hong-kong-stock-exchange/2024-12-09T11:47:40+08:00https://flcube.com/chia-tai-tianqing-and-china-resource-medicine-commercial-holdings-join-forces-for-pharmaceutical-industry-expansion/2024-12-09T11:47:39+08:00https://flcube.com/envonalkib-chia-tai-tianqings-next-gen-alk-inhibitor-wins-nmpa-approval-for-untreated-alk-nsclc/2024-12-09T11:47:38+08:00https://flcube.com/wuhan-yzy-biopharma-grants-rights-to-cd3-epcam-antibody-m701-to-chi-ta-tianqing-pharma-in-china/2024-12-09T11:47:37+08:00https://flcube.com/chia-tai-tianqings-benmelstobart-combo-approved-by-nmpa-for-endometrial-cancer-treatment/2024-12-09T11:47:36+08:00https://flcube.com/jiangsu-kanion-pharmaceutical-gets-fda-approval-for-kys202002a-clinical-study-in-multiple-myeloma/2024-12-09T11:33:54+08:00https://flcube.com/mega-lifesciences-secures-exclusive-rights-for-bio-theras-bevacizumab-biosimilar-in-indonesia/2024-12-09T11:25:20+08:00https://flcube.com/jiangsu-hengruis-dalpiciclib-approved-for-initial-therapy-in-hr-her2-breast-cancer/2024-12-09T11:04:01+08:00https://flcube.com/fosun-kites-yescarta-gains-nmpa-approval-for-refractory-large-b-cell-lymphoma/2024-12-09T10:59:47+08:00https://flcube.com/fosun-kite-and-medi-cover-launch-first-value-based-payment-plan-for-lymphoma-treatment/2024-12-09T10:37:38+08:00https://flcube.com/beijing-tiantan-biological-completes-phase-i-study-for-recombinant-coagulation-factor-viia/2024-12-09T00:03:09+08:00https://flcube.com/shanghais-smpa-notification-non-winning-bids-in-vbp-round-8-can-avoid-higher-price-label/2024-12-08T23:56:04+08:00https://flcube.com/us-fda-issues-warning-letter-to-chengdu-kecheng-fine-chemicals-over-communication-failures/2024-12-08T23:53:25+08:00https://flcube.com/allurions-non-invasive-weight-loss-balloon-debuts-at-ruijin-hospitals-hainan-subsidiary/2024-12-08T23:37:05+08:00https://flcube.com/grand-pharmaceutical-initiates-phase-i-study-for-tlx250-cdx-in-renal-mass-imaging/2024-12-08T23:26:58+08:00https://flcube.com/teva-pharmaceuticals-copaxone-approved-by-nmpa-for-multiple-sclerosis-treatment-in-china/2024-12-08T23:16:52+08:00https://flcube.com/fosun-pharmaceuticals-sisram-opens-wellness-center-in-chicago-for-beauty-and-health/2024-12-08T23:09:12+08:00https://flcube.com/sanyou-biopharmaceuticals-and-huadong-medicine-expand-partnership-on-macromolecule-therapeutics/2024-12-08T23:00:52+08:00https://flcube.com/daewoong-pharma-and-meheco-international-expand-partnership-for-chinas-market-entry/2024-12-08T21:31:04+08:00https://flcube.com/daewoong-pharmaceutical-files-nda-in-china-for-potassium-competitive-acid-blocker-fexuclu/2024-12-08T21:30:09+08:00https://flcube.com/insilico-medicines-ai-discovered-drug-ins018_055-reaches-phase-ii-clinical-trial-milestone/2024-12-08T20:39:15+08:00https://flcube.com/shandong-buchang-pharmaceuticals-bc001-gets-clinical-trial-approval-for-solid-tumors/2024-12-08T00:55:30+08:00https://flcube.com/pfizer-partners-with-cspc-pharmaceutical-to-localize-paxlovid-in-china/2024-12-08T00:53:24+08:00https://flcube.com/eoc-pharmas-lusutrombopag-receives-nmpa-approval-for-chronic-liver-disease-treatment/2024-12-08T00:47:42+08:00https://flcube.com/changchun-bcht-biotechnology-to-acquire-full-stake-in-mrna-rd-firm-transcend-biomedical/2024-12-08T00:42:58+08:00https://flcube.com/jiangsu-simceres-edaravone-borneol-sublingual-tablets-for-ais-accepted-by-nmpa-for-review/2024-12-08T00:31:45+08:00https://flcube.com/shanghai-junshi-biosciences-gets-fda-approval-for-phase-iii-study-of-tifcemalimab-in-small-cell-lung-cancer/2024-12-08T00:28:12+08:00https://flcube.com/worg-pharmaceuticals-secures-rmb-1-1-billion-in-series-c-financing-for-global-expansion/2024-12-08T00:26:07+08:00https://flcube.com/aim-vaccine-receives-nmpa-approval-for-mrna-vaccine-clinical-study-targeting-covid-19-variants/2024-12-08T00:22:37+08:00https://flcube.com/shanghai-pharmaceuticals-meditrust-health-partners-with-yuanda-shuyang-on-rare-disease-treatment-model/2024-12-07T22:22:16+08:00https://flcube.com/qilu-pharmaceuticals-iruplinalkib-receives-nmpa-approval-for-alk-nsclc-treatment/2024-12-07T22:11:04+08:00https://flcube.com/jiangsu-hengruis-oteseconazole-shr8008-approved-by-nmpa-for-severe-vulvovaginal-candidiasis/2024-12-07T22:07:47+08:00https://flcube.com/westgene-biopharma-secures-42-million-in-funding-to-advance-mrna-therapeutics/2024-12-07T22:04:10+08:00https://flcube.com/sinocelltech-group-receives-nmpa-approval-for-bevacizumab-biosimilar-for-multiple-cancers/2024-12-07T21:59:11+08:00https://flcube.com/cornerstone-robotics-secures-rmb-800-million-in-funding-for-surgical-robot-development/2024-12-07T21:56:22+08:00https://flcube.com/huadong-medicine-receives-nmpa-approval-for-dr30206-clinical-study-in-advanced-solid-tumors/2024-12-07T21:50:59+08:00https://flcube.com/nhsa-unveils-2023-work-plan-for-national-reimbursement-drug-list-update/2024-12-07T21:48:48+08:00https://flcube.com/sinocelltech-group-receives-nmpa-approval-for-covid-19-vaccine-bridging-phase-ii-study/2024-12-07T21:45:45+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-gets-nmpa-approval-for-phase-iii-studies-of-gallium-edotreotide-injection/2024-12-07T21:10:56+08:00https://flcube.com/jacobio-pharma-reports-promising-clinical-results-for-kras-g12c-inhibitor-gecirasib-in-crc/2024-12-07T21:06:55+08:00https://flcube.com/harbour-biomeds-batoclimab-for-generalized-myasthenia-gravis-accepted-for-nmpa-review/2024-12-07T20:50:17+08:00https://flcube.com/hansoh-pharmaceutical-gets-nmpa-approval-for-hs-10518-clinical-study-in-endometriosis-pain/2024-12-07T20:16:58+08:00https://flcube.com/microport-medbots-dragonfly-eye-3d-endoscopy-earns-ce-mark-for-intraperitoneal-procedures/2024-12-07T20:08:56+08:00https://flcube.com/merck-kgaa-expands-high-purity-reagents-production-in-nantong-china-with-eur-70-million-investment/2024-12-07T19:40:11+08:00https://flcube.com/immunofocos-imc002-car-t-therapy-receives-fda-fast-track-designation-for-gastric-cancer/2024-12-07T19:36:08+08:00https://flcube.com/shanghai-juncell-therapeutics-gc101-til-therapy-receives-cde-approval-for-pivotal-phase-ii-trial/2024-12-07T12:53:52+08:00https://flcube.com/ai-proteins-partners-with-bristol-myers-squibb-to-develop-miniprotein-based-therapeutics/2024-12-07T01:16:18+08:00https://flcube.com/novatim-immune-therapeutics-y-0301-receives-fda-clearance-for-clinical-trials/2024-12-07T00:42:34+08:00https://flcube.com/nmpa-releases-85th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2024-12-07T00:33:41+08:00https://flcube.com/highfield-biopharmaceuticals-hf50-receives-tacit-clinical-approval-from-nmpa-for-her-2-positive-tumors/2024-12-07T00:25:53+08:00https://flcube.com/shenyang-hongqi-pharma-secures-nmpa-approval-for-pretomanid-in-tb-treatment/2024-12-06T21:19:18+08:00https://flcube.com/chongqing-zhifei-biological-and-glaxosmithkline-amend-distribution-agreement-for-herpes-vaccine/2024-12-06T21:00:45+08:00https://flcube.com/jiangsu-hengruis-shr-a2102-earns-breakthrough-therapy-designation-for-urothelial-carcinoma/2024-12-06T17:39:55+08:00https://flcube.com/roches-columvi-supplemental-sbla-accepted-by-fda-for-relapsed-dlbcl-treatment/2024-12-06T17:24:49+08:00https://flcube.com/teva-pharmaceutical-to-divest-holdings-in-teva-takeda-pharma-to-jki/2024-12-06T17:15:07+08:00https://flcube.com/eyebright-medical-technology-aims-to-raise-rmb-300-million-for-contact-lens-production-expansion/2024-12-06T17:02:27+08:00https://flcube.com/cambrex-partners-with-eli-lilly-to-enhance-clinical-development-for-biotech-collaborators/2024-12-06T16:45:20+08:00https://flcube.com/dewpoint-therapeutics-partners-with-mitsubishi-tanabe-pharma-to-develop-als-treatment/2024-12-06T16:35:13+08:00https://flcube.com/astrazenecas-imfinzi-receives-fda-approval-for-limited-stage-small-cell-lung-cancer/2024-12-06T16:19:25+08:00https://flcube.com/eli-lilly-co-expands-wisconsin-manufacturing-facility-with-3-billion-investment/2024-12-06T16:10:59+08:00https://flcube.com/amgen-expands-biomanufacturing-footprint-in-north-carolina-with-second-facility/2024-12-06T16:00:10+08:00https://flcube.com/merck-initiates-phase-iii-move-now-study-for-lagevrio-covid-19-antiviral/2024-12-06T15:52:55+08:00https://flcube.com/cde-approves-rinuagenes-mrna-based-rg002-for-clinical-study-in-cervical-dysplasia/2024-12-06T15:19:52+08:00https://flcube.com/chinas-health-commission-issues-guidelines-to-strengthen-ties-between-healthcare-and-elderly-care/2024-12-05T23:21:08+08:00https://flcube.com/burning-rock-ltd-reports-q3-2024-financials-with-revenue-growth-and-rd-reduction/2024-12-05T23:06:23+08:00https://flcube.com/novavax-to-sell-czech-manufacturing-facility-to-novo-nordisk-for-200-million/2024-12-05T22:53:17+08:00https://flcube.com/eli-lillys-zepbound-outperforms-wegovy-in-surmount-5-weight-loss-study/2024-12-05T22:33:30+08:00https://flcube.com/phanes-therapeutics-pt217-earns-fda-fast-track-designation-for-neuroendocrine-prostate-cancer/2024-12-05T22:20:19+08:00https://flcube.com/cgenetechs-cetagliptin-receives-nmpa-approval-for-type-2-diabetes-treatment-in-china/2024-12-05T22:10:19+08:00https://flcube.com/eisai-and-biogens-leqembi-approved-in-mexico-for-early-alzheimers-disease-treatment/2024-12-05T21:59:27+08:00https://flcube.com/astrazeneca-appoints-iskra-reic-as-evp-international-amid-leon-wangs-investigation-in-china/2024-12-05T21:50:10+08:00https://flcube.com/shanghai-escugen-receives-nmpa-approval-for-second-phase-iii-trial-of-esg401-in-tnbc/2024-12-05T21:26:41+08:00https://flcube.com/johnson-johnson-submits-sblas-to-fda-for-tremfya-indications-in-pediatric-psoriasis-and-arthritis/2024-12-05T21:04:21+08:00https://flcube.com/gsk-plc-expands-pipeline-with-rgenta-therapeutics-partnership-for-rna-targeted-splice-modulators/2024-12-05T20:58:03+08:00https://flcube.com/merus-n-v-receives-fda-approval-for-bizengri-for-nrg1-pancreatic-and-lung-cancers/2024-12-05T20:48:37+08:00https://flcube.com/ipsens-bylvay-receives-nmpa-clearance-for-treating-itching-in-pfic-patients-in-china/2024-12-05T16:24:04+08:00https://flcube.com/tasly-pharma-receives-nmpa-approval-for-generic-lioresal-baclofen-oral-solution/2024-12-05T16:16:00+08:00https://flcube.com/haisco-pharmaceuticals-hsk46575-receives-nmpa-approval-for-prostate-cancer-clinical-trial/2024-12-05T15:52:23+08:00https://flcube.com/sichuan-kelun-biotechs-skb500-receives-nmpa-clinical-clearance-for-solid-tumor-treatment/2024-12-05T15:44:25+08:00https://flcube.com/cinclus-pharmas-linaprazan-for-gerd-receives-nmpa-marketing-approval/2024-12-05T15:34:31+08:00https://flcube.com/cspc-pharmaceuticals-crb-701-earns-fda-fast-track-designation-for-cervical-cancer-treatment/2024-12-05T15:19:32+08:00https://flcube.com/sisram-medicals-alma-harmony-and-alma-hybrid-receive-eu-medical-device-certification/2024-12-05T15:04:52+08:00https://flcube.com/shanghai-henlius-biotechs-hlx11-biosimilar-accepted-for-review-by-chinas-cde/2024-12-05T14:50:22+08:00https://flcube.com/wuhan-kaideweisi-biotechnology-secures-series-b-funding-for-gynecologic-oncology-expansion/2024-12-05T14:43:23+08:00https://flcube.com/shanghai-henlius-biotechs-hlx22-receives-nmpa-approval-for-phase-ii-her2-targeted-study/2024-12-05T14:30:52+08:00https://flcube.com/jiangsu-recbio-technology-secures-private-placement-with-yangtze-river-pharmaceutical-for-vaccine-development/2024-12-05T00:51:45+08:00https://flcube.com/hangzhou-chance-pharmaceuticals-partners-with-yiling-pharmaceutical-for-inhalation-powder-development/2024-12-05T00:44:06+08:00https://flcube.com/grit-biotechnology-and-vitalgen-biopharma-partner-on-crispr-aacas12bmax-cell-therapies/2024-12-05T00:31:34+08:00https://flcube.com/yichang-hec-changjiang-pharmaceutical-and-dp-technology-deepen-partnership-with-ai-focus/2024-12-05T00:23:10+08:00https://flcube.com/analytical-biosciences-sells-global-rights-to-pre-clinical-anti-tumor-drugs-to-gilead/2024-12-04T23:53:27+08:00https://flcube.com/zhida-pharma-secures-licensing-deal-for-vivesto-abs-apealea-in-china/2024-12-04T23:19:20+08:00https://flcube.com/guangzhou-innogen-pharmaceutical-files-for-ipo-on-hong-kong-stock-exchange/2024-12-04T22:57:36+08:00https://flcube.com/coherus-biosciences-sells-udenyca-franchise-to-intas-pharmaceuticals-in-asset-purchase-deal/2024-12-04T22:46:18+08:00https://flcube.com/keros-therapeutics-and-takeda-enter-licensing-agreement-for-elritercept-development/2024-12-04T21:35:42+08:00https://flcube.com/gilead-sciences-secures-exclusive-option-for-tubulis-tubutecan-and-alco5-platforms-to-develop-adc/2024-12-04T21:14:53+08:00https://flcube.com/ophthalmology-biotech-cloudbreak-pharma-inc-pursues-hong-kong-ipo/2024-12-04T20:55:15+08:00https://flcube.com/cour-pharmaceutical-enters-licensing-agreement-with-genentech-for-autoimmune-disease-treatment/2024-12-04T19:01:41+08:00https://flcube.com/guangzhou-virotechs-oncolytic-virus-m1-receives-tacit-clinical-approval-from-nmpa/2024-12-04T18:51:52+08:00https://flcube.com/ipsen-secures-global-licensing-agreement-for-biomunex-pharmaceuticals-bmx-502-t-cell-engager/2024-12-04T18:41:15+08:00https://flcube.com/ipsen-secures-fda-approval-for-onivyde-regimen-as-first-line-treatment-for-metastatic-pancreatic-adenocarcinoma/2024-12-04T18:29:15+08:00https://flcube.com/oncoc4-inc-receives-fda-clearance-for-ai-081-a-pd-1-and-vegf-bispecific-antibody/2024-12-04T18:25:37+08:00https://flcube.com/luye-pharmas-zepzelca-receives-nmpa-approval-for-metastatic-small-cell-lung-cancer-treatment/2024-12-04T18:17:27+08:00https://flcube.com/abbisko-therapeutics-gets-fda-green-light-for-phase-i-study-of-absk131-inhibitor/2024-12-04T17:21:34+08:00https://flcube.com/hefan-medicines-piracetam-production-and-marketing-suspended-over-gmp-violations/2024-12-04T17:01:05+08:00https://flcube.com/inventisbios-oral-tyk2-inhibitor-d-2570-achieves-positive-results-in-phase-ii-psoriasis-study/2024-12-04T16:38:33+08:00https://flcube.com/shanghai-henlius-biotechs-serplulimab-approved-for-first-line-nsnsclc-treatment-in-china/2024-12-04T16:28:15+08:00https://flcube.com/zhejiang-huahai-pharmaceutical-initiates-clinical-study-for-hb0056-in-new-zealand/2024-12-04T16:17:28+08:00https://flcube.com/hutchmed-and-innovent-biologics-fruzaqla-tyvyt-combo-gets-nmpa-conditional-approval-for-endometrial-cancer/2024-12-04T15:55:06+08:00https://flcube.com/acotec-scientifics-acoart-camellia-receives-nmpa-approval-for-coronary-artery-disease-treatment/2024-12-04T15:42:40+08:00https://flcube.com/shanghais-huangpu-district-launches-rmb-fund-to-boost-fintech-ai-and-biotech-firms/2024-12-04T13:19:59+08:00https://flcube.com/transcentas-osemitamab-combo-shows-promising-pfs-data-in-advanced-gc-gej-cancer-study/2024-12-04T13:16:43+08:00https://flcube.com/hybio-pharmaceuticals-liraglutide-biosimilar-withdrawn-from-nmpa-filing/2024-12-04T13:12:45+08:00https://flcube.com/sinotau-pharmaceutical-secures-over-rmb-1-1-billion-in-latest-financing-round/2024-12-04T13:06:46+08:00https://flcube.com/innovent-biologics-and-iaso-biotherapeutics-fucaso-approved-for-multiple-myeloma-treatment-in-china/2024-12-04T13:00:26+08:00https://flcube.com/iaso-biotechnology-and-umoja-biopharma-join-forces-for-innovative-cell-and-gene-therapies-development/2024-12-04T12:55:30+08:00https://flcube.com/iaso-biotechnology-secures-nmpa-approval-for-fucaso-in-refractory-myasthenia-gravis/2024-12-04T12:49:32+08:00https://flcube.com/innovent-biologics-and-iaso-biotechnology-amend-partnership-focusing-on-car-t-therapy-fucaso/2024-12-04T12:42:10+08:00https://flcube.com/iaso-biotechnologys-car-t-therapy-fucaso-receives-fda-ind-approval-for-multiple-sclerosis/2024-12-04T12:41:11+08:00https://flcube.com/chinas-nmpa-gives-tacit-nod-to-iaso-biotechnologys-iaso-782-for-sle-clinical-trials/2024-12-04T12:37:29+08:00https://flcube.com/iaso-biotechnologys-car-t-therapy-fucaso-gets-fda-green-light-for-lupus-treatment/2024-12-04T12:36:21+08:00https://flcube.com/sciclone-pharmaceuticals-danyelza-officially-launched-in-china-for-neuroblastoma-treatment/2024-12-04T12:19:39+08:00https://flcube.com/zai-labs-vyvgart-receives-nmpa-approval-as-first-in-class-fcrn-antagonist-for-myasthenia-gravis/2024-12-04T12:14:39+08:00https://flcube.com/innocare-pharma-and-keymed-biosciences-initiate-clinical-trial-for-icp-b02-with-first-subcutaneous-injection/2024-12-04T12:06:50+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-approval-for-hrs-4357-clinical-study-in-prostate-cancer/2024-12-04T12:03:25+08:00https://flcube.com/sichuan-biokin-pharmaceutical-gets-fda-approval-for-bl-b01d1-clinical-study/2024-12-04T12:00:39+08:00https://flcube.com/rarestone-groups-pitolisant-earns-priority-review-status-for-narcolepsy-treatment-in-china/2024-12-04T11:54:13+08:00https://flcube.com/joincare-pharmaceutical-initiates-phase-iii-study-for-anti-il-17a-mab-in-plaque-psoriasis/2024-12-04T11:45:33+08:00https://flcube.com/bio-hearts-iberis-htn-study-shows-promising-results-in-treating-primary-hypertension/2024-12-04T11:38:43+08:00https://flcube.com/sisram-medicals-alma-lasers-acquires-photonmed-international-ltd-expanding-global-presence/2024-12-04T11:32:22+08:00https://flcube.com/beijing-sun-novo-and-zhejiang-anglikang-enter-licensing-agreement-for-hypertension-drug-candidate-nhkc-1/2024-12-04T11:14:09+08:00https://flcube.com/beijing-sun-novo-and-zhejiang-anglikang-deepen-ties-with-new-drug-development-partnership/2024-12-04T11:08:30+08:00https://flcube.com/beijing-sun-novo-gets-nmpa-green-light-for-stc008-clinical-trial-in-tumor-cachexia/2024-12-04T11:08:29+08:00https://flcube.com/sun-novo-pharmaceuticals-gets-green-light-for-car-t-therapy-clinical-trial-in-lupus-treatment/2024-12-04T11:08:28+08:00https://flcube.com/zsp1273-by-guangdong-zhongsheng-pharma-shows-promise-in-phase-iii-flu-treatment-study/2024-12-04T11:02:00+08:00https://flcube.com/hansoh-pharmaceuticals-phenylheptal-peptide-receives-nmpa-approval-for-anemia-treatment/2024-12-04T10:58:19+08:00https://flcube.com/helio-genomics-sister-company-lamh-wins-nmpa-approval-for-liver-cancer-test-in-china/2024-12-04T10:52:23+08:00https://flcube.com/nhsa-unveils-updated-national-reimbursement-drug-list-rules-for-2023/2024-12-04T10:40:51+08:00https://flcube.com/binhui-biopharmaceutical-and-topgene-biotechnology-partner-for-new-drug-rd-and-ai-platform-development/2024-12-04T10:36:31+08:00https://flcube.com/huadong-medicines-mirvetuximab-soravtansine-heads-for-priority-review-by-chinas-cde/2024-12-04T10:27:53+08:00https://flcube.com/nmpa-proposes-revisions-to-drug-inspection-management-measures-seeks-public-feedback/2024-12-04T10:19:59+08:00https://flcube.com/henlius-biotech-suspends-ipo-on-star-market-aims-to-optimize-capital-strategy/2024-12-04T10:16:52+08:00https://flcube.com/cde-releases-72nd-batch-of-generic-reference-preparations-with-new-specifications/2024-12-03T23:48:42+08:00https://flcube.com/huadong-medicines-liraglutide-biosimilar-gains-nmpa-approval-for-weight-loss-indication/2024-12-03T23:46:59+08:00https://flcube.com/abbisko-therapeutics-egfr-inhibitor-absk112-clears-fda-for-global-phase-i-nsclc-study/2024-12-03T23:41:49+08:00https://flcube.com/jacobio-pharmas-kras-inhibitor-glecirasib-advances-to-pivotal-pancreatic-cancer-trial/2024-12-03T23:30:54+08:00https://flcube.com/innocare-pharma-initiates-clinical-trial-for-tyk2-inhibitor-icp-488-in-psoriasis-patients/2024-12-03T23:11:17+08:00https://flcube.com/zap-x-gyroscopic-radiosurgery-platform-receives-nmpa-approval-for-brain-tumor-treatment/2024-12-03T23:08:09+08:00https://flcube.com/nmpa-approves-pitolisant-for-narcolepsy-related-excessive-daytime-drowsiness-and-cataplexy/2024-12-03T23:03:10+08:00https://flcube.com/ascentage-pharmas-olverembatinib-gets-nmpa-greenlight-for-phase-iii-study-in-ph-all/2024-12-03T22:53:22+08:00https://flcube.com/amoytop-biotechs-pegfilgrastim-y-shape-approved-for-marketing-by-nmpa/2024-12-03T22:49:11+08:00https://flcube.com/jacobio-pharma-retakes-global-rights-to-shp2-inhibitors-after-terminating-abbvie-agreement/2024-12-03T22:41:58+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-approval-for-esflurbiprofen-patch-clinical-study/2024-12-03T22:11:31+08:00https://flcube.com/jiangsu-hengrui-medicine-receives-nmpa-approval-for-shr-1703-clinical-study/2024-12-03T22:10:45+08:00https://flcube.com/jiangsu-hengrui-medicine-receives-nmpa-approval-for-hrs-9815-radiodiagnostic-drug-clinical-study/2024-12-03T22:10:02+08:00https://flcube.com/jiangsu-hengrui-medicine-receives-clinical-trial-approvals-for-irinotecan-and-bupivacaine-liposome-injections/2024-12-03T22:09:20+08:00https://flcube.com/jiangsu-hengrui-medicines-irinotecan-and-bupivacaine-liposome-injections-get-clinical-trial-green-light-in-china/2024-12-03T22:08:22+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-approval-for-shr-a1811-and-pyrotinib-combo-study/2024-12-03T22:07:30+08:00https://flcube.com/jiangsu-hengrui-medicine-and-hansoh-pharmaceutical-group-get-nmpa-approval-for-solid-tumor-treatment/2024-12-03T22:06:34+08:00https://flcube.com/jiangsu-hengruis-camrelizumab-and-apatinib-combo-accepted-for-fda-review-for-hcc-treatment/2024-12-03T22:05:46+08:00https://flcube.com/national-health-commissions-anti-corruption-drive-impacts-chinas-pharmaceutical-sector/2024-12-03T22:05:05+08:00https://flcube.com/jiangsu-hengrui-medicine-strikes-licensing-deal-with-one-bio-inc-for-tslp-targeted-mab-shr1905/2024-12-03T22:04:25+08:00https://flcube.com/jiangsu-hengrui-medicine-reports-9-19-yoy-revenue-growth-in-h1-2023-financial-report/2024-12-03T22:03:47+08:00https://flcube.com/lees-pharmaceuticals-socazolimab-becomes-chinas-first-pd-l1-mab-for-cervical-cancer/2024-12-03T22:03:00+08:00https://flcube.com/jiangsu-hengrui-medicines-fluzoparib-files-for-new-indication-with-chinas-nmpa/2024-12-03T22:01:52+08:00https://flcube.com/jiangsu-hengrui-submits-market-approval-filing-for-shr0302-in-ankylosing-spondylitis/2024-12-03T22:00:55+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-approval-for-phase-ib-iii-study-of-dalpiciclib-in-mhspc/2024-12-03T21:59:57+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-approval-for-hrs-7450-acute-ischemic-stroke-study/2024-12-03T21:59:13+08:00https://flcube.com/jiangsu-hengrui-medicine-entangled-in-legal-disputes-with-beyondspring-and-reistone/2024-12-03T21:58:27+08:00https://flcube.com/jiangsu-hengrui-medicine-wins-nmpa-approval-for-two-novel-drug-candidates/2024-12-03T21:57:33+08:00https://flcube.com/jiangsu-hengrui-medicine-secures-nmpa-approvals-for-two-cancer-drug-candidates/2024-12-03T21:56:48+08:00https://flcube.com/jiangsu-hengrui-licenses-pyrotinib-to-dr-reddys-for-indian-market/2024-12-03T21:56:01+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-approval-for-anti-tumor-drug-candidate-shr-2022/2024-12-03T21:55:25+08:00https://flcube.com/jiangsu-hengrui-licenses-camrelizumab-apatinib-combo-to-elevar-therapeutics/2024-12-03T21:54:39+08:00https://flcube.com/aiolos-bio-inc-raises-usd-245-million-in-series-a-funding-led-by-top-investors/2024-12-03T21:54:05+08:00https://flcube.com/merck-kgaa-and-jiangsu-hengrui-ink-strategic-collaboration-deal-for-next-gen-parp1-inhibitor/2024-12-03T21:53:32+08:00https://flcube.com/jiangsu-hengrui-medicine-subsidiary-shengdi-pharmaceuticals-receives-nmpa-approval-for-hrs-9057/2024-12-03T21:53:04+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-hr20031-accepted-for-review-by-chinas-nmpa-for-type-2-diabetes/2024-12-03T21:52:04+08:00https://flcube.com/jiangsu-hengrui-medicine-receives-nmpa-approval-for-phase-ib-ii-study-of-dalpiciclib-and-hrs-8080/2024-12-03T21:51:23+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-esophageal-cancer-and-breast-cancer-clinical-trials/2024-12-03T21:50:36+08:00https://flcube.com/jiangsu-hengrui-seeks-nmpa-approval-for-camrelizumab-famitinib-combo-in-cervical-cancer/2024-12-03T21:49:48+08:00https://flcube.com/jiangsu-hengrui-medicine-wins-nmpa-approvals-for-sle-and-lymphoma-drug-candidates/2024-12-03T21:48:59+08:00https://flcube.com/hengrui-medicine-backed-nanjing-tianyinshan-hospital-opens-as-class-3a-oncology-specialist-center/2024-12-03T21:47:18+08:00https://flcube.com/jiangsu-hengruis-shr-a2009-earns-fast-track-status-for-metastatic-nsclc-treatment/2024-12-03T21:46:07+08:00https://flcube.com/jiangsu-hengrui-medicine-secures-nmpa-approval-for-abiraterone-in-prostate-cancer-treatment/2024-12-03T21:45:22+08:00https://flcube.com/jiangsu-hengrui-medicine-advances-novel-cancer-therapies-with-nmpa-clinical-trial-approval/2024-12-03T21:43:35+08:00https://flcube.com/jiangsu-hengrui-medicine-wins-nmpa-nod-for-sglt-2-inhibitor-and-metformin-combo-for-type-2-diabetes/2024-12-03T21:42:32+08:00https://flcube.com/hengrui-medicine-gets-nmpa-green-light-for-phase-ib-ii-study-of-shr-a1921-combo-in-advanced-solid-tumors/2024-12-03T21:41:42+08:00https://flcube.com/hengrui-medicine-receives-nmpa-approval-for-phase-ii-cervical-cancer-study/2024-12-03T21:40:59+08:00https://flcube.com/hengrui-medicine-scores-first-mover-status-with-fda-approval-for-generic-astagraf-xl/2024-12-03T21:39:40+08:00https://flcube.com/jiangsu-hengrui-receives-chinese-approval-for-first-domestic-category-1-opioid-analgesic-for-postoperative-pain/2024-12-03T21:38:48+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-phase-ii-study-of-glp-1-agonist-for-weight-loss/2024-12-03T21:37:58+08:00https://flcube.com/jiangsu-hengruis-cd79b-targeting-adc-shr-a1912-earns-fda-fast-track-designation-for-r-r-dlbcl/2024-12-03T21:37:02+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-hrs-1167-clinical-trials-in-advanced-solid-tumors/2024-12-03T21:36:16+08:00https://flcube.com/hengrui-medicine-gets-nmpa-green-light-for-kras-g12c-inhibitor-clinical-trial-in-advanced-solid-tumors/2024-12-03T21:35:37+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-phase-ib-ii-study-of-hrs2398-in-advanced-solid-tumors/2024-12-03T21:34:46+08:00https://flcube.com/jiangsu-hengruis-generic-version-of-tepadina-approved-for-transplantation-conditioning-in-china/2024-12-03T21:34:05+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-shr-7631-adc-clinical-study-in-solid-tumors/2024-12-03T21:33:29+08:00https://flcube.com/jiangsu-hengruis-shr-a1921-earns-fda-fast-track-status-for-platinum-resistant-ovarian-cancer-therapies/2024-12-03T21:31:56+08:00https://flcube.com/jiangsu-hengruis-fluzoparib-receives-breakthrough-therapy-designation-for-her2-negative-breast-cancer/2024-12-03T21:31:12+08:00https://flcube.com/jiangsu-hengrui-medicine-secures-ind-approvals-for-two-drug-candidates-from-chinas-nmpa/2024-12-03T21:30:26+08:00https://flcube.com/jiangsu-hengrui-medicine-gains-nmpa-approval-for-hrs-4642-clinical-trial-in-kras-g12d-mutated-tumors/2024-12-03T21:29:20+08:00https://flcube.com/jiangsu-hengrui-medicine-advances-pipeline-with-nmpa-approvals-for-three-drugs/2024-12-03T21:28:25+08:00https://flcube.com/jiangsu-hengrui-secures-nmpa-approval-for-clinical-study-of-shr-a2102-and-shr-8068-in-advanced-tumors/2024-12-03T21:27:25+08:00https://flcube.com/hengrui-medicine-gets-nmpa-approval-for-clinical-study-of-cdk-4-6-inhibitor-combo-in-breast-cancer/2024-12-03T21:26:39+08:00https://flcube.com/jiangsu-hengrui-medicine-reports-7-26-revenue-growth-in-2023-driven-by-innovative-drugs/2024-12-03T21:25:50+08:00https://flcube.com/hengrui-medicine-gets-green-light-from-nmpa-for-two-anti-cancer-drugs/2024-12-03T21:25:10+08:00https://flcube.com/jiangsu-hengruis-shr-a2102-earns-fda-fast-track-status-for-urothelial-carcinoma-treatment/2024-12-03T21:23:26+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-go-ahead-for-camrelizumab-combination-therapy-study-in-pancreatic-cancer/2024-12-03T21:22:51+08:00https://flcube.com/jiangsu-hengrui-medicine-advances-hrs-5965-with-nmpa-clinical-trial-approval-for-glomerular-diseases/2024-12-03T21:22:00+08:00https://flcube.com/jiangsu-hengruis-shr-2173-gets-green-light-for-clinical-trial-in-iga-nephropathy/2024-12-03T21:21:02+08:00https://flcube.com/hengrui-medicine-strikes-deal-with-hercules-cm-newco-to-supply-glp-1-products-for-global-markets/2024-12-03T21:20:22+08:00https://flcube.com/jiangsu-hengruis-camrelizumab-apatinib-combo-denied-fda-approval-over-manufacturing-issues/2024-12-03T21:19:35+08:00https://flcube.com/jiangsu-hengruis-shr1905-anti-tslp-mab-gets-green-light-for-copd-clinical-trial/2024-12-03T21:18:51+08:00https://flcube.com/jiangsu-hengruis-fluzoparib-gains-nmpa-approval-as-maintenance-therapy-for-ovarian-cancer/2024-12-03T21:18:07+08:00https://flcube.com/jiangsu-hengruis-shr-a1921-anticipated-to-gain-nmpa-breakthrough-designation-for-ovarian-cancer/2024-12-03T21:17:19+08:00https://flcube.com/hengrui-medicines-vitiligo-treatment-shr0302-and-diabetes-drug-hrs9531-get-green-light-from-chinas-nmpa/2024-12-03T21:16:40+08:00https://flcube.com/hengrui-medicine-advances-two-drug-candidates-following-nmpa-clinical-trial-green-lights/2024-12-03T21:15:28+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-to-begin-clinical-trials-for-new-anticancer-biologic/2024-12-03T21:14:39+08:00https://flcube.com/jiangsu-hengrui-medicine-receives-fda-form-483-following-inspection-discrepancies/2024-12-03T21:14:00+08:00https://flcube.com/jiangsu-hengruis-her2-targeted-adc-shr-a1811-poised-to-earn-breakthrough-designation-in-china/2024-12-03T21:12:53+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-green-light-for-breast-cancer-drug-combo/2024-12-03T21:12:02+08:00https://flcube.com/jiangsu-hengruis-henagliflozin-gains-expanded-indication-for-type-2-diabetes-treatment-in-china/2024-12-03T21:11:13+08:00https://flcube.com/chinas-jiangsu-hengrui-first-to-market-generic-exparel-in-the-us-with-fda-anda-approval/2024-12-03T21:10:37+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-green-light-for-hrs-9813-ipf-clinical-trial/2024-12-03T21:09:47+08:00https://flcube.com/jiangsu-hengruis-subsidiary-conducts-first-surgical-dosing-in-parkinsons-gene-therapy-clinical-trial/2024-12-03T21:08:46+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-faces-fda-setback-with-warning-letter-for-quality-control-issues/2024-12-03T21:07:53+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-to-study-cdk-4-6-inhibitor-dalpiciclib-in-combination-with-hrs-1358-for-breast-cancer/2024-12-03T21:06:57+08:00https://flcube.com/shanghai-medicilon-and-jiangsu-hengrui-join-forces-to-advance-pre-clinical-drug-evaluation/2024-12-03T21:06:12+08:00https://flcube.com/hengrui-medicine-advances-in-breast-cancer-treatment-with-nmpa-clinical-trial-greenlight/2024-12-03T21:05:16+08:00https://flcube.com/jiangsu-hengrui-medicine-receives-nmpa-approval-for-shr-a1921-clinical-study-in-advanced-solid-tumors/2024-12-03T21:04:23+08:00https://flcube.com/jiangsu-hengrui-medicine-gains-nmpa-approval-for-five-drug-candidates-including-il-17a-mab-for-psoriasis/2024-12-03T21:03:31+08:00https://flcube.com/chinese-nmpa-approves-hengrui-meds-generic-abraxane-for-metastatic-pancreatic-cancer-treatment/2024-12-03T21:02:30+08:00https://flcube.com/hengrui-medicine-launches-phase-ii-trial-for-shr7280-to-treat-uterine-fibroids/2024-12-03T21:01:24+08:00https://flcube.com/cstone-to-manufacture-gavreto-locally-following-nmpa-approval-expanding-market-presence/2024-12-03T21:00:32+08:00https://flcube.com/jiangsu-hengrui-secures-nmpa-approval-for-clinical-trials-of-shr-2106-in-primary-sjogrens-syndrome/2024-12-03T20:59:42+08:00https://flcube.com/jiangsu-hengrui-medicine-expands-rd-footprint-with-jinan-innovation-zone-partnership/2024-12-03T20:58:52+08:00https://flcube.com/jiangsu-hengrui-medicine-reports-21-78-yoy-revenue-growth-and-48-67-increase-in-net-profit-for-h1-2024/2024-12-03T20:57:43+08:00https://flcube.com/jiangsu-hengrui-medicine-co-ltd-announces-resignations-of-two-deputy-general-managers/2024-12-03T20:56:49+08:00https://flcube.com/jiangsu-hengruis-vunakizumab-receives-nmpa-approval-as-first-homegrown-autoimmune-il-17a-drug/2024-12-03T20:55:20+08:00https://flcube.com/jiangsu-hengruis-ivarmacitinib-for-adult-alopecia-areata-accepted-for-review-by-chinas-cde/2024-12-03T20:52:14+08:00https://flcube.com/jiangsu-hengruis-angptl3-inhibitor-shr-1918-earns-breakthrough-designation-for-hofh-treatment/2024-12-03T20:51:18+08:00https://flcube.com/jiangsu-hengruis-her2-targeted-adc-shr-a1811-receives-priority-review-from-chinas-nmpa/2024-12-03T20:50:30+08:00https://flcube.com/jiangsu-hengrui-medicines-shr-1701-combo-therapy-for-gastric-cancer-accepted-for-review-by-chinas-nmpa/2024-12-03T20:49:43+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-green-light-for-generic-vizamyl-clinical-trial/2024-12-03T20:48:35+08:00https://flcube.com/jiangsu-hengrui-medicine-gets-nmpa-green-light-for-clinical-trial-of-tslp-targeted-asthma-treatment/2024-12-03T20:47:33+08:00https://flcube.com/hengrui-medicines-hr19042-capsules-designated-as-breakthrough-therapy-for-autoimmune-hepatitis-by-china-nmpa/2024-12-03T20:46:36+08:00https://flcube.com/kailera-therapeutics-emerges-with-usd-400-million-in-series-a-funding-for-anti-obesity-pipeline/2024-12-03T20:44:03+08:00https://flcube.com/jiangsu-hengrui-secures-fda-nod-for-generic-abraxane-strengthening-oncology-portfolio/2024-12-03T20:43:23+08:00https://flcube.com/jiangsu-hengruis-shr2554-gets-priority-review-for-lymphoma-treatment-strengthening-global-ezh2-inhibitor-market/2024-12-03T20:42:39+08:00https://flcube.com/jiangsu-hengruis-rgl-193-receives-nmpa-greenlight-for-parkinsons-disease-clinical-study/2024-12-03T20:41:49+08:00https://flcube.com/jiangsu-hengruis-hr19042-earns-breakthrough-designation-for-autoimmune-hepatitis-treatment-in-china/2024-12-03T20:40:56+08:00https://flcube.com/jiangsu-hengruis-hetrombopag-olamine-receives-nmpa-review-for-severe-aplastic-anemia-indication/2024-12-03T20:40:04+08:00https://flcube.com/jiangsu-hengrui-resubmits-application-for-camrelizumab-combo-in-hcc-to-fda/2024-12-03T20:39:05+08:00https://flcube.com/jiangsu-hengrui-medicine-initiates-phase-iii-clinical-trial-for-shr-a1904-in-gastric-cancer/2024-12-03T20:01:39+08:00https://flcube.com/hengrui-medicine-considers-hkex-secondary-listing-amid-financing-challenges-in-mainland-china/2024-12-03T20:00:28+08:00https://flcube.com/jiangsu-hengrui-medicine-advances-clinical-trials-for-cancer-therapies-with-nmpa-clearance/2024-12-03T19:59:32+08:00https://flcube.com/jiangsu-hengrui-medicine-receives-nmpa-clearance-for-multiple-clinical-trials-of-oncology-drugs/2024-12-03T19:58:28+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-shr-2173-clinical-trial-in-itp/2024-12-03T19:56:17+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-hrs-6208-solid-tumor-clinical-study/2024-12-03T19:54:44+08:00https://flcube.com/henlius-biotech-posts-67-8-yoy-revenue-growth-and-first-annual-profit-in-2023-financials/2024-12-03T18:58:37+08:00https://flcube.com/aligos-therapeutics-and-xiamen-amoytop-biotech-partner-to-test-hepatitis-b-combination-therapy/2024-12-03T18:58:07+08:00https://flcube.com/henlius-pharmaceutical-expands-licensing-agreement-with-kgbio-for-pd-1-inhibitor/2024-12-03T18:57:20+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-fluzoparib-and-apatinib-gain-nmpa-approval-for-metastatic-breast-cancer-treatment/2024-12-03T18:56:22+08:00https://flcube.com/accuredit-therapeutics-art001-shows-over-90-ttr-reduction-in-attr-amyloidosis-trial/2024-12-03T18:51:38+08:00https://flcube.com/sanofi-announces-eur-1-billion-investment-for-new-beijing-manufacturing-plant/2024-12-03T18:38:21+08:00https://flcube.com/huadong-medicines-saiyuexin-biosimilar-accepted-for-review-by-nmpa-for-pediatric-psoriasis/2024-12-03T18:30:18+08:00https://flcube.com/fangzhou-inc-expands-partnerships-with-tencent-healthcare-and-baidu-health-at-digital-summit/2024-12-03T17:30:04+08:00https://flcube.com/mgi-tech-co-ltd-partners-with-universidad-de-san-martin-de-porre-for-genomic-sequencing-advancement/2024-12-03T16:38:30+08:00https://flcube.com/vflo-medical-partners-with-inari-medical-to-expand-access-in-greater-china/2024-12-03T16:22:08+08:00https://flcube.com/uni-bio-science-group-achieves-milestones-in-medical-aesthetics-with-new-product-approvals/2024-12-03T16:04:16+08:00https://flcube.com/ocumen-therapeutics-ot-301-phase-iii-denali-study-surpasses-140-patient-enrollment-in-china/2024-12-03T15:32:38+08:00https://flcube.com/china-medical-system-holdings-secures-exclusive-rights-to-atom-therapeutics-gout-drug-abp-671/2024-12-03T15:13:34+08:00https://flcube.com/novartis-secures-global-rights-to-ptc-therapeutics-huntingtons-disease-treatment-ptc518/2024-12-03T14:57:20+08:00https://flcube.com/ucb-partners-with-bioray-biopharmaceutical-for-bimzelx-commercial-promotion-in-china/2024-12-03T14:21:31+08:00https://flcube.com/nmpa-approves-hangzhou-ruidi-biotechnologys-steep-pulse-therapy-equipment-for-tumor-treatment/2024-12-03T14:14:21+08:00https://flcube.com/sirnaomics-ltd-partners-with-edirna-inc-to-advance-rna-editing-therapy/2024-12-03T11:33:30+08:00https://flcube.com/cde-launches-trial-procedures-for-adding-pediatric-information-to-drug-inserts/2024-12-03T11:18:28+08:00https://flcube.com/sino-biopharmaceuticals-f-star-therapeutics-inks-third-licensing-deal-with-takeda-for-immunotherapies/2024-12-03T11:16:23+08:00https://flcube.com/3sbio-inc-receives-nmpa-approval-for-nalfurafine-tablets-to-treat-hemodialysis-related-pruritus/2024-12-03T11:06:29+08:00https://flcube.com/tot-biopharmaceutical-and-gl-biotech-collaborate-on-disaclink-technology-for-adc-advancements/2024-12-03T11:01:30+08:00https://flcube.com/shanghai-escugen-partners-with-foreseen-biotechnology-for-adc-development/2024-12-03T10:57:33+08:00https://flcube.com/biocytogen-pharmaceuticals-enters-antibody-license-agreement-with-pheon-therapeutics-for-adc-development/2024-12-03T10:25:15+08:00https://flcube.com/nanjing-kati-medical-and-leman-biotech-partner-to-advance-immune-metabolism-reprogramming-in-car-t-therapy/2024-12-03T10:17:21+08:00https://flcube.com/brii-biosciences-expands-collaboration-with-vbi-vaccines-on-hepatitis-b-virus-therapies/2024-12-03T10:06:30+08:00https://flcube.com/nmpa-launches-drug-standard-management-measures-to-enhance-drug-quality-and-safety/2024-12-03T09:50:39+08:00https://flcube.com/chinas-mofcom-hosts-symposium-with-multinational-corporations-promises-development-opportunities/2024-12-03T09:47:47+08:00https://flcube.com/genprex-inc-receives-chinese-patent-protection-for-reqorsa-immunogene-therapy/2024-12-03T09:41:17+08:00https://flcube.com/roche-and-genprex-initiate-phase-i-trial-combining-tecentriq-and-reqorsa-for-es-sclc/2024-12-03T09:36:59+08:00https://flcube.com/moderna-inc-plans-usd-1-billion-investment-in-shanghai-for-mrna-vaccine-production/2024-12-03T09:30:06+08:00https://flcube.com/cspc-pharmaceutical-group-receives-marketing-approval-for-desvenlafaxine-in-china/2024-12-03T09:26:21+08:00https://flcube.com/abbvies-rinvoq-receives-nmpa-approval-for-moderate-to-severe-crohns-disease-treatment/2024-12-03T09:21:34+08:00https://flcube.com/chinas-nafr-enhances-tax-benefits-for-private-health-insurance-purchases/2024-12-03T09:17:29+08:00https://flcube.com/jacobio-pharma-secures-rmb-150-million-investment-to-advance-pipeline-programs/2024-12-03T09:15:01+08:00https://flcube.com/genesis-medtech-secures-chinese-market-approval-for-artisential-laparoscopic-surgical-device/2024-12-03T09:11:58+08:00https://flcube.com/shanghai-fosun-pharmaceutical-submits-daxibotulinumtoxin-a-rt002-for-nmpa-approval/2024-12-03T09:08:51+08:00https://flcube.com/c-mer-eye-care-holdings-ltd-partners-with-hong-kong-ophthalmologist-for-novel-drug-development/2024-12-03T08:58:46+08:00https://flcube.com/chengdu-shengnuo-biotechnology-aims-to-raise-rmb-160-million-for-peptide-drug-cdmo-expansion/2024-12-03T08:49:32+08:00https://flcube.com/peijia-medical-receives-nmpa-approval-for-dcwire-micro-guide-wire-device-in-china/2024-12-03T08:34:05+08:00https://flcube.com/wuxi-biologics-proposes-spin-off-and-listing-of-wuxi-xdc-on-hong-kong-stock-exchange/2024-12-02T23:47:52+08:00https://flcube.com/shanghai-bdgene-technology-receives-us-fda-approval-for-hsv-1-stromal-keratitis-gene-therapy/2024-12-02T23:40:32+08:00https://flcube.com/jenscare-scientifics-lux-valve-plus-accepted-for-us-fda-review-in-ide-process/2024-12-02T23:38:17+08:00https://flcube.com/broncus-medical-inc-launches-first-regulatory-clinical-study-for-targeted-lung-denervation-system/2024-12-02T23:35:45+08:00https://flcube.com/hainan-boao-lecheng-partners-with-medlive-for-medical-tourism-and-online-doctor-education/2024-12-02T23:32:00+08:00https://flcube.com/hutchmed-ltd-initiates-phase-i-clinical-study-for-shp2-inhibitor-hmpl-415-in-solid-tumors/2024-12-02T23:09:50+08:00https://flcube.com/genscript-biotech-expands-cgmp-manufacturing-for-gene-and-cell-therapy-in-zhenjiang-facility/2024-12-02T23:07:20+08:00https://flcube.com/jiangxi-jemincare-group-launches-omalizumab-biosimilar-cmab007-in-china-for-asthma-and-dermatology/2024-12-02T23:00:02+08:00https://flcube.com/zhejiang-doer-biologics-partners-with-biontech-for-global-development-of-innovative-biological-drugs/2024-12-02T22:51:15+08:00https://flcube.com/c4-therapeutics-cft8919-earns-fda-approval-for-clinical-trials-targeting-egfr-l858r-mutations/2024-12-02T22:43:30+08:00https://flcube.com/nhsas-2022-report-bmi-fund-income-rises-7-6-outgoing-expenditure-increases-2-3/2024-12-02T22:40:02+08:00https://flcube.com/zai-labs-vyvgart-receives-nmpa-review-for-subcutaneous-injection-form-in-gmg-treatment/2024-12-02T22:37:39+08:00https://flcube.com/sino-medical-sciences-receives-approval-for-next-generation-drug-eluting-stent-in-indonesia/2024-12-02T22:31:45+08:00https://flcube.com/shanghais-smpa-initiates-volume-based-procurement-for-national-vbp-drugs-in-alliance-region/2024-12-02T22:26:54+08:00https://flcube.com/everest-medicines-and-sinopharm-group-ink-mou-to-enhance-distribution-and-collaboration/2024-12-02T22:21:41+08:00https://flcube.com/bayer-and-peking-university-enter-fourth-phase-of-partnership-to-advance-drug-discovery/2024-12-02T22:00:32+08:00https://flcube.com/transcenta-holding-ltd-secures-global-clinical-trial-approvals-for-osemitamab-in-gastric-cancer/2024-12-02T21:58:11+08:00https://flcube.com/pentax-medical-to-establish-endoscope-manufacturing-and-rd-site-in-shanghai/2024-12-02T21:55:16+08:00https://flcube.com/minghui-pharmaceuticals-mh004-ointment-meets-primary-endpoints-in-atopic-dermatitis-phase-iii-study/2024-12-02T21:13:22+08:00https://flcube.com/chinas-nhc-launches-pilot-plan-to-expand-wholly-foreign-owned-hospital-sector/2024-12-02T18:24:20+08:00https://flcube.com/hua-medicines-second-generation-gka-hm-002-1005-completes-phase-ia-study-in-the-us/2024-12-02T18:18:13+08:00https://flcube.com/shanghai-micurxs-mrx-4-contezolid-meets-primary-endpoint-in-phase-iii-cssti-study/2024-12-02T18:06:51+08:00https://flcube.com/cbc-group-and-mubadala-acquire-ucbs-neurology-and-allergy-business-in-china-for-680-million/2024-12-02T17:36:08+08:00https://flcube.com/simcere-zaiming-launches-phase-iii-trial-for-serd-inhibitor-sim0270-in-breast-cancer/2024-12-02T17:12:39+08:00https://flcube.com/hua-medicines-sensitize-study-illuminates-dorzagliatins-%ce%b2-cell-glucose-sensitivity-mechanism/2024-12-02T17:01:18+08:00https://flcube.com/sunflower-pharmaceutical-group-to-establish-joint-lab-with-peking-university-for-bacterial-enzyme-research/2024-12-02T16:35:04+08:00https://flcube.com/simcere-pharmaceuticals-edaravone-and-borneol-sublingual-tablets-approved-for-ais-treatment-in-china/2024-12-02T16:22:03+08:00https://flcube.com/shanghai-pharmaceuticals-concludes-phase-ii-study-for-i037-in-acute-ischemic-stroke/2024-12-02T16:09:08+08:00https://flcube.com/affinity-shanghai-secures-over-rmb-400-million-in-series-b2-financing-to-advance-oncology-drugs/2024-12-02T15:52:45+08:00https://flcube.com/abogen-biosciences-and-ruijin-hospital-launch-ruijin-abogen-nucleic-acid-drug-research-institute/2024-12-02T14:54:05+08:00https://flcube.com/henlius-biotech-initiates-us-commercial-supply-of-hanquyou-biosimilar-to-herceptin/2024-12-02T14:39:13+08:00https://flcube.com/immuneonco-biopharmaceuticals-receives-nmpa-approval-for-lupus-nephritis-phase-ii-study/2024-12-02T14:30:06+08:00https://flcube.com/biocytogen-pharmaceuticals-awarded-cnipa-patent-for-renmab-human-antibody-mice-platform/2024-12-02T10:55:50+08:00https://flcube.com/guangdongs-optomedic-secures-over-27-8-million-in-pre-ipo-financing-for-endoscopy-innovations/2024-12-02T10:53:13+08:00https://flcube.com/shanghai-junshi-biosciences-tuoyi-files-for-9th-indication-in-china-for-rcc-treatment-2/2024-12-02T10:44:36+08:00https://flcube.com/shanghai-junshi-biosciences-tuoyi-files-for-9th-indication-in-china-for-rcc-treatment/2024-12-02T10:38:18+08:00https://flcube.com/next-generation-gene-therapeutics-secures-40-million-in-series-b-financing-for-gene-therapy-development/2024-12-02T10:35:20+08:00https://flcube.com/ji-xing-pharmaceuticals-and-tsh-biopharm-announce-collaboration-for-dry-eye-treatment-in-taiwan/2024-12-02T10:24:44+08:00https://flcube.com/hrain-biotechnologys-anti-cd70-t-cell-therapy-hr010-gets-tacit-approval-for-renal-cancer-trial/2024-12-02T10:18:09+08:00https://flcube.com/huadong-medicines-elahere-receives-approval-for-fr%ce%b1-positive-cancer-treatment-in-china/2024-12-02T10:10:56+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-enhertu-gains-new-indication-approval-in-china-for-her2-low-breast-cancer/2024-12-01T23:32:53+08:00https://flcube.com/us-fda-approves-additional-shipments-of-qilu-pharmaceuticals-cisplatin-to-address-shortage/2024-12-01T23:29:35+08:00https://flcube.com/shanghai-fosun-pharmaceutical-submits-tenapanor-approval-application-to-chinas-nmpa/2024-12-01T23:27:03+08:00https://flcube.com/dne-group-launches-485-million-fund-for-life-sciences-park-in-shanghai-pudong/2024-12-01T23:21:52+08:00https://flcube.com/lianbio-secures-clinical-supply-agreement-with-astrazeneca-for-shp2-inhibitor-trial/2024-12-01T23:13:50+08:00https://flcube.com/medidata-partners-with-ecco-and-gobroad-to-transform-cancer-trials-with-digital-tech/2024-12-01T22:58:11+08:00https://flcube.com/shanghai-circode-bio-and-pfizer-collaborate-to-explore-circular-rna-therapy-potential/2024-12-01T21:08:00+08:00https://flcube.com/kedrion-biopharma-achieves-first-product-approval-in-china-for-human-albumin/2024-12-01T21:02:07+08:00https://flcube.com/grit-biotechnologys-gt201-til-therapy-approved-for-clinical-studies-by-chinas-cde/2024-12-01T20:51:06+08:00https://flcube.com/silence-therapeutics-receives-4-million-milestone-payment-from-hansoh-pharmaceutical/2024-12-01T20:46:03+08:00https://flcube.com/harbour-biomed-reports-first-ever-profit-in-h1-2023-interim-financial-results/2024-12-01T20:40:28+08:00https://flcube.com/innocare-pharma-and-arrivent-biopharma-partner-on-shp2-inhibitor-and-egfr-inhibitor-combination/2024-12-01T20:33:08+08:00https://flcube.com/gsks-cabotegravir-receives-nmpa-approval-for-hiv-treatment-in-china/2024-12-01T20:29:29+08:00https://flcube.com/beijing-tinavi-medicals-knee-replacement-navigation-system-approved-by-nmpa/2024-12-01T20:24:04+08:00https://flcube.com/genequantum-healthcare-and-aimed-bio-expand-partnership-to-develop-five-novel-adc-drugs/2024-12-01T20:18:26+08:00https://flcube.com/brightgene-bio-receives-fda-clearance-for-generic-eribulin-apis-advancing-in-breast-cancer-treatment/2024-12-01T20:12:46+08:00https://flcube.com/brightgenes-bgm0504-shows-promise-in-phase-ii-obesity-study-without-diabetes/2024-12-01T20:11:55+08:00https://flcube.com/chile-expands-financial-coverage-for-abbvies-rsv-prophylaxis-synagis/2024-12-01T19:48:53+08:00https://flcube.com/antengene-corp-ltd-receives-hong-kong-nda-approval-for-xpovio-in-relapsed-multiple-myeloma/2024-12-01T19:47:00+08:00https://flcube.com/shanghai-xinhengrui-medical-technology-secures-series-a-funding-for-heart-failure-device-development/2024-12-01T19:39:02+08:00https://flcube.com/beyond-therapeutics-secures-tens-of-millions-in-pre-series-a-financing-for-ophthalmology-and-oncology-pipeline/2024-12-01T19:34:04+08:00https://flcube.com/mabwell-bioscience-receives-nmpa-approval-to-launch-9mw2921-clinical-study/2024-12-01T19:29:24+08:00https://flcube.com/centre-medical-secures-tens-of-millions-in-series-a-financing-to-expand-globally/2024-12-01T19:27:08+08:00https://flcube.com/transthera-sciences-tt-00420-receives-breakthrough-designation-for-cholangiocarcinoma-treatment/2024-12-01T19:18:25+08:00https://flcube.com/shenzhen-salubris-pharmaceuticals-sal0120-for-iga-nephropathy-accepted-for-nmpa-review/2024-12-01T19:10:31+08:00https://flcube.com/nhsa-unveils-2023-flying-inspection-plan-for-medical-insurance-fund-oversigh/2024-12-01T19:06:50+08:00https://flcube.com/betta-pharmaceuticals-mcla-129-combo-therapy-for-nsclc-gets-nmpa-clinical-approval/2024-12-01T19:04:32+08:00https://flcube.com/pfizer-launches-phase-iii-trial-for-quadrivalent-influenza-modrna-vaccine-in-argentina/2024-12-01T19:00:27+08:00https://flcube.com/zai-lab-initiates-phase-iii-trial-for-bemarituzumab-in-first-line-gastric-cancer-treatment/2024-12-01T18:57:50+08:00https://flcube.com/sanofi-and-astrazeneca-receive-fda-approval-for-rsv-prevention-treatment-beyfortus/2024-12-01T18:49:56+08:00https://flcube.com/nmpa-releases-70th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2024-12-01T18:47:14+08:00https://flcube.com/cutia-therapeutics-cu-40101-completes-phase-i-clinical-trial-for-androgenetic-alopecia/2024-12-01T18:43:55+08:00https://flcube.com/mabwell-biosciences-7mw3711-adc-for-b7-h3-gets-clinical-trial-approval-in-china/2024-12-01T18:41:10+08:00https://flcube.com/bayers-kerendia-officially-launched-in-china-for-type-2-diabetes-related-ckd/2024-12-01T18:38:56+08:00https://flcube.com/sensview-secures-tens-of-millions-in-series-a-funding-for-x-ray-detector-tech/2024-12-01T18:36:26+08:00https://flcube.com/nanjing-enrui-kainuo-biotechnology-secures-pre-series-a-funding-for-cell-therapy-development/2024-12-01T18:31:06+08:00https://flcube.com/shenzhen-salubris-pharmaceuticals-receives-fda-clearance-for-sal0119-clinical-trial/2024-12-01T18:23:36+08:00https://flcube.com/bio-thera-solutions-receives-nmpa-approval-for-ctla-4-and-pd-1-inhibitor-combo-study/2024-12-01T17:05:01+08:00https://flcube.com/shanghai-pharmaceuticals-gets-nmpa-green-light-for-recombinant-human-adenovirus-type-5-trial/2024-12-01T16:58:54+08:00https://flcube.com/grand-pharmaceutical-gets-nod-for-phase-ii-sepsis-study-of-stc3141-in-china/2024-12-01T16:56:16+08:00https://flcube.com/chinas-nhc-issues-guidelines-to-enhance-clinical-department-capacities-for-serious-diseases/2024-12-01T16:53:05+08:00https://flcube.com/nanjing-immunophage-biotechs-ipg11406-approved-for-sle-clinical-trial-in-china/2024-12-01T16:49:33+08:00https://flcube.com/pyrotech-beijing-biotechnology-secures-97-37-million-in-series-a-financing/2024-12-01T16:42:58+08:00https://flcube.com/shanghai-henlius-biotech-announces-executive-leadership-changes/2024-12-01T16:37:58+08:00https://flcube.com/zai-lab-and-argenx-report-positive-preliminary-results-from-vyvgart-hytrulo-cidp-study/2024-12-01T16:33:15+08:00https://flcube.com/zai-labs-partner-argenx-receives-fda-approval-for-cidp-treatment-vygart-hytrulo/2024-12-01T16:30:36+08:00https://flcube.com/jj-files-nda-for-fcrn-blocker-nipocalimab-targets-myasthenia-gravis-market/2024-12-01T16:30:35+08:00https://flcube.com/obseva-sa-regains-full-rights-to-nolasiban-after-terminating-yuyuan-biological-license-deal/2024-12-01T16:26:09+08:00https://flcube.com/janssens-rybrevant-meets-primary-endpoint-in-phase-iii-nsclc-study/2024-12-01T16:13:27+08:00https://flcube.com/boyu-capital-acquires-hong-kong-medical-device-company-quasar-for-over-600-million/2024-12-01T16:07:58+08:00https://flcube.com/novartis-q2-2023-results-exceed-expectations-with-9-yoy-sales-growth/2024-12-01T15:53:19+08:00https://flcube.com/shanghai-pharmaceuticals-and-mindray-form-strategic-alliance-for-medical-equipment-and-ivd-products/2024-12-01T15:50:27+08:00https://flcube.com/mindrank-ltd-secures-over-20-million-in-series-a-funding-to-advance-ai-drug-development/2024-12-01T15:46:15+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-northeast-infectious-diseases-alliance-to-enhance-surveillance/2024-12-01T15:41:00+08:00https://flcube.com/novartis-acquires-dtx-pharma-and-its-falcon-technology-for-up-to-1-billion/2024-12-01T15:38:49+08:00https://flcube.com/allen-institute-for-immunology-partners-with-eli-lilly-to-study-atopic-dermatitis-and-rheumatoid-arthritis/2024-12-01T15:30:58+08:00https://flcube.com/pfizer-and-flagship-pioneering-invest-100-million-in-drug-candidates-development/2024-12-01T15:27:12+08:00https://flcube.com/major-pharma-companies-pledge-support-for-250000-genomes-sequencing-project/2024-12-01T15:13:24+08:00https://flcube.com/sumitomo-pharma-to-invest-30-million-in-china-for-new-product-development/2024-12-01T15:07:25+08:00https://flcube.com/antengene-initiates-phase-i-eraser-study-for-atg-017-in-combination-with-nivolumab/2024-12-01T15:04:43+08:00https://flcube.com/sichuan-huiyu-pharmaceuticals-kras-g12c-drug-hyp-2090ptsa-accepted-for-nmpa-review/2024-12-01T15:00:36+08:00https://flcube.com/puncture-robotic-secures-13-9-million-in-series-a-funding-to-advance-medical-robotics/2024-12-01T14:58:26+08:00https://flcube.com/alibaba-health-and-daiichi-sankyo-partner-to-innovate-in-digital-healthcare-services/2024-12-01T14:48:33+08:00https://flcube.com/pfizers-gbs-vaccine-candidate-gbs6-shows-promise-in-phase-ii-maternal-immunization-study/2024-12-01T14:43:13+08:00https://flcube.com/us-merger-guidelines-updated-public-comment-sought-on-antitrust-law-changes/2024-12-01T14:41:18+08:00https://flcube.com/merck-and-telix-pharmaceuticals-initiate-phase-i-study-for-caix-expressing-tumors-therapy/2024-12-01T14:39:24+08:00https://flcube.com/janssens-sirturo-bedaquiline-expands-indication-to-include-adolescents-with-mdr-tb/2024-12-01T14:32:45+08:00https://flcube.com/chongqing-zhifei-biological-launches-phase-i-clinical-trial-for-group-b-meningococcal-vaccine/2024-12-01T14:26:26+08:00https://flcube.com/chipscreen-pharmaceuticals-epidaza-granted-priority-status-for-dlbcl-treatment-in-china/2024-12-01T14:23:47+08:00https://flcube.com/nmpa-approves-chengdu-chipscreens-bilessglu-for-type-2-diabetes-in-combination-with-metformin/2024-12-01T14:20:16+08:00https://flcube.com/chipscreens-hdac-inhibitor-chidamide-to-be-tested-in-combination-therapy-for-crc-by-nmpa/2024-12-01T14:15:39+08:00https://flcube.com/casi-pharmaceuticals-enters-assignment-agreement-with-mundipharma-for-folotyn-commercialization-in-china/2024-12-01T14:14:22+08:00https://flcube.com/chinas-nmpa-approves-shenzhen-chipscreens-chidamide-for-dlbcl-indication/2024-12-01T14:13:16+08:00https://flcube.com/chipscreens-chidamide-in-sight-of-breakthrough-therapy-designation-in-china-for-mss-pmmr-colorectal-cancer/2024-12-01T14:12:17+08:00https://flcube.com/hutchmeds-elunate-tyvyt-combo-receives-breakthrough-therapy-designation-in-china-for-endometrial-cancer/2024-12-01T14:02:31+08:00https://flcube.com/kintor-pharmaceutical-initiates-long-term-safety-trial-for-androgenetic-alopecia-treatment-kx-826/2024-12-01T13:57:43+08:00https://flcube.com/hybribio-ltd-and-united-imaging-healthcare-form-strategic-partnership-to-advance-medical-technology/2024-12-01T13:55:29+08:00https://flcube.com/novomics-partners-with-topgene-to-expand-genomic-testing-services-in-china/2024-12-01T13:46:03+08:00https://flcube.com/stemirna-therapeutics-halts-mrna-vaccine-factory-construction-amid-low-demand/2024-12-01T13:34:05+08:00https://flcube.com/bgi-genomics-partners-with-thai-entities-to-combat-thalassemia-through-genomics-and-cell-therapy/2024-12-01T12:59:57+08:00https://flcube.com/shanghai-junshi-biosciences-tuoyi-receives-nmpa-review-for-es-sclc-treatment/2024-12-01T12:57:42+08:00https://flcube.com/sichuan-gowell-pharmaceutical-wins-reversal-in-forxiga-patent-infringement-case/2024-12-01T12:47:01+08:00https://flcube.com/healthgen-biotechnologys-plant-made-albumin-breakthrough-a-milestone-in-serum-therapy/2024-12-01T11:31:06+08:00https://flcube.com/shanghai-cell-therapy-groups-second-attempt-at-hk-ipo-receives-green-light-from-cicc-and-ccb-international/2024-12-01T11:12:14+08:00https://flcube.com/gempharmatech-partners-with-daxiang-biotech-to-advance-preclinical-evaluation-models/2024-12-01T00:28:19+08:00https://flcube.com/abbott-reports-q2-2023-revenue-growth-exceeding-estimates-despite-covid-19-dip/2024-12-01T00:26:07+08:00https://flcube.com/jiangsu-simcere-pharmaceutical-gets-nmpa-approval-for-quviviq-anti-insomnia-drug/2024-12-01T00:23:37+08:00https://flcube.com/livzon-pharmaceutical-secures-licensing-agreement-for-synergy-pharmas-hht120-in-greater-china/2024-12-01T00:13:58+08:00https://flcube.com/antengene-corp-receives-fda-fast-track-designation-for-xpovio-in-myelofibrosis-treatment/2024-11-30T23:54:05+08:00https://flcube.com/riparian-pharmaceuticals-secures-exclusive-license-agreement-with-pfizer-for-cardiovascular-program/2024-11-30T23:49:18+08:00https://flcube.com/acotec-scientific-and-boston-scientific-announce-comprehensive-collaboration-agreement/2024-11-30T23:40:50+08:00https://flcube.com/hansoh-pharmaceuticals-ibrexafungerp-nda-accepted-for-review-by-chinas-nmpa-for-vvc-treatment/2024-11-30T23:36:30+08:00https://flcube.com/genscript-biotechs-car-t-therapy-carvykti-reports-usd-117-million-in-sales/2024-11-30T23:30:05+08:00https://flcube.com/scg-cell-therapy-launches-global-manufacturing-and-rd-center-in-singapore-with-automated-system/2024-11-30T23:26:49+08:00https://flcube.com/zennova-pharmaceutical-group-secures-rmb-100-million-in-series-b-financing-for-commercial-manufacturing-and-rd/2024-11-30T23:24:26+08:00https://flcube.com/ocumension-therapeutics-ot-101-s-myopia-treatment-accepted-for-cde-review/2024-11-30T23:18:12+08:00https://flcube.com/johnson-johnson-reports-7-5-yoy-sales-growth-in-q2-2023-driven-by-pharma-and-devices/2024-11-30T23:10:11+08:00https://flcube.com/sartorius-expands-global-footprint-with-new-cell-culture-facility-in-puerto-rico/2024-11-30T23:04:55+08:00https://flcube.com/sandoz-plans-usd-90-million-biosimilar-development-center-in-slovenia-by-2026/2024-11-30T23:01:08+08:00https://flcube.com/gsk-partners-with-limmatech-for-further-development-of-quadrivalent-shigellosis-vaccine/2024-11-30T19:44:18+08:00https://flcube.com/nhsa-releases-official-guidelines-for-drug-negotiations-and-bidding-for-nrdl-update/2024-11-30T19:30:22+08:00https://flcube.com/carbon-medical-technology-secures-over-rmb-100-million-in-series-a-financing-for-interventional-therapy/2024-11-30T19:27:47+08:00https://flcube.com/bavarian-nordics-rsv-vaccine-candidate-fails-phase-iii-trial-discontinues-program/2024-11-30T19:10:53+08:00https://flcube.com/national-health-commission-launches-one-year-anti-corruption-campaign-in-pharmaceutical-sector/2024-11-30T18:53:33+08:00https://flcube.com/fda-assures-no-disruption-to-us-drug-supply-chain-after-pfizer-warehouse-tornado/2024-11-30T18:51:16+08:00https://flcube.com/fda-approves-daiichi-sankyos-vanflyta-for-flt3-itd-positive-aml-maintenance-treatment/2024-11-30T18:48:53+08:00https://flcube.com/gilead-sciences-halts-development-of-magrolimab-for-hr-mds-following-phase-iii-trial-results/2024-11-30T17:29:20+08:00https://flcube.com/eu-commits-eur-3-million-to-strengthen-healthcare-access-in-latin-america-and-caribbean/2024-11-30T17:11:44+08:00https://flcube.com/abbvies-aquipta-and-novartiss-piqray-receive-regulatory-approvals-in-mexico/2024-11-30T17:08:34+08:00https://flcube.com/oxford-and-peking-university-study-unveils-genetic-risk-factors-in-east-asian-population/2024-11-30T17:04:22+08:00https://flcube.com/roche-and-alnylam-partner-on-rnai-therapeutic-zilebesiran-for-hypertension-treatment/2024-11-30T16:39:08+08:00https://flcube.com/pfizer-ends-partnership-with-syros-pharmaceuticals-for-sickle-cell-disease-program/2024-11-30T16:15:01+08:00https://flcube.com/ascletis-pharmas-asc22-combo-therapy-shows-promise-in-hiv-functional-cure-clinical-trial/2024-11-30T14:00:15+08:00https://flcube.com/taiwans-tfda-orders-recall-of-two-nucala-batches-due-to-glass-fragments/2024-11-30T13:54:08+08:00https://flcube.com/amoy-diagnostics-and-astrazeneca-expand-partnership-for-companion-diagnostic-development/2024-11-30T13:45:46+08:00https://flcube.com/vcanbios-vum02-stem-cell-therapy-accepted-for-review-by-chinas-cde-for-agvhd-treatment/2024-11-30T13:36:44+08:00https://flcube.com/nmpa-updates-list-of-medical-devices-exempt-from-clinical-evaluation-in-china/2024-11-30T13:33:29+08:00https://flcube.com/chinese-health-authorities-unveil-key-reform-tasks-for-medical-system-in-h2-2023/2024-11-30T13:31:54+08:00https://flcube.com/nanjing-leads-biolabs-and-aditum-bio-launch-oblenio-bio-with-focus-on-cd19-tri-specific-antibody/2024-11-30T12:35:45+08:00https://flcube.com/xellsmart-bio-pharmaceutical-achieves-milestone-with-first-patient-enrollment-in-global-ipsc-clinical-study-for-als/2024-11-30T12:25:30+08:00https://flcube.com/stem-cell-startup-xellsmart-secures-over-rmb-100-million-in-series-b1-financing-for-neurological-therapies/2024-11-30T12:03:47+08:00https://flcube.com/stem-cell-startup-xellsmart-earns-fda-orphan-drug-designation-for-als-therapy/2024-11-30T12:02:43+08:00https://flcube.com/novo-nordisks-turoctocog-alfa-pegol-for-hemophilia-a-accepted-for-review-by-chinas-cde/2024-11-30T01:05:20+08:00https://flcube.com/sisram-medicals-alma-veil-launches-in-the-us-for-vascular-lesion-treatment/2024-11-30T01:02:41+08:00https://flcube.com/astrazenecas-eplontersen-gains-tacit-approval-from-cde-for-attr-cm-clinical-study/2024-11-30T00:52:04+08:00https://flcube.com/kanova-biopharma-secures-over-rmb-100-million-in-financing-for-autoimmune-and-oncology-pipeline/2024-11-30T00:46:38+08:00https://flcube.com/boehringer-ingelheim-gets-nmpa-approval-for-phase-ii-study-of-bi-764532-in-sclc/2024-11-30T00:41:19+08:00https://flcube.com/hanchorbios-hcb101-receives-wfda-approval-for-multi-region-clinical-study/2024-11-30T00:37:37+08:00https://flcube.com/sosei-heptares-acquires-idorsias-korea-and-japan-units-in-jpy-65-billion-deal/2024-11-30T00:26:33+08:00https://flcube.com/innocare-pharmas-icp-723-receives-nmpa-approval-for-pediatric-clinical-study/2024-11-30T00:19:12+08:00https://flcube.com/boehringer-ingelheim-and-eli-lillys-jardiance-approved-by-ec-for-chronic-kidney-disease/2024-11-30T00:17:15+08:00https://flcube.com/biogens-q2-2023-report-reveals-struggles-with-aduhelm-and-1000-job-cuts/2024-11-30T00:15:16+08:00https://flcube.com/pharmaniaga-berhad-and-cspc-pharmaceutical-group-broaden-collaboration-in-pharma-and-biopharma/2024-11-30T00:12:49+08:00https://flcube.com/thermo-fisher-scientific-reports-q2-2023-revenue-dip-adjusts-full-year-forecast/2024-11-29T23:47:18+08:00https://flcube.com/abbvie-and-calibr-announce-strategic-collaboration-to-advance-preclinical-research/2024-11-29T23:42:06+08:00https://flcube.com/gsk-reports-4-yoy-sales-growth-in-q2-2023-upgrades-full-year-guidance/2024-11-29T23:21:35+08:00https://flcube.com/everest-medicines-launches-xerava-antibiotic-in-china-marking-commercial-milestone/2024-11-29T23:18:55+08:00https://flcube.com/jiangsu-recbios-shingles-vaccine-rec610-accepted-for-review-by-chinas-nmpa/2024-11-29T23:16:22+08:00https://flcube.com/mirxes-holding-company-secures-usd-50-million-in-series-d-financing-for-rna-technology/2024-11-29T23:13:43+08:00https://flcube.com/shanghai-henlius-completes-phase-i-ii-study-for-anti-vegf-mab-hlx04-o-in-wet-amd/2024-11-29T23:08:59+08:00https://flcube.com/innovent-biologics-altruist-biologics-partners-with-longbio-pharma-in-rmb-500-million-deal/2024-11-29T23:01:42+08:00https://flcube.com/suzhous-longbio-secures-rmb-100-million-in-series-b2-financing-to-advance-clinical-programs/2024-11-29T23:01:25+08:00https://flcube.com/ssy-group-ltd-receives-nmpa-approval-for-stiripentol-dry-suspension-for-dravet-syndrome/2024-11-29T22:35:09+08:00https://flcube.com/cutia-therapeutics-cu-20401-shows-positive-results-in-phase-ii-subcutaneous-fat-reduction-study/2024-11-29T18:54:14+08:00https://flcube.com/obio-technology-partners-with-hanxin-biotechnology-to-advance-lnp-delivery-system/2024-11-29T18:48:42+08:00https://flcube.com/nmpa-approves-shenzhen-mindrays-innovative-dual-mode-ultrasound-diagnostic-system/2024-11-29T18:42:03+08:00https://flcube.com/cde-expands-care-plan-with-approvals-for-ractigens-rag-17-and-vitalgens-vgr-r01/2024-11-29T18:27:32+08:00https://flcube.com/nmpa-drafts-medical-representative-management-measures-seeks-public-input/2024-11-29T18:18:29+08:00https://flcube.com/daiichi-sankyo-invests-rmb-1-1-billion-in-new-adc-manufacturing-plant-in-shanghai/2024-11-29T18:14:09+08:00https://flcube.com/jiangsu-kanion-pharmaceutical-gets-nmpa-clearance-for-oncolytic-virus-product-kys202003a/2024-11-29T18:09:16+08:00https://flcube.com/lingyi-biotechnology-and-jolly-pharmaceutical-ink-comprehensive-collaboration-agreement/2024-11-29T17:59:46+08:00https://flcube.com/sichuan-biokin-pharmaceuticals-bl-m08d1-adc-receives-nmpa-approval-for-clinical-trials/2024-11-29T17:49:00+08:00https://flcube.com/huadong-medicine-receives-fda-clearance-for-hdm1005-clinical-study-in-obstructive-sleep-apnea/2024-11-29T17:38:20+08:00https://flcube.com/corxel-partners-with-apeloa-pharmaceutical-for-cdmo-services-expansion/2024-11-29T17:15:49+08:00https://flcube.com/kunshan-yiyuan-medical-technology-secures-over-rmb-100-million-in-series-b-financing/2024-11-29T17:10:40+08:00https://flcube.com/ji-xing-pharmaceuticals-gets-cde-green-light-for-phase-iii-aficamten-study-in-nhcm/2024-11-29T17:04:02+08:00https://flcube.com/aficamten-market-filing-accepted-by-chinas-cde-for-hypertrophic-cardiomyopathy-treatment/2024-11-29T17:02:37+08:00https://flcube.com/ji-xing-pharmaceuticals-gets-cde-approval-for-phase-iii-presbyopia-trials-of-lnz100-and-lnz101/2024-11-29T17:02:00+08:00https://flcube.com/ji-xing-pharmaceuticals-partners-with-wuxi-sta-for-sterile-nasal-spray-production/2024-11-29T17:00:56+08:00https://flcube.com/ji-xing-pharmaceuticals-secures-licensing-rights-for-biogens-biib131-in-stroke-treatment/2024-11-29T16:59:37+08:00https://flcube.com/novartis-expands-gene-therapy-portfolio-with-acquisition-of-kate-therapeutics/2024-11-29T16:54:17+08:00https://flcube.com/ji-xing-pharmaceuticals-varenicline-nasal-spray-approved-by-nmpa-for-dry-eye-treatment/2024-11-29T16:51:55+08:00https://flcube.com/wuhan-union-hospital-to-transfer-hereditary-thrombophilia-detection-patent-to-kingmed-diagnostics/2024-11-29T16:11:44+08:00https://flcube.com/shanghai-yanyin-technology-partners-with-castalysis-bioscience-to-advance-crispr-software-development/2024-11-29T15:55:55+08:00https://flcube.com/eisai-and-biogen-launch-alzheimers-treatment-leqembi-in-south-korea/2024-11-29T15:42:46+08:00https://flcube.com/bayer-ag-launches-bayer-co-lab-berlin-focusing-on-life-science-innovation/2024-11-29T15:33:15+08:00